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Summary Statement 
Asthma is a chronic disease, which affects over 300 million people worldwide. 
Despite the introduction of both national and international guidelines, asthma 
control remains poor. The aim of this thesis is therefore to explore possible new 
strategies for improving the management of asthma. The first strategy to be 
explored is ‘titrating asthma treatment to suppress underlying airway 
inflammation’. The benefits of such a strategy have already been demonstrated, 
however, the lack of an adequate ‘inflammometer’ have limited its application to 
the research/ hospital setting. Mannitol challenge appears to be the most 
promising candidate, as it is portable and relatively cheap. The aim of the first 
study in this thesis is therefore to trial the use of mannitol challenge in a 
community setting. The selection of an appropriate ‘inflammometer’ is not limited 
to the clinical setting, it is equally important in research. This is particularly true 
when determining therapeutic equivalence between inhaled steroids. The aim of 
the second study in this thesis is therefore to determine which inflammatory 
outcomes demonstrate sufficient assay sensitivity, as part of a cross-over trial, to 
detect dose response effects on airway and systemic markers. 
 
The second strategy to be examined in this thesis is tailoring asthma therapy 
according to asthmatic phenotype. Two groups of asthmatics that differ 
significantly from traditional ‘inflammatory asthma’ have been selected. Asthmatic 
smokers are known to develop relative resistance to the beneficial effects of 
inhaled steroids. A recent post hoc analysis of the GOAL trial has suggested that 
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smokers may gain greater benefit from the addition of a long-acting beta-2 
agonist vs. doubling the dose of inhaled steroid. The third study in this thesis 
therefore aims to examine this in a prospective fashion. Another group of 
individuals in whom the traditional approach to asthma management and 
diagnosis may not be appropriate is elite athletes. In has been well documented 
that the mechanism of bronchospasm in athletes involves the drying/ cooling of 
airways. However, even within this category there are athletes to which this 
mechanism of action is unlikely to apply. Elite swimmers, for example, exercise in 
a warm, humidified environment. It therefore seems unlikely that tests designed 
to reproduce hyperosmolar shifts will have the same diagnostic sensitivity as they 
do in cold weather or track athletes. The aim of the fourth and fifth studies 
included in this thesis is therefore to compare various diagnostic tests in 
swimmers to determine which are the most sensitive.  
 
 
 
 
	  10	  
Introduction 
 
Burden of disease (incidence and prevalence of asthma) 
Asthma is a chronic disorder of the respiratory tract which is thought to affect 
over 300 million people worldwide [1].  It has been estimated that this figure will 
increase exponentially over the coming years as communities adopt western 
lifestyles and become increasingly urbanised [2-4]. Urbanisation of the world’s 
population is projected to increase from 45% to 59% in 2052, potentially leading 
to an additional 100 million new diagnoses of asthma worldwide [1].  
 
The projected increase in prevalence of asthma is of concern due to the 
significant burden which asthma places on society [5]. In 1996 Peter Barnes 
published a review article examining this burden, which he sub-divided into 
direct, indirect and intangible costs [5]. He determined that the direct costs of 
asthma associated with medical care in the UK were between £322- £686 million 
[5]. 22% of this was attributed to physician care (75% to GP consultations, 25% 
to specialists), 37% to drug costs, and 25% to hospital costs (70-80% to in-patent 
care, and 14-18% to emergency care) [5]. ‘Indirect’ costs were more difficult to 
accurately quantify as they only occurred when asthma became sufficiently 
intrusive to interfere with lifestyle. These were associated with loss of productive 
work, premature retirement, time spent by others caring for sick relatives and 
premature death [5]. The GINA (Global Initiative for Asthma) Committee 
quantified this by ranking common disorders in terms of disability-adjusted life 
	  11	  
years (DALYs), which combines information about mortality and morbidity in 
numbers of years lost. The number of DALYs lost due to asthma was estimated 
at about 15 million per year [1], ranking asthma as the 25th leading cause of 
DALYs lost worldwide. This is comparable with Diabetes Mellitus (23rd) cirrhosis 
of the liver (24th) and dementia (28th) [1]. ‘Intangible’ costs were associated with 
the impact of asthma on a patient’s quality of life [5]. This was examined as part 
of the UK Action Asthma Survey, which collected qualitative data from 61234 
asthmatic patients, through the provision of questionnaires in GP surgeries, 
pharmacies and outpatient clinics. They determined that 62% of patients felt that 
asthma had a moderate impact on their lives and 40% felt that it imposed a 
moderate restriction on their daily activities [6]. Jones et al examined the impact 
of asthma on an employed population using the St George’s Hospital Respiratory 
questionnaire and found that up to 95% of respondents had an impaired quality 
of life compared to age matched controls [7].  
 
National guidelines and the treatment of asthma 
In 1994 the British Thoracic Society implemented the first national guidelines on 
the management of asthma [8]. Their aim was to decrease the mortality and 
morbidity associated with asthma by standardising its management. They set 
about doing this by reviewing the most up to date evidence based medicine and 
issuing recommendations. Current guidelines outline a stepwise management 
plan, beginning with short acting beta-2 agonists for the treatment of mild 
intermittent asthma at step 1 (BTS guideline), and culminating with the use of 
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oral corticosteroids and immunosuppressants at step 5. The aims of 
pharmacological management are the control of symptoms (including nocturnal 
symptoms and exercise induced symptoms), prevention of exacerbations and the 
achievement of best pulmonary function with minimal side-effects [8].  
 
There is little doubt that inhaled corticosteroids (ICS) remain the treatment of 
choice for all severities of asthma.  They are potent anti-inflammatory agents, 
which act in a relatively non-specific manner, inhibiting a wide variety of 
inflammatory cells, cytokines, and transcription factors [9]. These effects have 
been confirmed clinically in bronchial biopsy studies [10]. Evidence also suggests 
that early intervention with inhaled corticosteroid drugs may prevent any long 
term decline in lung function resulting from airway remodelling caused by 
untreated chronic inflammation [9]. The benefits of early treatment with ICS were 
confirmed by the START trial in which 7241 steroid naïve persistent asthmatic 
patients were randomised to receive either daily budesonide or placebo for 3 
years. At the end of the study period, participants who had received budesonide 
had fewer severe exacerbations, fewer courses of oral corticosteroids, a longer 
time until their first exacerbation, and a greater number of symptom free days 
[11].  An earlier trial also found that mild-persistent asthmatics who received low-
dose budesonide had fewer exacerbations and better symptom control, than 
patients receiving placebo [12].  These trials have firmly established the role of 
ICS in treating persistent asthma, however there is increasing concern over the 
side effect profile of ICS. For most adults with mild to moderate asthma, the 
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steep part of the dose-response curve for anti-asthma effects generally occurs at 
doses below 800 µg/day BDP (beclomethasone dipropionate) or equivalent [13]. 
In addition, the curve for systemic adverse effects becomes much steeper at 
doses above 800 µg/day, resulting in an inverted U shaped curve for the benefit 
to risk ratio [13]. This has been shown to be true, even in severe asthmatics. The 
main side effects associated with inhaled steroids include: adrenal suppression, 
osteoporosis, growth suppression, skin bruising, cataracts and ocular 
hypertension [13]. Current guidelines therefore recommend starting treatment 
with a relatively high dose for four to eight weeks in order to gain rapid optimal 
control, then gradually tapering the dose to determine the lowest effective 
maintenance dose [8].  
 
 
Despite the publication of these guidelines and improvements in asthma 
treatment options, asthma remains a significant cause of mortality and morbidity 
for all age groups throughout the UK. This was echoed in the Asthma Insights 
and Reality Europe (AIRE) survey, which questioned asthmatic adults (n= 2083) 
from seven European countries about their symptom severity, healthcare use, 
exacerbation frequency, and perceived control [14]. Only 5.3% of all patients met 
all the criteria required for ‘asthma control’ as defined by the GINA guidelines 
[15]. 30.5% of adults complained of asthma-related sleep disturbance at least 
once a week, 27.9% had required an unscheduled urgent care visit over the last 
12 months, and 57.2% of adults reported symptoms such as shortness of breath, 
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cough, chest tightness and wheeze at least once a month [14]. 
 
Mortality associated with asthma also remains a significant problem, and it has 
been estimated that approximately 1 in 250 deaths worldwide are due to asthma 
[1]. Mathers et al predicted, using mathematical modeling, that the global 
mortality rate from asthma will rise from roughly 240 000 in 2002 to between 320 
000 - 402 000 by 2030 [16]. The most concerning aspect of this prediction is that 
mortality is mostly limited to those aged 15-59 [16].  Whilst new developments in 
pharmacological treatments do appear promising, none has made a radical 
impact on asthma mortality or morbidity. It is therefore clear that changes need to 
be made in the way we approach the management of asthma, in order to 
maximise the efficacy of treatments which are currently available to us. The aim 
of this thesis was to investigate this further: 
 
Strategy 1) Titrating anti-inflammatory treatment to suppress surrogate markers  
  of inflammation. In particular to identify which outcomes are most  
  suitable in different clinical and research situations. 
 
Strategy 2) Looking at different phenotypes of asthma rather than treating  
  asthma as a homogenous disease. 
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Strategy 1: Inflammation 
 
Airway inflammation is a salient feature of asthma. The link between asthma and 
inflammatory cells in the airways was first established during early case series of 
fatal asthma [17]. These described profound cellular infiltration of the respiratory 
mucosa associated with widespread mucus plugging [17]. More recently, Carroll 
et al compared the histological appearances of patients who died from asthma 
with those of non-asthmatic controls, and found a greater percentage of 
degranulated mast cells and increased numbers of neutrophils in the submucosal 
glands [18]. De Magalhaes Simoes et al described eosinophilic infiltration of the 
respiratory mucosa, extending from the nasal mucosa to the distal lung [19]. 
These results have been substantiated by a number of other studies, confirming 
that a diverse population of inflammatory cells including eosinophils, mast cells, 
neutrophils, and a variety of lymphocyte sub-sets are involved in the asthmatic 
process [20-22]. Interestingly, Carroll et al demonstrated that the distribution of 
inflammation within the lung varied with clinical severity [23]. Mild to moderate 
asthmatics were found to have predominantly central (i.e. large airways) 
infiltration, whereas patients with severe asthma had more distal disease [23].  
 
Sputum eosinophil counts have been shown to increase in severe or poorly 
controlled asthma [24, 25] and after allergen challenge [26]. High sputum 
eosinophil counts have been shown to predict the development of asthma 
exacerbations [25, 27] and to predict failure of steroid reduction in clinically stable 
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asthmatics  [26]. Green et al demonstrated that airway eosinophil counts 
decrease following treatment with inhaled corticosteroids and that this was linked 
with an improvement in symptoms and pulmonary function tests [28]. Reductions 
have also been noted following treatment with other anti-inflammatory agents 
such as theophyllines [29] and anti-leukotrienes [30].  
 
Airway inflammation is known to correlate very poorly with subjective symptoms 
and measures of airflow limitation [21]. This is particularly true in mild to 
moderate asthmatics, in which unsuppressed airway inflammation may occur 
despite clinically stable disease, potentially leaving many patients with 
unchecked indolent inflammation [31]. This could result in frequent exacerbations 
and eventually irreversible damage due to airway remodeling.  
 
Many studies have documented that asthmatic subjects have extensive structural 
changes in their airway [17, 32, 33]. These changes are present throughout the 
airway wall and the whole length of the bronchial tree and include basement 
membrane thickening, smooth muscle hypertrophy, abnormal deposition of 
matrix components, angiogenesis, proliferation of airway nerves and hypertrophy 
of glands [17]. Endobronchial biopsy studies have demonstrated that these 
changes, in particular reticular basement membrane thickness, are proportional 
to the number of inflammatory cells in the airways [34]. Autopsy studies have 
confirmed that extensive remodelling is present in both fatal and non-fatal 
asthma [35]. Laprise et al followed up 10 asymptomatic asthmatics and 10 
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control subjects with bronchial biopsy over a 2 year period. At baseline, groups 
had similar eosinophil counts, IgE levels and percentage predicted FEV1. At 2 
years, four had developed asthma and bronchial biopsies in these subjects 
revealed an increase in sub-epithelial fibrosis [31]. In a landmark trial Haahtela et 
al randomized 37 asthmatic patients to receive either 400µg budesonide or 
placebo in a double-blind manner for two years. A third group who had received 
terbutaline only for two years were crossed over in a open-label manner to 
treatment with 1200µg budesonide daily for the third year. They found significant 
differences between the placebo and budesonide groups in terms of FEV1 and 
histamine PC20. The condition of patients in the third group, who had initially 
been treated with terbutaline, improved, however, the degree of improvement 
appeared to be less than those who were treated with budesonide at the 
beginning of the three-year study. This suggests that early intervention with 
inhaled steroids is crucial when avoiding fixed airway obstruction [36]. These 
results were confirmed in the more recent Steroid Treatment as Regular Therapy 
(START) study, which involved 7,000 individuals (adults and children) with mild 
persistent asthma. The beneficial effects of ICS on accelerated decline of airway 
function over a 3 year period were established, as the rate of decline in post-
bronchodilator FEV1 was reduced by 22% in children and 42% in adults [11].  
 
The benefits of a treatment strategy based on targeting inflammation were first 
demonstrated in 1999 by Sont and colleagues who carried out a parallel group 
study involving 75 mild to moderate asthmatics [37]. Subjects were randomised 
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to a treatment strategy aimed at reducing airway hyper-responsiveness (a 
surrogate of inflammation) or standard BTS management. Patients in the AHR 
group had a 1.8 fold lower rate of exacerbations and a greater improvement in 
their FEV1 compared to the BTS group [37]. Bronchial biopsy specimens 
revealed that subjects in the AHR group also had a greater reduction in the 
thickness of their sub-epithelial reticular layer [37]. These findings were 
substantiated by Green and colleagues [38] who compared standard BTS 
management to titrating therapy with the aim of normalising induced sputum 
eosinophil counts. They found that eosinophil counts were 62% lower (p=0.002) 
in the treatment group, and that these patients suffered significantly fewer 
exacerbations and admissions compared with the BTS group [38]. The average 
steroid dose was the same in both groups [38]. These two studies have clearly 
demonstrated the benefits of a treatment strategy aimed at targeting surrogate 
markers of inflammation.  
 
In order to accurately target inflammation a number of non-invasive surrogate 
markers have been developed. The pros and cons of each are outlined below:  
 
Induced sputum  
Induced sputum is probably the most obvious surrogate marker of inflammation. 
Sputum from asthmatic subjects is known to contain increased numbers of 
inflammatory cells such as eosinophils, which are strongly implicated in the 
pathogenesis of asthma [39]. Raised sputum eosinophil counts have been shown 
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to predict impending loss of asthma control, and to be a robust predictor of 
improvement in FEV1 following a course of oral corticosteroids [25, 40]. Leuppi et 
al reported that, at a cut-off point of 6.3%, sputum eosinophils had a sensitivity of 
90% and a specificity of 63% for loss of control after stepwise reduction of 
inhaled steroid dose [41]. Using a cut-off point of 4%, Jones et al [42] reported a 
sensitivity of 59% and a specificity of 60% for loss of control after complete 
steroid withdrawal. In a landmark trial Green et al used these observations to 
titrate corticosteroid treatment against sputum eosinophil count [38]. Subjects in 
the eosinophil group had their treatment up-titrated if their counts were >3%. This 
led to a five-fold reduction in exacerbation rates compared to subjects titrated 
according to symptoms and measures of airflow limitation alone. Similar 
reductions were noted in other surrogate markers of inflammation such as FENO, 
and methacholine PC20 [38]. However, no differences were seen in symptoms or 
any spirometric measure, lending further weight to the argument that these 
methods are inefficient at monitoring disease activity [38].  Interestingly, no 
significant difference was seen in inhaled steroid dose between the two groups, 
indicating that this novel treatment strategy does not owe it’s success to 
increased steroid dose [38]. The main drawback of induced sputum is that it is 
technically difficult, requiring expertise in sputum induction, sputum handling, cell 
counting and interpretation. Whilst the Leicester group have obtained 
consistently good results, with high sputum yields, other centres, such as ours, 
have time and again failed to do so. In addition, the technical expertise required 
to collect and process these samples make it an inaccessible and impractical test 
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for use in the community, limiting its use to specialist centres.  
 
Peripheral blood eosinophil counts and ECP 
An alternative method of quantifying eosinophil counts is to measure them in 
peripheral blood. It has been suggested that peripheral eosinophil count is 
representative the overall ‘systemic burden’ of the disease [43, 44]. High blood 
eosinophil counts have been shown to predict failure of corticosteroid withdrawl 
[45]. Eosinophil counts have also been shown to reduce following treatment with 
inhaled corticosteroids [44]. However, it has been clearly established that 
eosinophils exhibit greater sensitivity for assessing the anti-inflammatory 
response in sputum than they do in blood [44]. This suggests that activated 
eosinophils in the target tissue are more important than the total number in the 
blood stream, making measurement of blood eosinophil counts less applicable to 
use in routine clinical practice [44].  
Eosinophil cationic protein (ECP) is a potent cytotoxic molecule that is released 
through the degranulation of eosinophils, and is thereby felt to indicate levels of 
eosinophil activation. It is therefore felt to be a more robust marker of asthmatic 
inflammation than total blood eosinophil count [46]. ECP levels in serum have 
been shown to correlate well with those in bronchiolar lavage fluid and sputum 
[47]. Studies looking at serum ECP in asthma indicate that levels are related to 
the severity of asthmatic disease, as measured by lung function and 
methacholine challenge [48]. ECP has been shown to rise following late phase 
allergen challenge and natural allergen exposure [49], and to decrease following 
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treatment with inhaled steroids [50]. However, ECP in sputum has been shown to 
be more sensitive than ECP in peripheral blood [44, 51]. Wever et al suggested 
that high ECP levels in serum can predict acute exacerbations, in spite of 
apparently satisfactory anti-inflammatory treatment [52]. However, these results 
conflict with those of Ferguson et al, who determined that ECP was a poor 
indicator of disease activity in chronic asthma, as it could not differentiate 
between bronchial and nasal inflammation [53]. Only one study has evaluated the 
efficacy of a treatment strategy based on ECP. In 2002, Lowhagen et al 
compared steroid titration according to serum ECP vs. pre-bronchodilator 
morning peak flow, and found no significant difference in exacerbation rates, 
symptom scores or FEV1 between the groups [54]. These results suggest that 
although ECP is a useful clinical tool, it is best used in combination with other 
markers of disease activity.  
 
Exhaled tidal nitric oxide 
Nitric oxide (NO) is a molecule which is synthesised throughout the pulmonary 
epithelium and vascular tree by nitric oxide synthase (NOS) enzymes [55]. Two 
isoforms of NOS exist: the constitutive form (cNOS) which appears to protect the 
airways from excessive bronchoconstriction, and the inducible form (iNOS) which 
has a modulatory role in inflammatory disorders [56]. cNOS is produced in 
platelets, neuronal, epithelial and endothelial cells. It releases tiny quantities of 
NO (fM or pM) when airway receptors are stimulated by agonists such as 
acetylcholine and bradykinin [56]. iNOS is produced by neutrophils, 
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macrophages, epithelial, mesangial and vascular smooth muscle cells [56][58]. It 
releases large quantities (nM) of pro-inflammatory NO in response to up-
regulation by immune cytokines, which may persist for hours or days [56]. NO 
has been detected in the exhaled breath of animals and humans by 
chemiluminescence [57]. Numerous authors have reported that the fraction of 
exhaled nitric oxide (FENO) measured in the expired breath of asthmatics is 
elevated compared to healthy controls. This has been linked to increased 
expression of iNOS [58], and is thought to reflect airway inflammation [59, 60]. 
FENO has been shown to increase during exacerbations and following exposure 
to allergen and viral infection [61, 62]. It correlates well with other markers of 
inflammation including sputum and peripheral eosinophil counts, ECP and airway 
hyper-responsiveness to methacholine [60, 63-67]. FENO has therefore been 
suggested as an aid in the diagnosis of asthma: A study by Berkman et al found 
it to have a similar diagnostic sensitivity to methacholine challenge, with a 
positive predictive value of more than 80%, however this finding was limited to 
steroid naïve patients [68]. Oral and inhaled corticosteroids have been shown to 
result in a rapid (6hrs after a single dose), dose dependent reduction in FENO [69-
71]. Non-compliance or cessation of treatment with ICS will return FENO levels 
rapidly (3 to 5 days) to the pretreatment level [69]. This decrease is thought to 
occur due to a reduction in airway inflammation and an inhibitory effect on iNOS 
expression [55]. FENO has therefore been suggested as a marker of treatment 
response [72]. It has also been used to predict exacerbations, both spontaneous 
[61] and those induced by steroid reduction [25, 73], as high levels in treated 
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asthmatics have been found to herald a loss of clinical control [42]. Jones et al 
reported that a 60% increase in FENO between two visits provided a positive 
predictive value of 83% for loss of control after stepwise reduction of inhaled 
steroid dose [42]. More recently, Michils et al reported that changes in FENO in 
relation to asthma control (as measured by the Asthma Control Questionnaire) 
were prognostically helpful, as a single FENO measurement of >45 ppb excluded 
well-controlled asthma with a negative predictive value of 89% [74]. On the basis 
of repeated measurements, a 40% decrease in FENO was found to have a high 
positive predictive value (83%) and similar negative predictive value (79%) for a 
clinically relevant improvement in asthma control. A FENO reading consistently 
<30 ppb was associated with a low likelihood of exacerbation within 3 months. 
Van Veen et al reported that persistently high FENO readings are a predictor of 
accelerated decline in lung function in ‘‘difficult asthma’’ [75]. This suggests that 
serial monitoring could be used to predict and thereby prevent exacerbations. 
However, studies in which steroid dose has been titrated to suppress FENO have 
proved disappointing [76-79]. Smith et al randomized 97 asthmatic subjects to 
titration of their treatment based on either FENO or symptoms for one year. They 
failed to demonstrate a significant difference in exacerbation rates between the 
two groups, however there was a trend towards decreased exacerbations in the 
FENO group. In addition, the FENO cohort required significantly less inhaled 
steroids at the end of the study [78]. These results were confirmed by those of 
Shaw et al who carried out a similar study involving 118 asthmatic patients [77]. 
FENO is known to have a relatively shallow dose response curve, with a plateau 
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at approximately 400µg of BDP or equivalent, which may explain it’s limited use 
in upwards steroid titration [80, 81]. iNOS is also suppressed by cigarette smoke, 
limiting the application of FENO to a wider patient population [82]. FENO should 
also be used with caution as a diagnostic tool, as increased levels have been 
noted in other conditions such as bronchiectasis [83], rhinitis [84], and atopy [85]. 
Nevertheless, when interpreted appropriately FENO remains a useful tool in the 
management of asthma. Measurement of FENO is quick, painless, and non-
invasive with a high degree of reproducibility and tolerability amongst subjects. It 
is easier to perform in a clinic environment than bronchial challenge, and the 
development of hand held analysers means that its use can be extended into a 
community setting. 
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Airway hyper-responsiveness and bronchial challenge 
Airway hyper-responsiveness is a characteristic feature of asthma. It represents 
the tendency of the airways to constrict and narrow in response to irritant stimuli 
[86]. AHR has been shown to correlate well with airway inflammation on 
bronchial biopsy [34, 37], and with other surrogate markers of inflammation 
including FENO, sputum and blood eosinophil count, and ECP [60, 66]. AHR is 
known to vary over time, increasing during exacerbations and decreasing 
following treatment with anti-inflammatory medications. Sont and colleagues 
demonstrated the efficacy of a treatment programme in which ICS dose was 
titrated in order to suppress AHR [37]. They were able to achieve a 1.8 fold 
reduction in mild exacerbations compared to conventional steroid titration using 
symptoms and spirometry alone (0.23 and 0.43 exacerbations per year per 
patient respectively). The clinical improvement in the AHR group was 
accompanied by a significant reduction in sub-epithelial reticular basement 
thickness at the end of the two-year follow-up period [37].  
 
AHR can be measured using either ‘direct’ or ‘indirect’ stimuli. ‘Direct’ stimuli 
include aerosols such as methacholine or histamine which act by stimulating 
specific receptors on the bronchial smooth muscle to cause bronchoconstriction 
[87]. ‘Indirect’ stimuli include adnosine monophosphate (AMP), mannitol, 
hypertonic saline, exercise and EVH. They provoke airway narrowing through the 
release of mediators from inflammatory cells and sensory nerves [88, 89]. These 
mediators then act on bronchial smooth muscle, causing it to contract and the 
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airways to narrow. The response to indirect stimuli is therefore dependent on the 
presence of inflammatory cells, and is thereby felt to be more reflective of 
airways inflammation than direct challenge. This theory was substantiated in a 
study by Van den Berge et al who demonstrated a stronger association between 
sputum eosinophil concentration and AHR to indirect stimuli, than direct stimuli 
[90].  
 
The major advantage of indirect challenges is their capacity to act on many 
different cells causing the release of a wide variety of inflammatory substances 
(e.g. histamine, leukotrienes, prostaglandins, neuropeptides) [88, 91-94]. As ICS 
are known to cause a reduction in the number of inflammatory cells in the airway, 
it has been suggested that indirect stimuli, which act via these cells, may better 
reflect inflammatory status following treatment [95]. For example, taking 
budesonide (400–1000 µg) daily for 4–8 weeks has been shown to markedly 
inhibit responses to exercise [96-99], hypertonic saline [100-102], mannitol [103], 
and AMP [95, 104, 105]. A negative response to an indirect challenge suggests 
that inflammatory cells are not present in sufficient numbers to cause airway 
narrowing. In other words, the subject either does not have asthma or their 
asthma is currently under control with treatment. By contrast, it is highly likely 
that the same subject treated for the same time and with the same dose of 
steroid will remain hyper-responsive to inhaled histamine or methacholine [38, 
101, 106, 107]. This suggests that direct stimuli may be more representative of 
airway ‘smooth muscle stability’ than inflammation per se.  
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Direct bronchial challenge (methacholine and histamine) 
Direct bronchial challenges act by stimulating histaminic or cholinergic receptors 
on airway smooth muscle to cause bronchoconstriction. They are highly sensitive 
for clinically current symptomatic asthma and particularly useful to exclude 
current asthma, as they have a high negative predictive value. AHR, as assessed 
by direct challenge, increases following allergen exposure, both in the laboratory 
[108] and following natural [109] exposure. AHR has in turn been shown to be an 
important determinant of the airway response to allergen. The early asthmatic 
response to allergen is dependent on the degree of allergen sensitisation and the 
level of airway smooth muscle hyper-responsiveness [110-112]. Indeed, studies 
have shown that methacholine PC20 can be used to predict the allergen PC20 to 
within 3 doubling concentrations in 94% of cases [113].  
 
Short-term within-subject repeatability studies (l-8 weeks) have shown that the 
95% confidence intervals for repeat determinations of methacholine PC20 lie 
within 1 doubling dilution [114]. Unlike other tests, methacholine challenge has a 
minimal significant difference equal to the variability of the test (i.e. 1 doubling 
dilution). The clinical significance of a change of this magnitude was clearly 
established by Sont et al who demonstrated that a difference of 0.64 doubling 
dilutions equated to a 1.8 fold reduction in exacerbation rates [37]. Responses to 
histamine have been shown to correlate closely with responsiveness to 
methacholine (r2 =0 85) [115].  Ward et al demonstrated significant 
improvements in methacholine PC20 following treatment with regular inhaled 
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corticosteroids. This was accompanied by improvements in inflammatory cell 
count on bronchoalveolar lavage at 3 months, and a decrease in reticular 
basement membrane thickness at 12 months, compared with placebo [34]. 
Methacholine challenge has also been shown to demonstrate dose response 
following treatment with high and low dose corticosteroids [116].  
 
Direct challenges have been found to have a sensitivity of only 57% for 
identifying people with asthma in a random population [117]. Their use is limited 
by their poor positive predictive value. A positive response can be seen in 
healthy people with no symptoms, smokers, congestive cardiac failure, and those 
with other diseases of the lung such as COPD, cystic fibrosis and bronchitis [118-
121]. About 30% of patients without asthma but with allergic rhinitis have a PC20 
in the borderline AHR range [122]. The clinical significance of a positive 
methacholine challenge in the absence of symptoms has yet to be fully 
determined. Several possible explanations have been suggested [123]: 
 
1. The patient has mild intermittent asthma but is a “poor perceiver’ of their 
asthma symptoms  
2. The patient never exercises or is never exposed to environmental triggers.  
3. The mild AHR is due to a cause other than asthma (e.g. post-viral upper 
respiratory tract infection or cigarette smoking)  
4. The patient has very mild or sub-clinical asthma that will become 
symptomatic in the future [36, 124].  Studies have shown that between 1.5 
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and 45% of asymptomatic patients with AHR develop asthma during 2-3 
years of follow- up. 
 
The pre-test clinical probability of asthma is therefore of vital importance in the 
assessment of results. Studies have also shown that the degree of AHR cannot 
be used to assess the clinical severity of asthma, as the correlation between the 
two is weak [125-127].  
 
Methacholine and histamine act on specific receptors on the bronchial smooth 
muscle causing it to contract. Thus an important limitation in using one or other of 
these agents is that AHR to only a single mediator is tested. The involvement of 
many cells in the airway inflammation of asthma means that there are many 
substances to which the smooth muscle could respond. Furthermore, it is known 
that some inflammatory mediators (e.g., leukotrienes and prostaglandins) are 
more potent than either histamine or methacholine in causing airways to narrow 
[128, 129]. Thus failure to find AHR to one mediator would not exclude a positive 
response to another. It should be noted that a diagnosis of EIB is not excluded 
on the basis of a negative test to challenge with histamine or methacholine [129-
131]. The most likely reason for this is that leukotrienes and prostaglandins [88, 
93] are involved in the response to exercise. 
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Indirect challenge (AMP, mannitol, hyperosmolar saline, exercise and EVH) 
Bronchial provocation tests (BPTs) have been used to assess patients with 
suspected AHR in clinical practice since the 1960s. Initially only direct aerosols, 
such as methacholine or histamine were used. However, in the 1970s, exercise 
as a BPT was developed for use in children [132]. It was recognised that most 
individuals with asthma experience symptoms when they exercise and that this is 
often one of the last symptoms to disappear following treatment with anti-
inflammatory medications [133]. Studies investigating the pathophysiology 
behind the effects of exercise determined that water and heat loss from the 
airways were the major factors leading to bronchoconstriction [134]. Thus, the 
water content of the air inspired and ventilation rate were identified as the factors 
to be controlled to provoke exercise induced asthma (EIA). This led to 
development of eucapnic hyperventilation with dry air as a surrogate of exercise. 
Eucapnic hyperventilation was standardized by members of the U.S. Army and 
used to assess recruits for EIA, making testing fast, simple, and less expensive 
to perform than exercise [135]. The complex machinery involved and 
requirements for highly trained staff limited the applicability of this test outside the 
armed forces. Hypertonic saline was therefore suggested as an alternative, as it 
mimicked the osmotic shift that occurs following water loss from the airways. 
Later, an alternative osmotic bronchial challenge using a dry powder of mannitol 
was introduced [136]. The use of adenosine monophosphate (AMP) as a 
bronchial challenge has been developed over the last 15 years, however the 
	  31	  
machinery and trained staff required limit its use to the research setting [137]. 
The airway response to AMP has many features in common with hyperpnoea 
and hypertonic stimuli. However, it differs in two specific ways: it is mediated via 
receptors (adenosine2b) and appears to be mast-cell-specific, rather than being 
a stimulus to all cells in the airways, as the osmotic and thermal stimuli have the 
potential to be.   
 
Indirect challenge tests are becoming increasingly recognised as useful tools for 
the monitoring of asthma following treatment with inhaled corticosteroids. The 
main advantage of indirect challenge over direct challenge is the lack of false 
positives: a positive response indicates that inflammatory cells and their 
mediators (prostaglandins, leukotrienes and histamine) are present in the 
airways in sufficient numbers and concentration to indicate that asthma is active 
at the time of testing. Healthy subjects respond with mean falls in FEV1 of 2 to 
6% [138-143] or small changes in conductance [144].  
 
Mannitol challenge appears to be the indirect challenge test with the most 
potential as a tool to monitor or guide asthma therapy. It has been shown to 
correlate very closely with other indirect challenges including hypertonic saline, 
AMP, EVH and exercise [136, 145, 146], and aside from demonstrating very 
good repeatability, it requires little specialist equipment, other than a spirometer 
and dry-powder inhaler [136]. These factors make mannitol challenge relatively 
cheap to perform, portable and therefore ideal for use in the community. 
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However, despite this potential, no studies have been carried out utilising 
mannitol in a primary care setting.  
 
Surrogate markers of inflammation and research 
Whilst the identification of a suitable inflammatory surrogate is of critical 
importance in the clinical management of asthma, it is just as essential in the 
research setting. This is particularly true when establishing therapeutic 
equivalence between inhaled steroids. Traditionally, studies have utilised 
endpoints such as symptom scores, spirometry and peak flow.  However, these 
are now known to be relatively insensitive measures for assessing response to 
ICS [147]. Surely it is fundamental to establish that supposedly equivalent 
inhaled steroids, whose clinical function is to suppress inflammation, do so to a 
comparable degree?  We therefore need to determine which outcome measures 
provide sufficient assay sensitivity for detecting dose response effects on airway 
and systemic markers. 	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Strategy 2: Phenotype 
 
The second alternative approach to asthma management, which will be explored 
in this thesis, is tailoring treatment/ diagnostic tools according to asthmatic 
phenotype. Current guidelines presume that asthma is a homogenous condition 
and only differentiate asthmatics on the basis of clinical severity. Asthma is in 
fact a very heterogeneous condition, which encompasses a wide range of clinical 
phenotypes. Preliminary studies have suggested that different subgroups 
respond differently to treatments and require different tests to diagnose and 
monitor treatment. We therefore propose that asthma treatment should be 
tailored to suit individual patients, or that at least subgroups should be identified, 
diagnosed and treated appropriately.   
 
Smokers 
Smoking is known to greatly increase the morbidity and mortality associated with 
asthma [148-150]. Asthmatic smokers are reported to have poorer symptom 
control [148, 150] an accelerated decline in lung function over time [149], more 
emergency department visits and hospitalisations [151] than non-smoking 
asthmatics. Cigarette smoke itself is a complex mixture of thousands of chemical 
compounds. It is thought to damage the airways in a number of ways, including 
direct toxicity to the epithelium, oxidative damage, and recruitment of 
inflammatory cells, especially neutrophils, to the airways [152, 153]. Smoking has 
been associated with increased airway inflammation and bronchial hyper-
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reactivity (BHR) even in non-asthmatic individuals [154-156]. In addition, 
smokers have been found to develop relative resistance to the beneficial effects 
of both inhaled and oral corticosteroids [157-160]. For these reasons, most 
studies looking at asthma exclude smokers as a matter of course. Current 
asthma guidelines are therefore based almost exclusively on studies that exclude 
smoking asthmatics. Despite the logical expectation that people with asthma 
would avoid exposure to cigarette smoke, many studies suggest that the 
prevalence of active smoking among individuals with asthma is approximately the 
same as in the population at large. Current smoking rates among asthmatic 
patients have been reported as ranging from 17-35% [148, 150, 151, 161, 162]. 
We therefore feel that it is insufficient to assume that smoking cessation and/ or 
escalation of therapy are the only treatment options available to smokers. 
Studies to date have suggested that smokers may benefit from slightly different 
therapy to non-smokers. A recent subgroup analysis of the ‘Gaining Optimal 
Asthma controL (GOAL) study’ [163] has revealed some interesting results. They 
discovered that smokers gained more benefit from FPSM vs. FP alone, as 
compared to non-smokers, in terms of reduction in exacerbation rates over 12 
months. Jackson et al published a letter attempting to put the results of this study 
into a clinical context. They determined that in the majority of patients who were 
non-smokers it would take 25 years to obtain an additional benefit to prevent an 
exacerbation by taking fluticasone/salmeterol vs. fluticasone alone. In smokers it 
would take 6.66 years to see the same benefit conferred by using combination 
therapy [164]. The reasons for the apparent increased benefits of treatment with 
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FP/SM in smokers are unclear. A potential explanation for this could be that, in 
the face of the relative steroid resistance seen in smokers, the smooth muscle 
stabilisation conferred by the LABA becomes of greater significance. Another 
possible explanation is that smoking induces greater hyper-reactivity in the 
airway smooth muscle, which responds well to the smooth muscle stabilisation 
offered by LABAs. We would therefore like to investigate this further by 
comparing the benefit of FP/SM vs. FP prospectively in a cohort of smokers and 
non-smokers. We will also attempt to provide a mechanistic explanation by 
measuring both mannitol and methacholine challenge. Methacholine challenge is 
primarily a measure of airway tone, whereas mannitol is an indirect bronchial 
challenge and therefore thought to more accurately assess underlying airways 
inflammation.  
 
Elite swimmers 
Exercise induced asthma (EIA) is defined as a transient increase in airway 
resistance, which occurs following vigorous exercise [133]. Most people with 
known asthma will exhibit exercise-induced symptoms, however EIA has also 
been shown to occur in otherwise healthy people [165, 166]. It is particularly 
prevalent in athletes, with the highest prevalence reported in endurance and 
winter sports athletes (cross-country skiers 50%, ice hockey players 43%, 
swimmers 36%, summer and winter Olympic athletes 17%).  This is thought to be 
due to a combination of high training loads and the training environment of the 
athletes. Two separate mechanisms have been proposed for this increased 
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prevalence. The first is the water loss/ humidity theory: increases in respiratory 
rate and increases in mouth breathing leads to drying of the respiratory 
epithelium. This drying results in changes in osmolarity of the pericilliary fluid, 
which in turn triggers mediator release, leading to bronchospasm [134].  The 
second theory is the heat exchange/ loss theory: heat loss from the bronchial 
tree in cold weather leads to reactive airways hyperaemia and mucous 
membrane swelling, which leads to the release of inflammatory mediators [167]. 
These increases in ventilation also substantially increase the exposure of the 
airways to cold air, allergens and pollutants; all of with may result in inflammation 
of the airways and therefore increased bronchial hyper-reactivity.  
 
Whilst the above mechanisms can easily be applied to cold weather and 
endurance athletes, they cannot as easily be applied to elite swimmers, who 
exercise in a warm, humidified environment. Surprisingly, swimmers have one of 
the highest reported prevalence rates of EIB [168]. Swimmers have also been 
reported to have higher rates of rhinoconjunctivitis than other athletes [168].  The 
most commonly used method to achieve swimming pool hygiene in developed 
countries is chlorination. Exposing chlorine to organic material (saliva, sweat and 
urine) causes the release of toxic by-products such as nitrogen trichloride or 
trichloramine. These form a gaseous layer on the surface of the water, which is 
readily breathed in by swimmers. Recent reports have suggested that swimming 
in outdoor pools treated with chlorine products can predispose children to the 
development of asthma and recurrent bronchitis [169]. It has even been 
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suggested that the increasing prevalence of childhood asthma is related to the 
availability of swimming pools in Europe (due to airway epithelial damage from 
chlorine metabolites) [170]. Accidental acute chlorine exposure has been shown 
to induce neutrophilic airways inflammation with increased leukotriene B4 levels 
in exhaled breath condensate [171].  Analysis of induced sputum in non-
asthmatic elite swimmers has shown an increased proportion of eosinophils and 
neutrophils compared with healthy controls [172]. Asthmatic swimmers have also 
been found to have increased numbers of eosinophils and lymphocytes 
compared with healthy subjects and of neutrophils compared with asthmatic 
patients [168]. During a 5-year prospective follow up study Helenius and 
colleagues demonstrated persistent mild eosinophilic and lymphocytic airway 
inflammation in swimmers who remained active. Whereas in those who stopped 
training eosinophilic airway inflammation, bronchial responsiveness and clinical 
asthma attenuated and in some cases even disappeared [173].  Interestingly 
studies looking at FEno in children regularly attending swimming pools, showed 
no increase. FENO was also found to be normal in swimmers with high LTB4 
levels in exhaled breath concentrate [171].  
 
Currently many asthma medications appear on the World Anti-Doping 
Association’s (WADA) list of prohibited medications [174]. This regulation came 
into play in response to reports that beta2-agonists given systemically in large 
doses might influence skeletal and heart ventricular muscle fibres in research 
animals. However, these effects have never been demonstrated in athletes. The 
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use of many asthma medications is therefore only permitted if an “abbreviated 
therapeutic use exemption” (ATUE) certificate is granted. Failure to obtain such a 
certificate can result in a ban of up to 2 years. In order to obtain an ATUE 
certificate athletes are requires to demonstrate objective evidence of airway 
narrowing [175]. A reliable test is therefore required to test for EIA. 
 
A number of different direct and indirect provocation tests are available to test for 
EIA. Direct challenge tests such as methacholine and histamine have been 
shown to have a low sensitivity for EIA [176]. Indirect tests have been found to be 
significantly more sensitive. The current gold standard test is Eucapnic Voluntary 
Hyperpnoea (EVH), which requires subjects to hyperventilate whilst breathing in 
cold dry air, thereby replicating the conditions required to provoke EIB.  However, 
as this test requires complex machinery, trained staff and is relatively expensive 
it is not widely used.  Indeed it is only available in 3 centres in the UK. Alternative 
tests include exercise challenge tests (field and lab based) and osmotic 
challenges such as hypertonic saline and Mannitol.  
 
Exercise tests can be performed either in the laboratory or in the field. Several 
studies have reported low sensitivity for EIA [177-179]. Dickinson et al [177] 
carried out a study comparing EVH and sport-specific exercise challenge testing 
(both lab and field). They found that 71% athletes had a positive EVH, whereas 
only 21% had a positive field test. None were positive to laboratory based 
exercise testing. The main problem with exercise testing is felt to be that trained 
athletes do not often reach high enough ventilatory rates to induce EIB (exercise-
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induced bronchoconstriction). There is also no standardisation of cardiovascular 
workload and environmental conditions (temperature, humidity, presence of 
aeroallergens), so tests performed out of season may prove negative. The value 
of sport-specific exercise testing is yet to be established in swimmers, since the 
exact trigger for EIB in this group has not been fully determined. It may be that 
the specific conditions of the training environment (chlorine metabolites) play 
such a large role in inducing airways inflammation and bronchial hyper-reactivity 
that field based challenge will prove much more sensitive than in other sports.   
 
Osmotic challenge tests such as hypertonic saline and Mannitol have been 
shown to be relatively cheap, easy to perform, and especially in the case of 
Mannitol practical for use at “point of need” [146]. In this regard mannitol, like 
exercise, acts via an osmotic mechanism. A positive response to Mannitol has 
been shown to identify individuals with EIB [146] and to have good repeatability 
[136]. A recent study by Holzer et al [180] which compared Mannitol challenge to 
EVH found mannitol to be highly sensitive (96%) and specific (92%) and have a 
positive predictive value of 92% and a negative predictive value of 96%.  
 
A screening test should be sensitive, specific, and acceptable to the patient and 
should pick up a condition at a stage where it is easily treatable. We believe 
Mannitol challenge could be such a test. It is not currently known whether 
treating athletes with either symptomatic or asymptomatic EIA will translate into 
an improvement in performance. If this were the case we could postulate that 
identifying EIA early in an athletes’ career could lead to more young athletes 
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continuing to participate at a higher level. It may also allow current elite athletes 
to reach their full potential. Moreover identifying and treating EIA might lead to 
improvements in training efficiency. 
 
We therefore propose to carry out a screening study to identify the prevalence of 
EIA in Scottish swimmers. We intend to use Mannitol challenge as our primary 
outcome and compare this to a sport-based exercise challenge. We plan to carry 
out this study during Scottish team training weekends. The exercise challenge 
will be performed when the swimmers have completed their “main set” which 
should be sufficient for them to reach the desired MVV (maximum voluntary 
ventilation) required to provoke EIB. We will also carry out nasal NO 
measurement and PNIF to identify rhinitis and measure FENO as another 
measure of airways inflammation. 
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Chapter 2: Methods 
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Detailed protocols for each study are described in individual chapters, however, 
many aspects of the methodologies are common to all studies and are therefore 
described in this section.  
 
Airway measurements 
 
Lung function 
Lung function (FVC (forced vital capacity), FEV1 (forced expiratory volume in 1 
second), FEF25-75 (forced expiratory flow between 25% and 75% of forced vital 
capacity)) were performed according to standard criteria laid down by the 
American Thoracic Society guidelines [181]. All measurements were carried out 
in triplicate, utilising a Micro Medical SuperSpiro (Micro Medical Ltd, Rochester, 
UK) spirometer, the highest of 3 values for FEV1, repeatable within 5%, was 
recorded and the percentage predicted (according to ethnicity, height and weight) 
was calculated. 
 
Mannitol challenge 
Mannitol bronchial challenge was performed by administering mannitol gelatine 
capsules  (OsmohaleTM Pharmaxis Ltd, Sydney, Australia), inhaled from a dry 
powder device (Osmohaler, Pharmaxis Ltd. French’s Forest, NSW, Australia) as 
previously described [136]. FEV1 was measured 60 seconds after delivery of 
each dose (5, 10, 20, 40, 80, 160, 160, 160 mg). The test continued until the 
FEV1 had fallen 15% (or there had been a >10% drop between two subsequent 
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doses) or the maximal cumulative dose of 635 mg had been administered. The 
provoking dose of mannitol to cause a 15% fall in FEV1 (PD15) was calculated by 
log linear interpolation. If a fall in FEV1 of 15% had not been reached, a censored 
value of 1270mg was assigned. 
 
Methacholine challenge 
Methacholine was made up into doubling dilutions (concentrations ranging 
between 0.03- 32mg/ml) using benzyl alcohol. Methacholine challenge was 
performed according to recommended guidelines using a validated computer-
assisted dosimetric method [182, 183]. An initial FEV1 was taken before each 
challenge test to ensure safety (patients with an FEV1 <60% predicted for age, 
gender and height were excluded from the challenge test). A further FEV1 was 
taken following administration of the diluent (benzl alcohol) from which the % fall 
was calculated. Methacholine was then administered in doubling cumulative 
doses from 3-32mg/ml at 5-minute intervals, until a 20% fall from the post-diluent 
measure was recorded. The PC20 values were calculated by computer-assisted 
log linear interpolation of the dose response curve [184]. If a fall in FEV1 of 20% 
had not been reached, a censored value of 64mg/ml was assigned. 
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NO measurement 
All participants underwent measurement of exhaled NO using either a NIOX 
(NIOX® Nitric Oxide Monitoring System, Aerocrine AB, Solna, Sweden) or a 
portable MINO (NIOX MINO® Airway Inflammation Monitor; Aerocrine AB, Solna, 
Sweden). The results of both devices have been shown to be directly 
comparable [185]. All measurements were made prior to measurement of 
spirometry to ensure accuracy of results. Participants were asked to avoid 
caffeine for 4 hours prior to measurement as this has been shown to cause a 
significant reduction in NO [186]. A sustained plateau of at least 8 seconds with a 
mouth flow rate of 50 ml/s and a pressure of 10 cm H2O were used.  The 
arithmetic mean was derived according to the current European Respiratory 
Society/American Thoracic Society recommendations [187].   
 
Impulse oscillometry (IOS) 
A Jaeger Masterscreen (Erich Jaeger, Hoechberg, Germany) was used to 
measure impulse oscillometry according to the guidelines [188]. Subjects 
supported their cheeks to reduce shunting, whilst impulses were applied for 
30secs during tidal breathing. All manoeuvres were performed in triplicate and 
means taken [188]. 
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Peak expiratory flow  
All subjects were issued with a peak expiratory flow meter (Clement Clarke, 
Essex, UK) and diary, and instructed in their use. They were asked to record 
their peak flow every morning (prior to adminstration of asthma medication). 
Participants were instructed to carry out three technically correct PEF 
measurements, with a one-minute interval between assessments, and record the 
best of the three values.   
 
Quality of life/ symptom measures 
 
Juniper mini AQLQ and ACQ 
The mini juniper asthma quality of life questionnaire (Mini-AQLQ) [189] and 
asthma control questionnaire (ACQ) [190] were used in several of the studies. 
They have been repeatedly validated, and have been shown to be sensitive 
measures of quality of life and control in asthma. The mini-AQLQ has a total of 
fifteen questions, each of which has a response scored out seven. The questions 
are then grouped into four domains: activity limitations, symptoms, emotions, and 
exposure. Each group is then averaged to obtain a score for each group. A 
change in score of greater than 0.5 is considered clinically relevant [191]. 
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Symptom scores 
Symptom scores varied from study to study, the method for each will be 
described in the individual methods sections. 
 
Skin prick testing 
Skin prick testing to eight common aeroallergens (grass, tree, weed, house dust 
mite, aspergillus, feathers, cat and dog) was carried out in several of the studies. 
Subjects were asked to withhold antihistamines and leukotriene receptor 
antagonists for at least 4 days prior to the test. Allergen drops (Bencard Testing 
Solutions: Welwyn Garden City, UK) were applied to the forearm; they were then 
pressed into the skin using disposable lancets. A positive response was defined 
as any wheal with a diameter that was 3mm greater than the negative control, at 
least 15 minutes after skin prick. 
 
Blood and Urine collection 
 
Overnight urinary cortisol creatinine clearance 
Subjects were instructed to empty their bladder at 10pm then collect all 
subsequent urine produced overnight for analysis (10pm-8am). They were also 
asked to provide an early morning (8am) spot sample. This sample concluded 
their overnight sample and as such was included in their overnight sample, 
however the 8am sample was also analysed separately. 5mls from both samples 
were stored in a freezer at -20˚C throughout each individual study and analysed 
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in batches on completion. The urinary cortisol was measured using a commercial 
radioimmunoassay kit (DiaSorin Ltd, Wokingham, Berkshire, UK), which has no 
cross reactivity with fluticasone. The intra assay coefficient of variation was 4% 
and the inter assay coefficient of variation was 8%. Urinary creatinine was 
measured on a Cobas-Bio auto analyser (Roche Products, Welwyn Garden City, 
UK). The intra assay and inter assay co-efficient of variation was 4.6% and 3% 
respectively.  
 
Blood eosinophil count and Eosinophilic cationic protein (ECP) 
Blood samples for eosinophils and ECP were taken prior to performing bronchial 
challenge. For the measurement of ECP, whole blood was allowed to rest for 60 
minutes at a temperature of 22-24˚C prior to being centrifuged for 10 minutes at 
a speed of 3000rpm (at 4˚C). The supernatant was then stored in a freezer at -
20˚C and analysed in batches on completion of the study by the departmental 
laboratory. It was measured using an enzyme linked immunoassay technique 
(UniCAP; Sweden Diagnostics UK Ltd, Milton Keyes, UK) with an intra-assay co-
efficient of variation of 3.3%. Blood eosinophil count was analysed by the 
Ninewells Hospital haematology laboratories using a Sysmex XE 2100 
Hematology auto analyzer.  
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Quality control 
 
Sensitivity, specificity and coefficients of variance were checked for each batch of 
assays carried out in-house. Eosinophil counts, measured in the Ninewells 
haematology lab were subject to NHS standards of quality. 
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Chapter 3: 
 Establishing the role of 
surrogate markers of 
inflammation in clinical 
and research settings 
 
Part a: supervised step-down of inhaled steroids in a community 
setting 
 
Study aims: To determine the effect of stepping down inhaled steroids in a  
   community setting on surrogate markers of inflammation. 
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Supervised Step-down of Inhaled Corticosteroids In the 
Community 
  
Introduction 
Inhaled corticosteroids (ICS) are the first line anti-inflammatory therapy in the 
treatment of asthma [192], however higher doses are associated with local and 
systemic adverse effects [13]. Current asthma guidelines recommend stepping 
down of steroid dose once asthma control has been achieved [8]. There is little 
evidence to suggest the best method to step down treatment, or to ensure the 
safety of this approach.  Hawkins and colleagues reduced the ICS dose in a 
range of asthmatic patients by a mean of 25% without a significant rise in asthma 
exacerbations or change in measures of health status [193]. They did not, 
however, examine surrogates of inflammation or airway hyper-responsiveness 
(AHR). It is recognised that symptoms correlate poorly with underlying 
inflammation [21]. Studies have demonstrated that titrating ICS to suppress 
surrogates of inflammation leads to reduced exacerbations and decreased 
airways remodelling [37, 38]. During the initial run-in phase of an ongoing 
community based clinical trial, ICS doses were stepped down to determine the 
lowest dose required to achieve stability. During this phase inflammatory 
surrogates including FENO and AHR to mannitol were measured, in additional to 
lung function and quality of life. Mannitol was selected because it is portable and 
easy to use in a community setting. In addition, AHR to mannitol has been shown 
to be a good predictor of failure of ICS step-down [41]. 
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Methods 
 
Participants 
119 eligible patients were recruited from 35 general practices throughout 
Tayside. This paper presents data obtained during the step-down phase of a 
large community based study. Participants were required to be aged 16 years 
and above, non-smokers, have a diagnosis of persistent mild to moderate 
asthma, be clinically stable, and currently treated with ≥ 400 µg beclomethasone 
diproprionate (BDP) equivalent. At point of entry into the study, patients were 
required to demonstrate AHR to mannitol challenge in terms of a 10% fall in 
FEV1 to a dose of mannitol of 635 mg or less. Exclusion criteria were: oral 
steroid in the preceding three months; aspirin intolerance; FEV1 ≤ 50% predicted; 
pregnancy; recurrent lower respiratory tract infections; and the presence of 
concomitant respiratory disease such as bronchiectesis. Patients who failed to 
become unstable on 200 µg BDP equivalent, or who were unable to step below 
800 µg were withdrawn, as these were entry criteria for the subsequent study. 
The study was approved by the Tayside Committee on Medical Ethics (CTA, 
MF8000/13398), and all participants gave written informed consent. 
 
 
 
 
 
	  52	  
Protocol 
Patients underwent systematic step-down of their medication with two weekly 
follow up. At screening patients were issued with a peak expiratory flow (PEF) 
and symptom diary card and asked to monitor their PEF for two weeks: this 
served as their baseline for the study. Additional asthma therapies (leukotriene 
receptor antagonists (LTRAs) or theophyllines) were discontinued. Patients on 
combination inhalers were switched to an equivalent dose of inhaled steroid only. 
The dose of inhaled steroid was then halved every two weeks till patients were 
on 200µg BDP equivalent or became clinically unstable. Clinical instability was 
defined as: diurnal variation in domiciliary PEF ≥ 20%; deterioration in FEV1 ≥ 
20% from baseline; mean use of inhaled reliever medication ≥ 0.5 puffs daily 
from baseline; an increase in symptom scores of ≥ 0.5 daily from baseline. (The 
asthma symptom score asks for a number analogue of symptoms from 0 to 3, 
where: 0 is symptom free; 1 is minimal symptoms; 2 is moderate symptoms 
which may limit activity; 3 severe symptoms which limit activity). Once unstable, 
participants stepped back up to the last stable dose of ICS (this was designated 
the ‘lowest dose required for stability’). FENO and AHR were recorded at the start 
and end of the step-down, while asthma quality of life questionnaires and 
spirometry were measured throughout the step down period.   
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Lung function 
Lung function (FVC (forced vital capacity), FEV1 (forced expiratory volume in 1 
second)) was measured using a Micro Medical SuperSpiro (Micro Medical Ltd, 
Rochester, UK) spirometer according to the American Thoracic Society 
guidelines [181]. The highest of 3 values for FEV1, repeatable within 5%, was 
recorded and the percentage of percent predicted was calculated. 
 
Mannitol challenge 
Mannitol bronchial challenge was performed by administering mannitol gelatine 
capsules  (OsmohaleTM Pharmaxis Ltd, Sydney, Australia), inhaled from a dry 
powder device (Osmohaler, Pharmaxis Ltd. French’s Forest, NSW, Australia) as 
previously described [136]. FEV1 was measured 60 seconds after delivery of 
each dose (5, 10, 20, 40, 80, 160, 160, 160 mg). The test continued until the 
FEV1 had fallen 10% or the maximal cumulative dose of 635 mg had been 
administered. The provoking dose of mannitol to cause a 10% fall in FEV1 (PD10) 
was calculated by log linear interpolation. 
 
NO measurement 
The measurement of FENO pre and post step down was introduced, as part of a 
substantial amendment, after recruitment had commenced. Consequently, 
83/119 participants underwent measurement of FENO using a portable MINO 
(NIOX MINO® Airway Inflammation Monitor; Aerocrine AB, Solna, Sweden). 
FENO was measured during a sustained plateau of at least 8 seconds with a 
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mouth flow rate of 50 ml/s and a pressure of 10 cm H2O following a tidal breath.  
The arithmetic mean was derived according to the current European Respiratory 
Society/American Thoracic Society recommendations [194].  
 
 
Mini juniper quality of life questionnaires (Mini-AQLQ) 
At each study visit each patient completed the Juniper mini-AQLQ [189]. 
 
Statistical analysis 
 
SPSS version 15 (SPSS Inc, Chicago, Illinois) was used to perform the statistical 
analysis. Normality of data was assessed using the Kolmogorov-Smirnov; non-
Gaussian data were log transformed prior to analysis. Gaussian data were 
assessed using paired Student’s t-tests. ICS dose and AQLQ pre- and post-step 
down was analysed using Wilcoxon Signed Rank Tests. A probability value of 
less than 0.05 (two tailed) was considered significant. 
 
Results 
 
Demographics 
One hundred and fifty patients entered the step down phase of the clinical trial. 
One hundred and nineteen (49% female, 52% male) of these were randomised 
and entered the subsequent clinical trial. Thirty one patients withdrew during the 
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step-down phase: 1 failed to become unstable when cut back to 200µg ICS; 2 
became unstable on ≥800 µg ICS; 3 were unable to discontinue long acting beta 
agonist therapy; 2 were withdrawn due to failure to comply with the protocol; 6 
withdrew due to personal reasons; and 17 were lost to follow-up (Figure 1). The 
mean (SEM) age of participants who dropped out was 57 years (2) compared 
with 52 years (1) in those who completed step-down. Drop-outs also had a 
significantly higher mannitol PD10: 184.5 mg (95 % CI 113.5 – 299.8) compared 
with 100 mg (95 % CI 76.2 – 131.2), p=0.036.  Other baseline characteristics did 
not differ significantly between the two groups (table 1). 
 
Table 1: Baseline characteristics of drop-outs vs. those who completed. 
 
 
Variable 
 
Completed Drop-outs p-value 
BDP equivalent ICS dose (mcg/day)* 400 (400-800) 800 (400-1000) 0.055 
Mannitol  (PD10 mg) † 99.99 (76.2 to 131.2) 184.47 (113.5 to 299.8) 0.036 
FENO (ppb) † 26.79 (22.1 to 32.5) 17.83 (9.9 to 32.0) 0.144 
Spirometry ‡    
       FEV1 % predicted 86.16 (1.512) 90.13 (3.396) 0.244 
       FVC % predicted 91.56 (1.376) 95.13 (3.215) 0.254 
       PEF % predicted 90.20 (1.695) 91.61 (3.910) 0.713 
Age 52.00 57.83 0.049 
Sex (F:M) 
 
48.7%: 51.3% 62.1%: 37.9%  
Abbreviations: ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak 
expiratory flow rate; PD10, provocative dose of mannitol causing a 10% decrease in FEV1. 
Data presented as arithmetic mean (SEM) unless otherwise indicated.  
*Expressed as median (inter-quartile range) 
† Shown as geometric mean (95% CI) 
‡ Expressed as percentage of that predicted by age, sex, and height, mean (SEM). 
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Figure 1: step down procedure 
 
 
150 patients 
recruited 
 
127 on 
ICS only 
23 on ICS 
plus ‘third 
line’ asthma 
therapy 
18 stepped 
off third-line 
therapy for 
2 weeks 
4 did not tolerate step-
down 
1 withdrew voluntarily 
146 had ICS dose halved 
every 2 weeks until 
they became clinically 
unstable or reached 200µg 
ICS 
 
Subject increased back up 
to last stable ICS dose 
2 became unstable on ≥ 800µg 
ICS 
2 failed to comply with the 
protocol 
6 withdrew due to personal 
reasons 
17 were lost to follow up 
 
119 subjects went on to be 
randomised and enter 
clinical trial 
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 Withdrawal of medication  
23 participants were taking additional third line asthma therapy (long-acting β2-
agonists (n=21), theophylines (n=1) or leukotriene receptor antagonists (n=1)) at 
the start of the step down. Only four participants did not tolerate withdrawal of 
their third line therapy; one withdrew voluntarily. In patients who completed step-
down, the median (interquartile range) dose of BDP or equivalent was 400 µg 
(400 – 800) at baseline, compared with 250 µg (200 – 400) post step-down, 
giving a median reduction of 150 µg (p < 0.0001) (Figure 2). Subjects underwent 
an average of 1.49 (0.07) step-downs prior to either becoming unstable or 
reaching 200µg BDP equivalent. 
 
Figure 2: median change in ICS dose (µg) pre and post step-down 
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Table 2: Baseline and post step-down values 
Variable Baseline Post step-down P value 
 
BDP equivalent dose (µg/day)* 400 (400-800) 250 (200-400) <0.0001 
FENO (ppb) † 26.9 (21.9 – 32.4) 28.2 (23.4 – 33.1) 0.43 
Spirometry‡    
     FEV1 % predicted 86.16 (1.51) 84.46 (1.46) 0.04 
     FVC % predicted 91.56 (1.38) 91.52 (1.44) 0.97 
     PEF % predicted 90.20 (1.70) 90.02 (1.56) 0.87 
AQLQ    
    Activity limitation 5.22 (0.11) 5.65 (0.10) <0.0001 
    Emotional function 5.18 (0.13) 5.68 (0.11) <0.0001 
    Symptoms 5.44 (0.11) 5.79 (0.10) <0.0001 
    Environmental stimuli 5.40 (0.11) 5.82 (0.10) <0.0001 
Total score 5.44 (0.10) 5.83 (0.09) <0.0001 
    
Abbreviations: ICS- inhaled corticosteroids; FEV1- forced expiratory volume in 1 second; FCV- forced vital capacity; PEF- 
peak expiratory flow; PD10- provocative dose of mannitol causing a 10% decrease in FEV1 
Data presented as arithmetic mean (SEM) unless otherwise indicated. Step-down measures where taken 2 weeks after 
reduction of steroid. 
*Expressed as median (inter-quartile range) † Shown as geometric mean (95% CI). ‡ Exressed as percentage of predicted for age, 
sex and height. 
 
 
Inflammatory Surrogates 
The geometric mean (95 % CI) mannitol PD10 was 100.0 (76.2 to 131.2) at 
baseline; and 137.2 (104.5 to 180.1) post step-down.  This represents a 0.46 
doubling dose difference for pre vs. post step-down (95 % CI 0.02 - 0.89), 
p=0.04. The geometric mean response-dose-rate (%fall in FEV1/ maximum dose 
mannitol given) was 1.73 (1.71 to 1.75) at baseline and 1.95 (1.93 to 1.96) post 
step-down, p=0.73.  Data for change from baseline in FENO was available for 83/ 
119 subjects. The geometric mean fold ratio for pre vs. post in exhaled FENO was 
0.96 (0.87 - 1.06), p=0.43.  
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Figure 3: Shift in mannitol challenge post step-down 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. Doubling dose shift (i.e. post step-down PD10 minus pre-step down PD10) in mannitol for each individual patient. The 
intra-individual biological variability of mannitol challenge is +/- 1dd, so individuals lying between +1 and -1 (depicted by 
interrupted line) can be assumed to show ‘no change’ in mannitol challenge post step-down (47%). Individuals with > +1dd 
demonstrated an improvement in mannitol challenge (34%). Those with a <-1dd shift demonstrated a worsening in mannitol 
challenge (19%).  
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Table 3:  Baseline and post-step-down data divided by change in mannitol 
challenge post step down 
 
 > +1 doubling dose change 
             “Improvement” (n=37) 
 
+/- 1 doubling dose change 
            “No change” (n=62) 
< - 1 doubling dose change 
           “Worsening” (n=20) 
 Pre Post Change 
from BL 
Pre Post Change 
from BL 
Pre Post Change 
from BL 
Mannitol PD10 (mg)‡ 47.8 
(1.3) 
328.2 
(1.2) 
-2.8 
(0.3)* † 
137.1 
(1.2) 
131.5 
(1.2) 
0.1 
(0.1) † 
180.6 
(1.3) 
30.3 
(1.3) 
2.6 
(0.2)* † 
FENO (ppb) 33.8 
(6.0) 
31.3 
(4.0) 
-2.6 
(3.7) 
39.6 
(5.2) 
38.3 
(5.4) 
0.9 
(1.5) 
33.0 
(8.4) 
36.7 
(7.7) 
3.7 
(6.0) 
Spirometry          
    FEV1 % predicted 86.4 
(2.5) 
84.4 
(2.8) 
-2.0 
(1.3) 
85.3 
(2.3) 
84.4 
(2.1) 
0.9 
(1.5) 
88.5 
(3.6) 
84.8 
(3.5) 
-3.7 
(1.8) 
    FVC % predicted 91.2 
(2.2) 
91.2 
(2.9) 
-0.03 
(1.7) 
93.7 
(2.1) 
93.1 
(2.1) 
0.6 
(1.4) 
90.4 
(4.0) 
89.5 
(3.6) 
-0.9 
(2.8) 
    PEF % predicted 88.1 
(2.8) 
90.0 
(2.7) 
1.9 
(1.8) 
89.8 
(2.8) 
89.3 
(2.4) 
0.5 
(2.1) 
94.8 
(3.6) 
91.8 
(3.3) 
-3.0 
(1.8) 
BDP equivalent ICS 
dose (mcg/day) 
622.9 
(52.2) 
350.0 
(35.6) 
-272.9 
(42.1)* 
634.7 
(56.8) 
338.8 
(27.4) 
-295.9 
(50.0)* 
752.6 
(115.6) 
397.4 
(46.0) 
-355.3 
(104.4)* 
AQLQ          
    Activity limitation 4.6 
(0.4) 
4.2 
(0.4) 
-0.4 
(0.4) 
4.4 
(0.4) 
4.5 
(0.4) 
0.0 
(0.3) 
4.2 
(0.5) 
4.5 
(0.6) 
0.4 
(0.2) 
    Emotional function 4.9 
(0.3) 
4.4 
(0.5) 
-0.4 
(0.4) 
4.7 
(0.4) 
4.5 
(0.4) 
-0.1 
(0.4) 
4.2 
(0.5) 
4.5 
(0.6) 
0.3 
(0.1) 
    Symptoms 4.7 
(0.3) 
4.3 
(0.5) 
-0.4 
(0.3) 
4.4 
(0.4) 
4.4 
(0.4) 
0.0 
(0.3) 
4.2 
(0.5) 
4.3 
(0.5) 
0.2 
(0.1) 
    Environmental   
    stimuli 
4.8 
(0.3) 
4.4 
(0.4) 
-0.4 
(0.4) 
4.5 
(0.4) 
4.6 
(0.4) 
0.0 
(0.3) 
4.4 
(0.5) 
4.6 
(0.6) 
0.2 
(0.1) 
    Total score 4.9 
(0.3) 
5.2 
(0.3) 
0.3 
(0.1)* 
4.7 
(0.3) 
5.1 
(0.3) 
0.4 
(0.1)* 
4.6 
(0.5) 
4.8 
(0.5) 
0.2 
(0.1) 
†Change from baseline presented as doubling dilutions 
* Significant change from baseline (P<0.05) 
Abbreviations: ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, 
peak expiratory flow rate; PD10, provocative dose of mannitol causing a 10% decrease in FEV1, BL, baseline. 
Data presented as arithmetic mean (SEM) unless otherwise indicated. ‡ presented as geometric mean (SEM). Baseline 
values are shown after washout before each randomised treatment period. Post step down measurements were made 2 
weeks after the final dose reduction. 
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Table 4: Individual data for subjects who had a worsening in dd-shift post 
step-down 
 
 Change from baseline 
 
Subject 
no 
DD 
shift 
FEV1 (% 
predicted) 
FVC (% 
predicted) 
PEF(% 
predicted) 
Change 
in FENO 
(% 
change) 
Total 
AQLQ 
score 
Drug 
dose 
(mg) 
2 -2.7 -17 -14 -16  0.7 200 
7 -3.5 -2 1 -9  0.7 750 
8 -2.2 -7 -7 -7  0.1 200 
11 -1.5 -13 -5 -3  -0.3 0 
13 -2.8 -9 -7 -2  0.0 200 
30 -2.3 -7 9 -2  -0.3 0 
31 -2.0 -3 4 -9  0.1 400 
32 -1.2 4 8 -2  0.4 250 
36 -3.4 8 29 2  0.7 0 
53 -1.1 -5 -9 0 70.6 0.0 200 
54 -1.1 0 -6 -3 79.3 0.0 400 
56 -4.9 15 24 0 28.6 -0.4 1750 
57 -1.8 5 -3 13 0.0 -0.4 500 
62 -3.7 -8 -12 -22  0.3 1250 
78 -3.2 4 -15 5  0.0 200 
79 -2.6 -12 -4 2 -34.8 0.9 0 
80 -2.6 -13 -9 4 -34.2 0.0 0 
91 -3.0 -6 -5 -13 2.0 0.9 200 
110 -3.8 0 15 4  0.5 250 
147 -2.2 -8 -12 -2 59.0 0.1 200 
Mean 
(SEM) 
-2.58 
(0.22) 
-3.65 
(1.78) 
-0.90 
(2.75) 
-3.00 
(1.78) 
21.21 
(16.03) 
0.19 
(0.09) 
347.50 
(99.31) 
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Table 5: Individual data for subjects who had an improvement in dd-shift 
post step-down 
 
 Change from baseline 
Subject 
no 
DD 
shift 
FEV1 (% 
predicted) 
FVC (% 
predicted) 
PEF(% 
predicted) 
Change 
in FENO 
(% 
change) 
Total 
AQLQ 
score 
Drug dose 
(mg) 
40 1.1 7 6 8 45.0 0.5 600 
4 2.2 -14 -13 33  -0.1 0 
10 1.4 -1 -9 -2  0.2 1000 
16 1.2 -7 -13 -2  0.5 200 
18 1.2 -7 -8 -6  1.4 0 
23 2.9 -5 -5 11  -1.4 200 
24 1.8 -4 -2 -10  0.1 200 
25 6.2 -16 3 -11  0.5 200 
26 6.5 0 -6 0  1.3 200 
33 2.3 -10 13 -10  -0.8 600 
34 1.4 -1 8 12  0.7 400 
35 1.8 8 17 3  -0.3 200 
37 5.9 1 5 -5 50.0 0.1 200 
39 7.8 19 10 18  1.1 400 
42 3.2 -8 3 11   0 
43 2.4 3 2 1 -31.0 0.1 600 
46 3.1 -2 -2 16 -37.5 0.3 200 
46 3.1 -2 -2 16 -37.5 0.0 200 
47 3.7 -12 -17 -10 -14.3 -0.7 200 
50 1.4 1 -5 21 16.1 0.8 0 
58 1.2 -4 -1 1 -21.1 -0.8 200 
61 2.8 -5 -5 -8  1.5 600 
64 2.2 1 2 3 11.1 2.1 0 
65 1.7 2 0 -2 -52.9 0.0 500 
67 2.4 -2 -4 -3 10.0 0.3 400 
72 1.7 0 -5 -2 17.5 0.2 200 
74 1.9 4 29 -5 -7.9 0.9 200 
82 5.7 5 4 22  0.1 400 
90 2.9 -4 2 10 -16.7 0.2 250 
92 2.8 -1 1 3 -20.0 0.3 200 
99 2.6 10 6 -3 35.7 1.3 200 
100 2.2 -5 -3 -11 46.7 0.6 0 
106 2.2 -23 -21 -12 26.7 -0.1 0 
108 3.3 -9 -3 -11 -59.2 0.3 400 
117 2.7 9 28 -6 64.7 1.0 0 
120 2.8 9 -2 2 3.6 -0.3 0 
121 1.1 -12 -14 -2 -29.7 0.2 800 
Mean 
(SEM) 
2.78 
(0.27) -2.0 (1.3) 
-0.03 
(1.73) 
1.89 
(1.80) 
13.45 
(11.63) 
0.33 
(0.12) 268.92 (39.86) 
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Figure 4: Shift in FENO post step-down 
 
Figure 5: Correlation between doubling dilution shift and % change in FENO 
(r= -0.14, P=0.27) 
Fig 4. Change in exhaled nitric oxide (i.e. post step down -  pre step down) for each individual. The biological variability for 
nitric oxide lies within +/- 30%, so individuals lying within +30% and -30% (depicted by interrupted line) can be assumed 
to show ‘no change’ in NO post step-down (43%). Individuals with >+30% change can be assumed to show a rise in NO 
(worsening inflammation) (36%). Those with a <-30% change demonstrated a decrease in NO (improvement in 
inflammation) (21%).   
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Lung function  
 
Mean (SEM) baseline spirometry values were: FEV1 of 86.2% (1.5), FVC 91.6% 
(1.4), PEF 90.2% (1.7). FEV1 post step-down was 84.5 % (1.5), p < 0.05. FVC 
and PEF showed no significant change post step-down (91.5 % (1.4), and 90.0 
% (1.6), p = 0.87). 
 
AQLQ 
 
The median (inter-quartile range) mini-AQLQ composite scores pre and post step 
down were 5.7 (4.7 – 6.3) vs. 6.1 (5.3 – 6.5) respectively, representing a median 
improvement of 0.4, p <0.001.  
 
Discussion 
The present study demonstrates that supervised step down of ICS in a 
community setting can be achieved without any worsening of airways 
inflammation, as measured by FENO and mannitol challenge. This is in 
agreement with work carried out by Leuppi et al, who determined that the 
majority of patients could undergo a halving of their ICS dose without 
exacerbation [41]. We hypothesize that this may be due to improved adherence 
with supervised treatment during step down. Whilst a significant reduction in ICS 
could also be achieved if patients had initially been over treated, there should 
have been a commensurate increase in airways inflammation on withdrawal of 
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treatment, as has been reported elsewhere [78]. In the absence of such a 
change we feel that enhanced adherence is the logical conclusion. Adherence 
with asthma medications, particularly ICS, is known to be poor [195]. Patient-
reported adherence rates are as low as 38% [196, 197], and actual drug use is 
often even lower. Rand et al compared patient-reported adherence to change in 
canister weight and demonstrated that although 73% of participants reported 
using their ICS three times daily, this was only confirmed in 15% by canister 
weight [197]. 
 
The commonest reasons to explain non-adherence include: patients’ perception 
of their disease; such that they only take ICS when they become unwell as 
opposed to using it as ‘preventer’ therapy [196]; and concerns over potential side 
effects [195]. There is evidence to suggest that regular disease monitoring 
addresses these issues and leads to benefits such as improved inhaler technique 
and adherence [198, 199]. In this regard, patients in the present study were 
reviewed fortnightly and may have additionally benefited from the positive 
reinforcement of regular spirometry, peak flow and symptom monitoring. Whilst 
this high level of supervision is too intensive to be reproduced in primary care, it 
suggests that the widespread practice of annual review may be too infrequent to 
adequately educate and support our asthmatic population. 
 
Control of airways inflammation is of critical importance in asthma, as if left 
uncontrolled long-term it can lead to airway remodelling, even in asymptomatic 
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patients [31]. Furthermore, studies in which asthma therapy was titrated to 
achieve suppression of surrogates of inflammation demonstrate that 
exacerbation rates can be reduced by up to five-fold, when compared with 
treatment guided by symptoms and lung function alone [37, 38]. To address this, 
the present study utilised bronchial challenge with mannitol and FENO as suitable 
surrogates of asthmatic inflammation. Bronchial challenge tests are traditionally 
used to diagnose the presence of AHR, and to monitor response to treatment 
[200]. AHR is a key feature of persistent asthma, which is considered to correlate 
well with underlying airways inflammation [21]. All participants in this study were 
required to exhibit AHR to mannitol as one of the inclusion criteria. Hence, we 
believe this makes an alternative diagnosis to asthma such as eosinophilic 
bronchitis unlikely. Nonetheless, we appreciate that AHR may vary over time, 
often increasing during exacerbations and decreasing during treatment with anti-
inflammatory therapy [200].  
 
Mannitol challenge is a relatively novel indirect bronchial challenge test, which is 
known to be reproducible, and to correlate well with other surrogate markers of 
airways inflammation [136, 201]. Unlike other challenge tests, it is portable, 
simple, and quick to perform, and therefore ideally suited for use in primary care. 
Moreover, mannitol is an indirect stimulus, which induces AHR by osmotically 
stimulating inflammatory cells to release mediators which constrict airway smooth 
muscle. Fardon et al showed that PD10 correlates well with PD15, allowing an 
abbreviated challenge to be utilised without loss of sensitivity, whilst exposing the 
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subject to less provocation agent [202].  The overall mean improvement 
observed in mannitol challenge (0.46 doubling dose shift in mannitol PD10) was 
statistically significant, but would not be considered clinically significant. 
Examination of change in PD10 in individual patients, as depicted in Figure 3, is 
more revealing than the magnitude of the overall mean shift for the group as a 
whole. A change in mannitol PD10 of +/- 1 doubling dose in a given patient is 
within the limits of intra-individual biological variability. Using these criteria we 
identified 31% of patients who had an improvement in PD10 (i.e. a change > +1 
doubling dose), 52 % who had no change (i.e. a change within +/- 1 doubling 
dose), and 17 % who had a worsening (i.e. change < - 1 doubling dose) when 
comparing pre vs. post step down (Fig 3). In other words it was evident that the 
majority of patients (i.e. 81%) either had no change in AHR or improved. A 
minority of patients showed a worsening of AHR, which would be expected if 
subjects were initially adherent with treatment. A rate of 19% is consistent with 
adherence rates reported in previous studies [197].  A comparison of the 
baseline and post step down characteristics of these three groups revealed no 
significant differences in terms of spirometry, FENO or ICS dose. Analysis of 
mannitol PD10 showed that those who improved post step down had significantly 
greater bronchial hyper-reactivity at baseline than the other two groups. Those 
who worsened post-step down had significantly more bronchial hyper-reactivity at 
the end of step down. This correlates well with data obtained by Leuppi et al who 
determined that developing AHR to mannitol during dose-reduction was a good 
predictor of step-down failure [41]. Changes in AHR correlated very poorly with 
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changes in symptoms, as subjects who either “improved” or had “no change” in 
AHR had statistically significant, albeit clinically insignificant, worsening of their 
symptom scores, whereas those who had a “worsening” had no change (table 3). 
Individual data for those with “improved” and “worsened” AHR post-step down 
are included in tables 4 and 5.  
 
FENO is an established surrogate of airways inflammation in asthma [59] and 
correlates closely to sputum eosinophil counts [60, 203] and mucosal 
eosinophilic markers [204, 205]. When used on its own as an inflammatory 
surrogate to titrate ICS, the results have been disappointing [76], indeed, a 
recent Cochrane review has determined that FENO cannot be recommended for 
tailoring the dose of inhaled corticosteroids in clinical practice [206]. However, its 
rapid response to changes in inflammatory status [71] and acute sensitivity to 
ICS make it helpful when used in conjunction with other measures. It has been 
used as an early predictor of under-treatment (predicting exacerbation with FENO 
and dose reduction) [78]. In this regard our cohort showed no net change in FENO 
during step-down. If the biological variability of FENO is assumed to be <30% 
[207]: 64% of subjects demonstrated no significant increase in FENO (figure 4), 
These results correlate well with those of Leuppi et al who found no significant 
increase in FENO during dose reduction or exacerbation [41]. Similarly, we found 
no correlation between doubling dilution shift in mannitol challenge and % 
change in FENO (r= -0.14, P=0.27). We know from previous studies that 200µg 
BDP is sufficient to suppress FENO, even in the presence of persisting AHR, 
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which may explain the disconnect with AHR, and it’s lack of response in these 
circumstances [200]. However, when this observation is taken in conjunction with 
mannitol AHR, we believe it offers good evidence that airway inflammation was 
well controlled in this study, despite the relatively rapid rate at which ICS was 
reduced. Larger studies with a longer duration of follow-up are required to 
determine whether these improvements are maintained long-term. 
 
Despite evidence to support the use of inflammatory markers in asthmatic 
assessment, current clinical practice dictates that ICS should be adjusted 
according to patient reported symptoms and spirometry [8]. In this respect, we 
observed a statistically significant improvement in quality of life scores, despite 
the reduction in ICS dose. There were no clinically significant changes in 
spirometry. 
 
Treatment of asthmatic patients in primary care has been driven by results 
obtained from randomised controlled trials, during which treatment compliance is 
reinforced. These therefore, do not reflect a real life scenario. The current paper 
highlights the potential pit falls of extrapolating data to a primary care setting 
where compliance rates may be poor. Perhaps there is a need for the 
development of more effective strategies which support asthmatics to use 
established therapies correctly rather than continue a culture of escalating 
therapy, without frequent review and step-down if appropriate. Improvement of 
asthma care in the community may require an approach that includes more 
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effective supervision and targeted assessment to enhance adherence and 
reduce airways inflammation.  
 
In conclusion we have demonstrated that achieving a significant reduction in ICS 
dose is possible, without any deterioration in surrogate markers of inflammation, 
or quality of life. This apparent disconnect between reduction in anti-inflammatory 
therapy and measured inflammation may reflect enhanced adherence through 
frequent supervision.  
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Critique 
This is the first study to utilise mannitol challenge in a community setting, 
confirming that it is safe and easy to use. Furthermore, we have demonstrated 
that inhaled steroids can be safely stepped down in general practice without a 
concomitant increase in airway inflammation. Whilst these results are 
encouraging, we would not advocate the back-titration of inhaled steroids in all 
community-based patients. We recognise that this observational study has 
several limitations, namely to do with study design: Firstly, we were unable to 
follow subjects up long term to ensure that their inflammation remained 
suppressed. Secondly, measuring FENO pre and post step-down was only 
introduced once recruitment had commenced; consequently FENO measures are 
not available for all subjects. Thirdly, as this was an observational study there 
was no control group. In order to verify our suspicions that the improvements 
seen were due to enhanced compliance we would like to repeat the study in a 
prospective fashion measuring canister weight. This study suggests that 
concordance with medication improves in patients who are entered into a clinical 
trial, indicating that perhaps a more targeted approach to asthma therapy, which 
includes more effective supervision, alongside the use of an appropriate 
“inflammometer”, such as mannitol (so patients can actually see an improvement 
following treatment) may be beneficial. A prospective study investigating the 
benefits of such a treatment strategy, as well as evaluating the benefits of 
mannitol as a tool for titrating asthma therapy, is required. 
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Part b:  Determining which outcomes provide  
sufficient assay sensitivity for detecting dose 
response effects on airway and systemic 
markers. 
 
 
 
Study aims: 
 
1.      To compare the pharmacodynamic characteristics of 
Hydrofluoroalkane (HFA) and Chlorofluorocarbon (CFC) Budesonide 
utilising methacholine challenge as the primary endpoint in a cross 
over study. 
2.      To determine which outcomes measures provide sufficient assay 
sensitivity for detecting dose response. 
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Pharmacodynamic Comparison of Hydrofluoroalkane and 
Chlorofluorocarbons Budesonide 
 
Introduction 
Inhaled corticosteroids (ICS) are the mainstay of treatment in persistent asthma 
[8, 192]. Budesonide is one of the most commonly prescribed ICS, and has been 
used effectively in the long-term management of persistent asthma for many 
years. A suspension aerosol formulation with chlorofluorocarbon (CFC) as the 
propellant was previously available for delivery of budesonide via pressurized 
metered-dose inhaler (pMDI). In recent years CFCs have been implicated in 
damage to the ozone layer, and are due to be phased out in accordance with the 
Montreal Protocol [208]. Hydrofluoroalkane-134a (HFA) has been found to act as 
adequate propellant for pMDI delivery systems without the same deleterious 
environmental effects. Budesonide has therefore been re-formulated in 
suspension with HFA as the propellant. Two strengths of budesonide HFA pMDI 
(100µg and 200µg per actuation) have been developed. Determination of 
therapeutic equivalence is essential for new drug formulations. Pharmacokinetic 
studies have shown the two formulations to be bioequivalent [209]. The aim of 
this study is therefore to present pharmacodynamic data comparing HFA and 
CFC formulations of budesonide delivered via pMDI.  
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Methods 
This was a single-centre, randomized, open-label, crossover study (Figure 6). At 
screening, entry requirements were checked and informed consent was 
obtained. Participants were considered eligible if they were aged 18-65 years, 
and had a diagnosis of stable persistent asthma while receiving ≤1000µg 
beclomethasone dipropionate (BDP) or equivalent. Subjects were excluded if 
they were pregnant or lactating, had concomitant respiratory disease or had been 
prescribed oral steroid or a change to their asthma therapy in the three months 
preceding the screening visit. Eligible patients then entered a step-down phase 
during which long-acting β2-agonists, theophyllines, cromones and leukotriene 
inhibitors were stopped. Participants then had their steroid dose gradually 
reduced in a manner similar to previously published studies from our department 
[210]. They then entered a 1-week pre-treatment (ICS-free) washout period. A 
methacholine PC20 of ≤4mg/ml and FEV1 ≥60% predicted post step-down was 
required for entry into the treatment period. Subjects not meeting the entry 
requirements at the end of this phase were given a further 1-2 weeks of washout.  
 
The study consisted of two treatment periods. Subjects received low-dose 
(200µg/day) budesonide, either via CFC or HFA pMDI, for 2 weeks followed by a 
further 2 weeks of medium-dose (800µg/day) budesonide. Participants then 
crossed over treatment arm, effectively acting as their own control. Treatment 
periods were separated by a 1–2 week washout period. Subjects were required 
to be within 1 doubling dilution of baseline methacholine PC20 at the end of 
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washout. During all study visits participants underwent pulmonary function testing 
(including FEV1, forced vital capacity, PEF, and FEF25-75%), FENO, and 
methacholine challenge. Methacholine challenge was performed using the five-
breath dosimeter technique in accordance with American Thoracic Society (ATS) 
recommendations [183]. The PC20 (provocative dose required to cause a 20% 
drop in FEV1) was calculated using log-linear interpolation of the dose response 
[123]. FENO was measured in line with current ATS recommendations using a 
NIOX analyzer (NIOX® Nitric Oxide Monitoring System, Aerocrine AB, Solna, 
Sweden) [194]. Subjects were asked to withhold short-acting β2-agonists and 
caffeine for 6 hours prior to study visits, and all study visits took place at the 
same time of day. At each visit inhaler technique was checked and peak 
flow/symptom diaries were reviewed. Subjects were asked to rate their asthma 
symptoms twice daily. Daytime scores were recorded each evening, and night 
time scores were recorded on waking. The following rating scales were used: 0 = 
no asthma symptoms, 1= mild (easily tolerable) symptoms, 2= moderate 
(interferes with normal activities/sleep) symptoms, 3= severe (prevents normal 
activities/sleep). Overnight (i.e. 10pm to 8am) urine was collected for cortisol and 
creatinine the night prior to study visits. Urinary cortisol was measured using a 
commercial radioimmunoassay kit (DiaSorin Ltd, Wokingham, Berkshire, UK). 
The intra-assay coefficient of variation was 4% and the inter-assay coefficient of 
variation was 8%. Urinary creatinine was measured on a Cobas-Bio auto 
analyzer (Roche Products, Welwyn Garden City, UK). The intra-assay and inter-
assay coefficients of variation were 4.6% and 3.0% respectively. 
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Statistical analysis 
The primary outcome measure was change in methacholine PC20 from pooled 
baseline (i.e. post run-in or washout periods) for each treatment. Any non-
Gaussian data were log transformed prior to analysis. Gaussian data were 
assessed using analysis of variance (ANOVA). To compare the relative 
microgram potency of the two devices, Finney’s bio-assay was used to estimate 
the relative potency. The relative potency is defined as the ratio of doses 
estimated to provide the same effect. Fieller’s theorem allowed for the calculation 
of 95%CIs for the relative potency [211]. The 95%CI for relative potency was 
required to be contained within equivalence limits of +/-50%  (i.e. a ratio of 0.5-
2.0 fold). Sample size was based on the results of a previous study by Lipworth 
Figure 6: Study flow chart 
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et al [212].  A comparison was also made between the two formulations at each 
dose using the EMEA equivalence limits of +/- 33%  (ratio of 0.67-1.50). 
 
Other outcome variables were considered as secondary and were analyzed 
using a similar model but without log transformation (except FENO and OUCC).  
Results 
133 adults with mild-moderate asthma were screened; 99 were randomized, and 
68 completed the study according to protocol. The demographic characteristics 
of subjects randomized to first treatment at screening are given in Table 4. 
Reasons for non-randomization included: FEV1 ≤60% predicted (n=4); PC20 
>4mg/ml (n=13); instability in step-down (n=8); voluntary discontinuation (n=8); 
lost to follow-up (n=1). During the study 31 patients were withdrawn for the 
following reasons: failure to wash-out (n=14); worsening of asthma (n=10); 
personal reasons (n=4); adverse events (n=3). Both treatment sequences were 
well matched for age, gender, height, weight and race. 
 
Primary efficacy variable 
There were no significant differences between baseline values prior to each 
treatment (i.e. after each wash-out period) for any of the primary or secondary 
outcome measures (table 6). Therefore, all analyses were performed compared 
with pooled baseline values. There was also no significant difference in 
compliance between the two treatments, or between doses.  
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Table 6: Baseline characteristics prior to first treatment with HFA and CFC 
pMDI 
Variable Before HFA Before CFC 
Age (years)* 40.0 (14.13) 
 
39.5 (14.65) 
Sex (male:female) 20:24 19:26 
Race (Caucasian: Black: Oriental: Other) 42:0:1:1 42:0:0:3 
Methacholine PC20 (mg/ml) 0.68 (0.33 – 1.03) 0.62 (0.31 – 0.93) 
FENO (ppb) 34.42 (23.62 – 45.22) 34.76 (25.13 – 44.39) 
Spirometry   
        FEV1 (L) 2.86 (2.62 – 3.10) 2.80 (2.55 – 3.05) 
        FVC (L) 3.83 (3.50 – 4.16) 3.75 (3.42 – 4.08) 
        FEF25–75 (L) 2.47 (2.15 – 2.79) 2.42 (2.09 – 2.75) 
        PEF (L/min) 445.25 (408.97 – 481.53) 438.80 (402.54 – 475.06) 
Cortisol/ creatinine ratio (nmol/ mmol) 3.49 (2.40 – 4.58) 3.50 (2.35 – 4.65) 
Abbreviations: FEF25–75, forced expiratory flow between 25% and 75% of forced vital capacity; FEV1, forced expiratory 
volume in 1 second; PC20, concentration of methacholine required to produce a 20% decrease in FEV1; PEF, peak 
expiratory flow. 
Data are presented as geometric mean (95%CI) unless otherwise indicated. Baseline values are shown after washout 
before each randomized treatment period. 
* Data are presented as arithmetic mean (SD).  
 
The number of patients who had both baseline and post-treatment data 
measured for the primary outcome variable (methacholine PC20) was n=80 for 
low-dose HFA, n=79 for medium-dose HFA, n=79 for low-dose CFC, and n=78 
for medium-dose CFC. Significant improvements in methacholine PC20 were 
observed following treatment with both budesonide HFA and CFC formulations. 
The geometric mean shift from baseline following treatment with 200µg and 
800µg budesonide HFA pMDI was 1.55-fold (95%CI 1.34–1.78) and 2.16-fold 
(95%CI 1.88–2.50), respectively. Similar changes were observed following 
treatment with 200µg and 800µg budesonide CFC: 1.67-fold (95%CI 1.45–1.93) 
and 2.08-fold (95%CI1.80–2.40), respectively. Both formulations demonstrated a 
significant dose response between 200µg and 800µg (Table 7). The geometric 
mean difference in PC20 shift between 800ug vs. 200ug budesonide was 1.24 
(95%CI 1.02–1.51; P=0.03) for CFC and 1.40 (95%CI 1.15–1.67; P=0.0008) for 
HFA. There were no statistically significant differences for either dose between 
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the two propellant types (Table 8): 200ug/day: HFA vs. CFC 0.93 (95%CI 0.76–
1.13; P=0.44), 800ug/day: HFA vs. CFC 1.04 (95%CI 0.85–1.27; P=0.70). Both 
of these 95%CI were contained within +/- 33% equivalence limits (ratio of 0.67-
1.50) 
 
The log-linear dose-response curves for HFA and CFC were parallel and the 
common slope was highly statistically significant (p<0.0001). The estimated 
relative potency between HFA and CFC budesonide, for the full analysis set 
(n=89), was 1.10 (95%CI 0.49–2.66). The 95% CI was not completely contained 
within the +/- 50% equivalence limits of 0.5–2.0.   
 
Secondary efficacy/safety variables 
There were statistically significant differences between medium and low doses of 
budesonide for both CFC and HFA formulations (except morning rescue 
medication and pulmonary function) (Table 7). There were no statistically 
significant differences when comparing low-dose budesonide CFC and HFA, and 
medium-dose budesonide CFC and HFA (Table 8). Relative potencies were 
calculated for secondary outcomes that were close to unity (Table 9). Only three 
patients discontinued following adverse events: two lower respiratory tract 
infections (CFC formulation); one oral candidiasis (HFA formulation). No serious 
adverse events were reported in this study. 
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Table 7: Comparison between doses for all outcomes with each formulation 
 
800µg vs. 200µg HFA 800µg vs. 200µg CFC Outcome 
Mean 95% CI 
 (P value) 
Mean 95% CI 
 (P value) 
Methacholine PC20  ratio  1.40 1.15 – 1.70 (<0.01) 1.25 1.02 – 1.51 (0.03) 
FENO ratio  0.86 0.80 – 0.93 (<0.01) 0.89 0.82 – 0.96 (<0.01) 
Spirometry     
        FEV1 (L) 0.02 -0.02 – 0.07 (0.27) 0.01 -0.03 – 0.06 (0.51) 
        FVC (L) 0.01 -0.03 – 0.06 (0.55) -0.01 -0.05 – 0.04 (0.78) 
        FEF25–75 (L) 0.04 -0.05 – 0.12 (0.38) 0.04 -0.04 – 0.13 (0.30) 
        PEF (L/min) 2.95 -5.11 – 10.99 (0.47) -2.83 -10.93 – 5.23 (0.49) 
OUCC ratio  0.67 0.54 – 0.83 (<0.01) 0.80 0.64 – 0.99 (0.04) 
Diary card data*     
        Morning PEF (L/min) 11.31 4.76 – 17.86 (<0.01) 9.37 2.75 – 15.99 (0.01) 
        Morning rescue medication  
        (no. puffs) -0.26 -0.41 - -0.11 (<0.01) -0.12 -0.27 – 0.04 (0.13) 
        Evening rescue medication  
        (no. puffs) -0.24 -0.43 –  -0.05 (0.01) -0.20 -0.39 – 0.01 (0.04) 
        Total rescue medication  
         (no. puffs) -0.48 -0.81 - -0.16 (<0.01) -0.34 -0.67 - -0.02 (0.04) 
Symptoms (0–3)*     
        Morning asthma symptoms -0.11 -0.18 - -0.04 (<0.01) -0.09 -0.16 - -0.02 (0.01) 
        Evening asthma symptoms -0.15 -0.22 - -0.08 (<0.01) -0.09 -0.17 - -0.02 (0.01) 
        Total asthma symptoms -0.26 -0.39 - -0.13 (<0.01) -0.19 -0.32 - -0.05 (<0.01) 
Abbreviations: FEF25%–75%, forced expiratory flow between 25% and 75%; FEV1, forced expiratory volume in 1 second; 
PEF, peak expiratory flow;OUCC overnight urine cortisol/creatinine  
Data for PC20 ,FENO and OUCC shown as the geometric mean ratio between 800 vs. 200 , for other outcomes the 
differences between doses are given in the units specified .  
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Table 8: Comparison between formulations for all outcomes at each dose 
 
HFA 200µg vs. CFC 200µg HFA 800µg vs. CFC 800µg Outcome 
Mean 
95% CI 
(P value) Mean 
95% CI 
(P value) 
Methacholine PC20 (mg/ml) 0.92 0.76 – 1.13 (0.44) 1.04 0.85 – 1.27 (0.71) 
FENO (ppb) 0.99 0.91 – 1.07 (0.78) 0.96 0.89 – 1.05 (0.38) 
Spirometry     
        FEV1 (L) -0.02 -0.06 – 0.02 (0.34) -0.01 -0.05 – 0.03 (0.62) 
        FVC (L) -0.02 -0.06 – 0.03 (0.42) 0.00 -0.04 – 0.05 (0.97) 
        FEF25–75 (L) -0.05 -0.13 – 0.04 (0.29) -0.05 -0.14 – 0.03 (0.23) 
        PEF (L/min) -2.26 -10.57 – 6.06 (0.41) 3.52 -4.87 – 11.91 (0.41) 
OUCC      
        Cortisol/ creatnine ratio  
        (nmol/ mmol) 1.04 0.83 – 1.31 (0.74) 0.87 0.69 – 1.10 (0.24) 
        Cortisol (nmol/L) 0.99 0.78 – 1.28 (0.99) 0.86 0.67 – 1.11 (0.25) 
Diary card data*     
        Morning PEF (L/min) -2.19 -8.61 – 4.23 (0.50) -0.23 -7.05 – 6.56 (0.94) 
        Morning rescue medication  
        (no. puffs) 0.09 -0.06 – 0.24 (0.24) -0.05 -0.21 – 0.11 (0.56) 
        Evening rescue medication  
        (no. puffs) 0.06 -0.13 – 0.24 (0.56) 0.02 -0.18 – 0.21 (0.86) 
        Total rescue medication  
         (no. puffs) 0.19 -0.13 – 0.50 (0.25) 0.05 -0.29 – 0.38 (0.78) 
Symptoms (0–3)*     
        Morning asthma symptoms 0.002 -0.07 – 0.07 (0.95) -0.01 -0.08 – 0.06 (0.78) 
        Evening asthma symptoms 0.02 -0.05 – 0.09 (0.58) -0.04 -0.11 – 0.03 (0.30) 
        Total asthma symptoms 0.02 -0.11 – 0.15 (0.74) -0.05 -0.18 – 0.09 (0.47) 
Abbreviations: CI, confidence interval; FEF25-75,  forced expiratory flow between 25% and 75%; FEV1, forced expiratory 
volume in 1 second; OUCC, overnight urinary cortisol-creatinine ratio; PC20, concentration of bronchial provocation agent 
causing a 20% decrease in forced expiratory volume in 1 second; PEF, peak expiratory flow. 
Data for PC20 ,FENO and OUCC shown as the geometric mean ratio between HFA vs. CFC at either 200µg or  800µg 
doses. For other outcomes the differences between formulations are given in the units specified.   
 
 
 
Table 9: Summary of relative dose potency for budesonide  
 
Parameter Relative dose potency Estimate 95% Confidence interval 
PC20 HFA/CFC 1.104 0.489, 2.660 
Morning PEF * HFA/CFC 1.186 0.611, 2.523 
Morning asthma symptoms* HFA/CFC 0.949 0.413, 2.117 
Evening asthma symptoms* HFA/CFC 0.913 0.481, 1.681 
Total asthma symptoms* HFA/CFC 0.929 0.483, 1.740 
*From diary 
95%CI for relative dose potency was determined using Fieller’s theorem. 
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Discussion 
The aim of this study was to determine whether budesonide HFA and 
budesonide CFC pMDI were therapeutically equivalent. Suppression of airway 
hyper-responsiveness (AHR) to methacholine was selected as the primary 
endpoint as it is a characteristic feature of asthma, which varies over time, often 
increasing during exacerbations and decreasing during treatment with anti-
inflammatory medications [31]. AHR has been shown to correlate well with 
airways inflammation and to be a reliable surrogate of disease activity [34, 37]. 
Since asthma is an inflammatory condition and the role of ICS is to suppress 
inflammation, we feel that using methacholine challenge as a primary outcome is 
justified. The results of this study demonstrated that there was no significant 
difference in response between budesonide formulations in methacholine PC20 
with either 200ug or 800ug per day doses. The ratio of HFA to CFC was close to 
unity, and the 95%CIs lay within +/- 33% equivalence limits (0.67-1.50) at each 
dose level. We also demonstrated sensitivity of the methacholine bioassay, as 
there was a significant dose-response relationship for both formulations. 
Significant dose separation has previously been reported using methacholine 
PC20 with 100µg vs. 500µg fluticasone propionate [213]. The common slope for 
the overall log dose-response relationship was highly significant, demonstrating 
that the doses selected coincided with the steep part of the dose-response curve 
for BHR. The 95%CIs for the relative dose potency ratio of HFA vs. CFC were 
close to unity at 1.10, however, the 95%CI (0.49–2.66) was outside of the  +/-
50% limits of 0.5-2.0 [212]. Comparable results have been shown in a similar 
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dose-response study published previously from our own laboratory [212]. It could 
be argued that the change observed in the step up from 200µg to 800µg could be 
a time effect, however we feel this is extremely unlikely. Sovijarvi et al found the 
doubling dilution difference between fluticasone and placebo to be 1.19, 1.33 and 
1.27 after 72 hours, 2 weeks and 4 weeks respectively, indicating that near 
maximal response in methacholine PC20 is seen after 2 weeks treatment [214]. 
The differences observed in the present study are too large to be due to a time 
effect alone. FENO is another reliable surrogate of airway inflammation [59, 60, 
203]. Results revealed no significant difference between products, indicating that 
airway inflammation was equally controlled by both formulations.  
 
This improvement in airway inflammation was mirrored by an improvement in 
diary data, including symptoms and rescue medication. All measured outcomes, 
with the exception of spirometric measures, demonstrated a significant dose-
response relationship for budesonide with both the HFA and CFC formulations. 
Comparison of HFA and CFC formulations at each dose demonstrated no 
significant differences between products for any measure.  The lack of detectable 
dose-response for spirometric measures is likely due to our patients having mild 
to moderate asthma with relatively well-preserved airway calibre and little room 
for improvement. Previous studies have successfully demonstrated small, 
clinically insignificant, improvements in lung function within this time frame [200]. 
Spirometric indices are known to be relatively insensitive measures for assessing 
response to ICS in mild-to-moderate persistent asthmatic patients [147], studies 
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utilising these as primary endpoints have typically required large numbers of 
patients with prolonged follow-up [215]. Despite these issues current EMEA 
guidelines still recommend the use of spirometry as the primary outcome when 
determining the equivalent efficacy of ICS. Additionally, they recommend the use 
of a parallel-group study design, which requires careful matching of study groups. 
This raises further problems due to the inherent heterogeneity of asthma. The 
study design is also far more robust provided reliable, repeatable endpoints are 
used. The only potential concern regarding crossover studies is unequal carry-
over of steroid effect between treatment periods. In this respect, for all endpoints 
we found no important differences between the respective pre-treatment baseline 
values at run-in and washout periods.  
 
In order to be considered equivalent products also need to demonstrate similar 
safety profiles. HPA-axis suppression has been shown to be one of the most 
sensitive markers of systemic bioavailability for ICS [216]. It has also been used 
as a surrogate marker for potential adverse effects in other tissues. In this 
respect we found no significant difference between formulations at either dose. 
Furthermore, assay sensitivity was demonstrated in terms of a significant dose 
response between 200 and 800ug/day for levels of OUCC. A review of adverse 
events also revealed no significant differences between the two products.  
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Conclusion 
In conclusion, pharmacodynamic assessments of HFA vs. CFC pMDI 
formulations of budesonide have demonstrated therapeutic equivalence in terms 
of airway efficacy and systemic effects. This suggests in turn that both products 
were therapeutically interchangeable when used in clinical practice on a puff per 
puff basis. 
 
Critique 
This was an extremely well designed study, which utilised a reproducible primary 
endpoint and a robust study design. Furthermore, it included measuring canister 
weight as a measure of compliance.  
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Chapter 4: Tailoring 
treatment according to 
clinical asthma 
phenotype  
 
 
Part a: Smoking asthmatics 
 
 
Study aims: 
1. To evaluate the benefits of adding a long-acting ß-2 agonist to low dose 
steroid vs. doubling the dose of steroid in smoking asthmatics, and 
compare this to non-smoking asthmatics. 
2. To dissect the underlying mechanism by employing both methacholine 
and mannitol challenge.   
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Fluticasone/ Salmeterol combination confers benefits in 
smoking asthmatics 
 
Introduction  
Smoking is known to greatly increase the morbidity and mortality associated with 
asthma [149-151]. Asthmatic smokers are reported to have poorer symptom 
control [150] an accelerated decline in lung function over time [149], and more 
emergency department visits and hospitalizations than non-smoking asthmatics 
[151]. The reasons for this are two-fold: firstly smoking has been associated with 
increased airway inflammation and airway hyper-reactivity (AHR) [153, 156]. 
Secondly, smokers have been found to develop relative resistance to the 
beneficial effects of corticosteroids [157, 158, 160]. Whilst smoking cessation 
remains the single most effective intervention in this groups of asthmatics [217], 
many do not wish to consider this. Indeed, the prevalence of active smoking 
among asthmatics is the same as in the population at large, with rates ranging 
from 17-35% [218]. Alternative treatment strategies therefore need to be found. 
 
Tomlinson et al reported that treatment with high doses of inhaled corticosteroid 
(2000µg beclomethasone) reduced the disparity of response between smokers 
and non-smokers with asthma [159]. However, at high doses the risk of 
developing long term adverse effects from inhaled corticosteroid treatment (ICS) 
is increased [13]. Additional controller therapy is therefore required as add on to 
inhaled corticosteroid. In non-smoking asthmatics the addition of long-acting 
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beta-2 agonists (LABAs) have been shown to have a ‘steroid sparing effect’, and 
current guidelines recommend the addition of these if control is not achieved with 
200-800µg BDP.  
 
A recent subgroup analysis of the GOAL study [163] has suggested that smokers 
gained more benefit from fluticasone/salmeterol (FPSM) vs. a higher dose of FP 
in terms of reduction in exacerbation rates over 12 months. Expressing the 
magnitude of gains in a clinical context; for non-smokers it would take 25 years to 
prevent an exacerbation by taking fluticasone/ salmeterol (FPSM) vs. fluticasone 
(FP) alone, as compared to 6.7 years in smokers [164]. The greater benefit of 
FPSM in smokers was thought to be due to either relative resistance to the FP 
moiety on asthmatic inflammation, or greater benefit of the SM moiety on airway 
smooth muscle.  
 
The aim of the present study was to evaluate the effects on AHR of adding SM to 
FP or doubling the dose of FP, comparing smoking and non-smoking asthmatics. 
To further dissect the underlying mechanisms we employed two different 
bronchial challenges, methacholine which is a direct cholinergic smooth muscle 
stimulus, and mannitol that acts indirectly as an osmotic stimulus to release 
inflammatory mediators. 
 
 
 
	  89	  
Methods 
Participants  
38 mild to moderate persistent stable asthmatics (17 smokers and 21 non 
smokers) which met the following inclusion criteria were recruited: 18-65 years, 
stable persistent asthma with an FEV1 ≥ 60% (<30% PEF variablilty) on ≤ 
1000µg beclomethasone diproprionate (BDP) or equivalent, and a methacholine 
PC20 <4mg/ml at the end of run-in. Smoking asthmatics were required to have an 
FEV1 /FVC ratio of >70%. Those with a ratio <70% had to have a clear clinical 
history of asthma (diurnal variation in symptoms, symptoms in relation to 
exercise or allergen exposure, and lack of productive cough), and demonstrate 
either bronchodilator reversibility or diurnal variation in peak flow of >15% during 
the run-in period. Subjects with an exacerbation of asthma requiring oral steroids, 
a change in their asthma medications or hospitalisation in the preceding three 
months, or a respiratory tract infection in the preceding two months were 
excluded from the trial. Non-smokers were required to have never smoked or to 
have quit > 1 year previously. Smokers were given smoking cessation advice 
prior to being recruited for the trial. Only smokers who did not wish to stop 
smoking were recruited. They were requested to smoke a constant amount for 
the duration of the trial. 
 
Study design 
A single centre, randomised, double-blind, double-dummy, cross-over design 
was employed (see figure 6). The Tayside committee for medical research ethics 
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approved the study protocol, and all participants gave written informed consent. 
(eudraCT number 2008-001027-59, ClinicalTrials.gov Identifier NCT00830505). 
Subjects were required to stop all antihistamines, leukotriene receptor 
antagonists, and theopyllines for the duration of the study. Following an initial 
screening visit, all participants had their inhaled steroid dose halved at weekly 
intervals. They then entered a 1-2 week steroid free run-in period. Subjects who 
achieved a methacholine PC20 <4mg/ml, whilst remaining clinically stable, at the 
end of this period (baseline) were randomised to receive either FPSM (Cipla, 
Mumbai, India) 125/25µg pMDI two puffs BiD and placebo to FP (Neolab, UK) or 
active FP (Allen and Hanbury’s, Middlesex, UK) 250µg pMDI two puffs BiD and 
placebo to FPSM (Neolab, UK) for two weeks each. Both medications were 
administered through spacer devices (FP and placebo to FP via Volumatic® 
(GSK UK), FPSM and placebo to FPSM via Synchro-breathe® (Neolab, UK). In 
this regard we have previously shown that the fine particle dose and lung 
bioavailblity of FPSM are equivalent in vitro and in vivo for Neolab and GSK 
formulations when used via pMDI alone or with spacer [209] while the Synchro-
breathe and Volumatic produce a similar lung bioavailability for both moieties 
when used with FPSM via pMDI [219]. 
 
Each treatment period comprised of four study visits (see figure 7), which all took 
place at 2pm. On the first visit subjects underwent FENO measurement, 
spirometry, impulse oscillometry (IOS), methacholine challenge and blood was 
taken for eosinophil count, and ECP.  During visit 2, which was scheduled to take 
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place within 1-3 days of visit 1, subjects underwent mannitol challenge. 
Participants were required to carry out an overnight urine collection (10 hours) 
prior to attending for visit 2. Subjects were issued with their study inhalers at the 
end of visit 2.  Visit 3 was scheduled to be within 2 weeks of visit 2, and was 
identical to visit 1. Subjects continued their study medications until after their 
mannitol challenge at visit 4. Patients were required to keep peak flow diaries 
throughout the duration of the trial. Juniper Asthma Control Questionnaires 
(ACQ) was assessed at visits one and three. The treatment periods were 
separated by a 1-2 week steroid-free washout period. Subjects were required to 
be within 1 doubling dilution of their initial baseline methacholine PC20 to obviate 
any carry-over effect. 
 
Figure 7: Study diagram 
 
 
 
Screening  Step-down  
0-3 weeks 
Run-in 
1 (to 2) 
weeks 
FPSM 125/25µg 2 
puffs BD & 
placebo to FP 
FP 250µg 2 puffs 
BD & placebo to 
FPSM 
Wash-out  
1 (to 2) 
weeks  FPSM 125/25µg 2 
puffs BD & 
placebo to FP 
FP 250µg 2 puffs 
BD & placebo to 
FPSM 
    V1 V2+2a V3+3a V4+4a V5+5a 
Methacholine challenge, IOS, FeNO, Peak flow diary, spirometry, and eosinophils taken at V2, V3, V4, V5 
Mannitol challenge performed and urine for OUCC collected at V2a, V3a, V4a, V5a 
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Measurements 
FENO was recorded prior to any pulmonary function measurements using a Niox 
Nitric oxide analyser (Aerocrine 2 AB, Sweden) using ATS criteria [194]. 
Bronchial provocation testing using methacholine was performed using the five 
breath dosimeter technique in accordance with ATS recommendations to 
determine the PC20 threshold at baseline, after each treatment period, and after a 
corticosteroid free washout using log-linear interpolation [183]. Mannitol 
challenge was performed by administering spray-dry mannitol powder in gelatine 
capsule form (AridolTM Pharmaxis Ltd, Sydney, Australia), inhaled from a dry 
powder device (Osmohaler, Pharmaxis Ltd. French’s Forest, NSW, Australia) as 
previously described by Anderson and colleagues [136]. A Jaeger Masterscreen 
(Erich Jaeger, Hoechberg, Germany) was used to measure impulse oscillometry 
according to the guidelines [188]. Subjects supported their cheeks to reduce 
shunting, whilst impulses were applied for 30secs during tidal breathing. All 
manoeuvres were performed in triplicate and means taken. Adrenal suppression 
from systemic absorption of the inhaled corticosteroid treatment was assessed 
by measuring overnight 10h urinary free cortisol and creatinine ratios as 
described previously in literature [220].  
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Laboratory assays 
All assays were performed in duplicate in a blinded fashion. The serum ECP was 
measured using an enzyme linked immunoassay technique (UniCAP; Sweden 
Diagnostics UK Ltd, Milton Keyes, UK) with an intra-assay co-efficient of variation 
of 3.3%. Blood Eosinophil count was analysed using the Sysmex XE 2100 
Hematology auto analyzer. The urinary cortisol was measured using a 
commercial radioimmunoassay kit (DiaSorin Ltd, Wokingham, Berkshire, UK), 
which has no cross reactivity with fluticasone. The intra assay coefficient of 
variation was 4% and the inter assay coefficient of variation was 8%. Urinary 
creatinine was measured on a Cobas-Bio auto analyser (Roche Products, 
Welwyn Garden City, UK). The intra assay and inter assay co-efficient of 
variation was 4.6% and 3% respectively.  
 
Statistical analysis 
SPSS version 16 (SPSS Inc, Chicago, IL, USA) was used to carry out the 
statistical analysis. A sample size of 13 completed patients was estimated to give 
>80% power to detect a one doubling dilution (dd) difference  (minimal important 
difference) in methacholine PC20. The sample size estimations were supported 
by a previous studies from our department where the within subject standard 
deviation was 0.95dd [221]. Data were analysed within each group for patients 
who completed the crossover study per protocol. Any non-Gaussian data were 
log transformed prior to analysis. Gaussian data were assessed using paired and 
unpaired t-tests. Post run-in and washout were compared with a paired t-test to 
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demonstrate no carry over effect. The primary outcome measure was change in 
methacholine PC20 from respective baseline (i.e. post run-in or washout periods) 
for each treatment. All other outcomes were considered secondary. Response-
dose-ratios and ACQ were subjected to non-parametric analysis. Median 
differences were calculated within group using the Wilcoxon Rank-Sum test for 
paired data, and between group using the Mann-Whitney test. 
 
Results 
38 participants were randomised, of which 31 completed per protocol (16 non-
smokers, 15 smokers). 5 withdrew because of personal reasons, 2 had an FEV1 
<60% following wash-out. The mean (SEM) cotinine levels for non-smokers was 
4.37 (1.26) ng/ml, while all smokers had cotinine levels above 50 ng/ml. Baseline 
data for smokers and non-smokers are shown in table 10. 13/15 smokers had no 
baseline obstruction (i.e.FEV1/FVC ratio of >70%), the 3/15 who did not 
demonstrated >15% variability in PEFR. There was no significant difference in 
pre-treatment baseline vs. post washout values for the primary outcome. 
Similarly, there were no differences in pre-treatment baselines for all secondary 
outcomes, except FENO.  
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Table 10: Baseline characteristics 
Parameter Non smokers Smokers P value 
 
Methacholine PC20 (mg/ml) 
 
0.76 (0.34 – 1.69) 
 
1.02 (0.58 – 1.78) 
 
0.32 
Methacholine RDR (%/ml) † 6.05 (3.67- 46.80) 9.07 (3.39 – 17.81) 0.86 
Mannitol PD15 (mg) 158.8 (56.7 – 444.8) 123.6 (67.9 – 225.3) 0.68 
Mannitol RDR (%/mg) † 0.04 (0.03 - 0.12) 0.06 (0.04 - 0.21) 0.17 
Spirometry (% predicted)*    
     FEV1  82.7 (2.9) 87.9 (3.1) 0.24 
     FVC 98.4 (2.3) 99.4 (3.0) 0.49 
     PEF 92.6 (4.4) 98.4 (4.1) 0.58 
     FEF25-75 71.2 (2.4) 75.4 (2.4) 0.66 
FENO (ppb) 41.2 (26.4 – 64.4) 13.8 (8.9 – 21.4) 0.04 
Impulse oscillometry (kPa.L-1.s)*    
      R5 0.47 (0.08) 0.55 (0.14) 0.05 
      R20 0.37 (0.06) 0.44 (0.10) 0.03 
      R5-20 0.09 (0.02) 0.12 (0.02) 0.04 
      X5 -0.14 (0.02) -0.18 (0.02) 0.20 
AM peak flow (l/min)* 441 (23.3) 384 (22.6) 0.09 
PM peak flow (l/min)* 447 (21.5) 394 (24.1) 0.11 
ACQ† 1.1 (0.0-2.0) 1.9 (0.4-3.0) 0.03 
Reliever use (puffs/day) † 1.5 (0-5) 2.4 (0-5) 0.07 
Data presented as geometric mean (95% confidence intervals) unless otherwise stated 
* Data presented as mean (SEM) 
†Data presented as median (range) 
 
Primary outcome 
Both treatments led to similar significant improvements in methacholine PC20 
from pre-treatment baseline in non-smokers (see figure 8): FP produced a 
2.34dd shift (95%CI 1.43–3.26, P<0.01); FPSM produced a 2.72dd shift (95%CI 
1.54–3.91, P<0.01). There was no significant difference between treatments: 
0.22dd (95%CI -1.03–1.47) P=0.71. Smokers did not gain any benefit from FP as 
change from baseline: -0.04dd (-0.58–0.58) P=0.88. However, in smokers there 
was a 1.62dd (95%CI 0.99–2.24) P<0.01 improvement with FPSM. This equated 
to a 1.65dd (95%CI 0.92–2.39) difference between FPSM and FP, P<0.01. There 
was a significant difference in response to FP between smokers and non-
smokers: 2.54dd (95%CI 1.51–3.56) P<0.01, but not in response to FPSM: 
1.10dd (95%CI -0.13–2.34), P=0.08. When comparing smokers vs. non-smokers, 
there was a greater benefit from FPSM vs. FP 1.4dd (95%CI 0.01–2.8), P<0.05. 
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Methacholine response-dose-ratio (RDR) (% max fall in FEV1/cumulative dose) 
showed similar trends: non-smokers demonstrated median (inter-quartile range) 
4.69 (1.56–45.50, P<0.01) vs. 5.56 (3.02 – 50.08, P<0.01) %/ml improvements 
from baseline with FP and FPSM respectively. There was no significant 
difference between treatments (i.e. delta-FP vs. delta-FPSM), P=0.84. Smokers 
demonstrated 0.63%/ml (-4.30–5.46, P=0.80) vs. 5.44 %/ml (2.51–16.84, 
P<0.01) improvements from respective baseline with FP and FPSM respectively. 
There was a significant (P=0.02) difference between treatments (delta-FP vs. 
delta-FPSM). 
 
 
Figure 8: Change in methacholine PC20 from respective baseline 
 
 
 
Data presented as geometric mean (95% confidence intervals) 
 
	  97	  
Secondary outcomes 
 
Mannitol 
There were more mannitol non-responders amongst the non-smokers than 
smokers: 5/16 (31%) vs. 2/15 (13%). Non-responders at either baseline were 
therefore removed and not included in the per protocol analysis of PD15. In total 
11 non-smokers and 12 smokers were included in the per protocol analysis.  
Non-smokers gained significant benefit from both FP and FPSM: 1.41 dd (95%CI 
0.57–2.26), P<0.01, and 2.41dd (95%CI 1.56–3.26), P<0.01 respectively.  FPSM 
conferred a significantly greater improvement in mannitol PD15 in non-smokers 
than FP: a difference of 1.00dd (95%CI 0.23–1.78), P=0.02. Smokers had no 
significant improvement following treatment with FP: 0.59dd (95%CI -0.23–1.42), 
P=0.24, but FPSM caused a significant improvement: 1.20dd (0.34–2.07), 
P=0.02. There was a significant difference in response to FPSM between non-
smokers vs. smokers:  1.31dd (95%CI 0.21–2.41), P=0.02, but not in response to 
FP: 0.92dd (95%CI -0.15–2.00), P=0.09. Analysis of the RDR for mannitol 
revealed similar trends to PD15, but allowed the inclusion of all 31 cases: Non-
smokers demonstrated significant improvement from respective baseline with 
both treatments: median (inter-quartile range) 0.02 %/mg (0.003–0.07, P<0.01) 
and 0.04 %/ml (0.01–0.15, P<0.01) with FP and FPSM respectively. Smokers 
demonstrated significant improvement from respective baseline with FPSM: 0.02 
(0.01–0.80), P=0.03, but not with FP: 0.01 (-0.02–0.09), P=0.25. There were no 
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significant differences between treatments for either FP (P=0.22) or FPSM 
(P=0.51). 
 
Figure 9: Change in mannitol PD15 from respective baseline 
 
 
 
Data shown as geometric mean (95% confidence interval) 
 
Table 11: Change from respective baseline in challenge outcomes 
  Change from respective baseline with FP  
Change from respective 
baseline with FPSM 
(FPSM vs. FP) 
P value 
S -0.04 (-0.58 – 0.58) 1.62 (0.99 – 2.24)* <0.01 Methacholine 
(dd shift) NS 2.50 (1.43 – 3.26)* 2.72  (1.54- 3.91)* 0.71 
S 0.63 (-4.30 – 5.46) 5.44 (2.51 – 16.8)* 0.02 Difference in MCT 
RDR (%/ml) † NS 4.69 (1.56 – 45.50)* 5.56 (3.02 – 50.1)* 0.84 
S 0.59 (-0.23 – 1.42) 1.20 (0.34 – 2.07)* 0.17 Mannitol 
(dd shift) NS 1.41 (0.57 – 2.26)* 2.41 (1.56 – 3.26)* 0.02 
S 0.01 (-0.02 – 0.09) 0.02 (0.01 – 0.08)* 0.76 Difference in 
Mannitol RDR 
(%/mg) † NS 0.02 (0.003 – 0.07)* 0.04 (0.01 – 0.15)* 0.17 
RDR= response-dose-ratio (% max fall in FEV1/cumulative dose), dd= doubling dilution 
All data presented as geometric mean (95% confidence interval)  
* significant change from respective baseline 
†Data presented as median (range) 
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Measures of airway calibre 
Non-smokers saw a significant improvement in mean (SEM) FEV1 (% predicted) 
with both treatments: 5.94% (1.78), P<0.01 and 7.88% (2.72), P=0.01 with FP 
and FPSM respectively. There were no significant differences between 
treatments (P=0.57). Smokers saw significant improvement with FPSM but not 
with FP: 6.07% (2.32), P=0.02 and -1.21% (1.80), P=0.51 respectively. Non-
smokers gained significantly greater benefit from FP than smokers, 8.68% (2.99), 
P<0.01, but there was no difference between groups for FPSM, -1.66% (5.20), 
P=0.62. Differences in FVC, PEF, FEF25-75, IOS, and morning peak flow are 
detailed in table 12. 
 
Figure 10: Change in FEV1 from respective baseline 
 
 
 
Data shown as mean (SEM) 
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Table 12: change from respective baseline with measures of airway calibre 
 
 
 
Change from 
respective 
baseline with FP  
Change form 
respective 
baseline with 
FPSM 
Mean difference P value 
Spirometry  
(% predicted)       
S -1.21 (1.80) 6.07 (2.31)* 7.29 (2.24 – 12.32) <0.01          FEV1 
NS 5.94 (1.78)* 7.88 (2.72)* 1.94 (-5.08 – 8.96) 0.57 
S 2.79 (1.79) -2.36 (2.23) -5.14 (-10.87 - 0.59) 0.07          FVC  
NS 4.13 (1.85)* 3.13 (1.85) -1.00 (-6.59 – 4.59) 0.71 
S 0.71 (2.35) 8.14 (2.74)* 7.43 (1.92 – 15.79) 0.02          PEF  
NS 3.44 (1.28)* 8.50 (2.78)* 5.06 (-0.84 – 10.96) 0.09 
S 2.01 (2.76) 9.44(3.03)* 7.44 (-2.52 – 17.39) 0.13          FEF25-75  
NS 9.84 (3.98)* 14.1 (4.61)* 4.25 (-2.55 – 11.05) 0.12 
Impulse oscillometry 
(kPa.L-1.s)      
S 0.01 (0.03) 0.08 (0.02)* 0.07 (0.002 – 0.17) 0.06           R5  
NS 0.07 (0.02 )* 0.06 (0.02)*  -0.01 (-0.07 – 0.08) 0.85 
S -0.003 (0.02) 0.03 (0.02)* 0.04 (-0.02 – 0.10) 0.20           R20  
NS 0.03 (0.02) 0.02 (0.01)  -0.01 (-0.03 – 0.05) 0.67 
S 0.01 (0.02) 0.03(0.01)* 0.02 (-0.02 – 0.07) 0.31            X5  
NS 0.03 (0.01)* 0.04(0.01)* 0.003 (-0.03 – 0.04) 0.86 
S -0.01 (0.01) 0.04 (0.01)* 0.05 (0.01 – 0.08) 0.03           R5-20  
NS 0.04 (0.03) 0.04 (0.01) 0.005 (-0.08 – 0.09) 0.90 
Am PEFR (l/min)  S 6.1 (6.7) 4.9 (4.5) -1.0 (7.6) 0.90 
 NS 33.9 (6.7)* 20.2 (6.1)* -13.8 (8.7) 0.14 
Pm PEFR (l/min)  S 9.5 (6.3) 1.4 (2.8) -8.2 (1.5) 0.27 
 NS 30.3 (8.1)* 23.9 (7.4)* -6.4 (1.1) 0.50 
PEFR= change in average peak flow rate (over 1 week preceding the study visit) from respective baseline 
R5= total airway resistance, R20= proximal airway resistance, X5= peripheral reactance, R5-20= peripheral airway 
resistance. 
Mean diff represents the magnitude of change between each treatment  
*Significant change from respective baseline 
All data presented as mean (SEM) 
 
FENO 
Baseline FENO was significantly lower in smokers than non-smokers: 13.8ppb 
(95%CI 8.9-21.4) and 41.2ppb (95%CI 26.4–64.4) respectively, P=0.04. Non-
smokers showed significant reductions from baseline in FENO with both 
treatments: 55% (95%CI 37.4–68.3), P<0.01 with FP and 47% (95%CI 27.5–
61.8) P=0.02 with FPSM. There were no significant differences between 
treatments, 19% (95%CI -10-40), P= 0.16. Smokers demonstrated a 4% (95%CI 
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-33.3–37.1) reduction in FENO post FP (P=0.49), and a 47% (95%CI 34.1–57.5) 
reduction post FPSM (P<0.01). However, the pre-FPSM baseline in smokers was 
significantly higher than the pre-FP baseline: 13.7ppb (95%CI 8.9–21.4) P= 0.04. 
There was a 54% (25-71) difference between the response to FP in non-smokers 
vs. smokers, P<0.01, but no significant difference for response to FPSM, 0.3% 
(95%CI -31-44), P=0.99.  
 
ACQ  
Non-smokers had significantly lower scores at baseline than smokers:  median 
(range) 1.1 (0.0-2.0) and 1.9 (0.4-3.0) respectively. Non-smokers showed 
significant improvements in ACQ with both FP (P=0.01) and FPSM (P=0.02). 
There was no significant difference between treatments (P=0.57). No 
improvements were seen in smokers with either treatment: P=0.31 and P=0.32.  
 
Laboratory measures  
Neither treatment caused significant suppression of blood eosinophil counts from 
baseline: -0.01 (95%CI -0.05–0.04), P=0.13 vs. 0.03 (95%CI -0.03–0.09), P=0.53 
in non-smokers, and 0.01 (-0.07–0.09), P=0.61 vs. 0.04 (-0.01-0.09), P=0.71 in 
smokers, with FP and FPSM respectively. In keeping with the eosinophil data, 
neither treatment led to a significant reduction in ECP from respective baselines: 
-0.04 (95%CI -0.18–0.11), P=0.60 vs 0.05 (95%CI -0.07–0.17), P=0.41 in non-
smokers, and -0.04 (95%CI -0.16–0.08), P=0.51 vs 0.04 (95%CI -0.13–0.21), 
P=0.63 in smokers, with FP and FPSM respectively. In smokers FP produced 
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significant adrenal suppression of OUCC compared to baseline: -2.82 (1.24) 
nmol/mmol (P=0.03), but not with FPSM, -0.90 (0.91) nmol/mmol, P=0.34. In 
non-smokers neither treatment produced a significant fall in OUCC: -1.24 (1.01) 
nmol/mmol (P=0.24) and 0.12 (0.74) nmol/mmol (P=0.88) with FP and FPSM 
respectively. 
 
Discussion 
Studies in non-smokers have shown LABA’s to have a relative ‘steroid sparing 
effect’, allowing comparative improvements in lung function and reductions in 
exacerbations to doubling the dose of inhaled steroid [221-223]. This is in 
keeping with our non-smoking cohort, which demonstrated significant 
improvements in AHR, FENO, and spirometric indices that were comparable 
between treatments.  Smokers on the other hand, showed significantly greater 
improvements from the addition of SM to FP (500ug/day) compared to doubling 
the dose of FP alone (1000ug/day), in terms of AHR (methacholine PC20 and 
RDR), spirometry (FEV1) and IOS (R5-R20). Furthermore, smokers appeared to 
gain proportionally greater benefit from the addition of SM than non-smokers on 
methacholine AHR. These results support the observation that smokers would 
need 18 years less treatment, by taking FP/SM vs. FP alone, to prevent an 
exacerbation than non-smokers [164].  
 
Current asthma guidelines emphasize the importance of establishing asthmatics 
on ICS prior to addition of long-acting b2-agonist [8]. The OPTIMA trial clearly 
demonstrated that the addition of low dose ICS in steroid naïve individuals led to 
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a significant reduction in severe exacerbations and improvements in asthma 
control. Whereas the addition of a LABA led to improvements in lung function, 
but did not confer any additional clinical benefit [192]. In the present study we 
found no significant benefit, in any primary or secondary outcome, from high 
dose inhaled FP (1000ug/day) in smokers. Whilst smoking asthmatics are known 
to develop relative steroid resistance [157], it is currently thought that this can be 
partially overcome through increased doses [159]. This assumption is based on a 
study by Tomlinson et al, who demonstrated that high dose ICS decreased peak 
flow variability to a similar degree in both smokers and non-smokers [159]. Peak 
flow, like spirometry, reflects airway caliber and as such is relatively distant from 
the underlying asthmatic inflammatory process [21].  In this respect we saw no 
significant improvement in either peak flow dairy cards or ACQ in smokers. It 
could be argued that two weeks duration of treatment with FP may not have been 
sufficient to observe the changes in PEF seen by Tomlinson et al, however, it 
has previously been shown by Sovijarvi et al that 2 weeks is sufficient in 
achieving near maximal effects on AHR in response to FP 250ug bid via spacer 
[214].  
 
Our result has important implications as it suggests that higher doses of ICS fail 
to control inflammation in smokers, exposing them to significant risk of side 
effects. Addition of LABA on the other hand, allows improvements in AHR similar 
to those seen in non-smokers. We showed a significant systemic effect on 
adrenal suppression in smokers with FP 500µg bid but not with FPSM 250µg bid. 
This further emphasizes the importance of adding salmeterol rather than 
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increasing the dose of FP, in terms of optimizing the risk-benefit. Whilst smoking 
cessation should always be advocated as the best and most effective treatment 
for persistent asthma [217], we would advocate that smoking asthmatics who do 
not wish to consider cessation be started on combination therapy as first line 
rather than being treated with inhaled steroid alone. 
 
Some mechanistic insights can also be gleaned by examining the relative effects 
on mannitol and methacholine challenges. Mannitol is an indirect osmotic 
challenge, which is thought to correlate more closely with airway inflammation 
than methacholine, a direct bronchial smooth challenge [90]. A study utilising 
AMP, another indirect challenge, found FPSM 250µg bid to be inferior to 500µg 
bid in non smokers [221]. Since mannitol has been shown to correlate closely 
with AMP challenge [201], the results obtained in the present study were  
somewhat surprising in that improvements in mannitol PD15 following FPSM were 
greater than FP in non-smokers. Since SM exhibits no clinically meaningful in 
vivo anti-inflammatory activity [224], the superiority of FP/SM vs. FP alone on 
mannitol in non-smokers is likely due to an alternative mechanism: LABAs are 
known to have a stabilizing effect on airway smooth muscle [225]; to increase 
mast cell stabilization, thereby inhibiting the release of inflammatory mediators 
such as histamine or cysteinyl leukotrienes [226]  and to preserve the integrity of 
the respiratory eithelium [227]. This in turn suggests than mannitol may be less 
specific for inflammation than originally thought. However, we did not see any 
difference in effect on methacholine AHR in non-smokers between FPSM vs. FP, 
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that is perhaps, counter intuitive since methacholine acts directly on airway 
smooth muscle. 
 
In smokers we saw a significant difference between FPSM vs. FP on 
methacholine AHR, with a similar non-significant trend on mannitol. The greater 
improvements with FP/SM in smokers were also seen on airway caliber on 
outcomes of spirometry such as FEV1 and on imuplsue oscillometery on R5-
R20. The effect of salmeterol is due to a direct action on the airway smooth 
muscle leading to both bronchodilation and a protective effect due to functional 
antagonism against bronchoconstriction. This functional antagonism can be 
considered to be a surrogate for stabilization of airway smooth muscle and 
determines the degree of protection when exposed to a challenge stimulus.  It 
therefore appears that in the face of relative steroid resistance the smooth 
muscle stabilization conferred by the LABA becomes relatively more important in 
smokers than in non-smokers. Studies looking at the effect of smoking cessation 
on AHR to AMP and methacholine have shown significant improvements in AMP 
but not methacholine 6 months after smoking cessation in quitters [226], 
suggesting that smokers may have a greater degree of smooth muscle 
dysfunction than non-smokers.  
 
CT studies have shown smokers to have a reduced airway lumen area compared 
with non-smokers [228]. Similarly our results have shown that smokers have 
higher peripheral resistance (R5-20) at baseline compared with non-smokers, 
suggesting a greater degree of peripheral smooth muscle dysfunction, and 
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potentially increased peripheral inflammation. In combination products the 
bronchodilator component might conceivably result in improved peripheral lung 
deposition of the ICS, thereby producing enhanced anti-inflammatory activity in 
smaller airways. It has been suggested that oscillometry is a sensitive measure 
of small airway dysfunction and changes in R5-20, and X5 may reflect small 
airway physiology [228]. Thus, the changes in IOS demonstrated in this study 
with smokers may indicate beneficial small airway effects with FP/SM. The 
mechanism by which smoking causes FENO reduction is not fully understood, but 
may include reduction in NO synthesis due to feedback inhibition induced by high 
concentrations of NO contained in cigarette smoke [229]. Pre-treatment 
baselines for FP/SM vs. FP were significantly different, accounting for increased 
suppression with FP/SM in smokers.  
 
In conclusion, combination therapy with FP/SM conferred significant 
improvements in AHR and airway caliber in smoking asthmatics as compared to 
double the dose of FP alone. It is likely that in the face of the relative steroid 
resistance seen in smokers, the bronchodilation and smooth muscle/ mast cell 
stabilization conferred by the LABA become more important in terms of achieving 
superior clinical control. Future guidelines should take into account the 
differences in treatment response between smokers and non-smokers. 
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Critique 
Therapeutic studies, which form the basis for current asthma guidelines, often 
exclude current smokers due to concerns about recruiting participants with 
chronic obstructive pulmonary disease (COPD). 87% of participants in the 
present study had an FEV1/FVC ratio of ≥70% suggesting that they had no 
baseline obstruction, making a diagnosis of COPD unlikely. However, due to the 
difficulties that we encountered in recruiting smoking asthmatics, we also had to 
include subjects with a ratio of <70%. These subjects were required to 
demonstrate either >15% bronchodilator reversibility or >15% diurnal variation in 
peak flow, alongside a clinical history suggestive of asthma (i.e. diurnal variation, 
nocturnal, or exercise related symptoms).  However, a recent study by Calverley 
et al has clearly demonstrated that bronchodilator response is a poor diagnostic 
test for COPD, as up to 52% of patients changed responder status between visits 
[230]. Fortunately, all 3 patients with a ratio <70% demonstrated >15% diurnal 
variation in peak flow during the run-in period. However, we acknowledge that 
despite the above inclusion criteria, we may have included subjects with very 
mild COPD. A further criticism that could be leveled at this study is that we did 
not include a measure of compliance. 
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Part b: Elite swimmers 
 
 
 
Study aims: 
 
1. Determine the prevalence of EIB and rhinoconjunctivitis in adolescent elite 
swimmers. 
2. To determine what happens to airway inflammation following exposure to 
chlorine and exercise. 
3. To compare standardised field-based exercise challenge to mannitol 
challenge,  
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Effects of chlorine and exercise on the unified airway in 
adolescent elite Scottish swimmers 
 
Introduction 
Elite swimmers have higher rates of rhinoconjunctivitis and exercise induced 
bronchospasm (EIB) compared with any other groups of athletes [168, 231]. 
Proposed mechanisms include a combination of chronic exposure to toxic 
chlorine metabolites, and high ventilatory rates leading to osmotic degranulation 
of mast cells and subsequent bronchoconstriction [232]. In adult elite swimmers, 
significantly higher levels of airway inflammatory cells have been demonstrated 
compared with healthy controls. This reverts back to normal following long-term 
cessation of the sport [172]. There is a paucity of data on the prevalence of 
rhinoconjunctivitis and exercise induced bronchoconstriction in adolescent elite 
swimmers. This is of particular importance as rhinoconjunctivitis has been shown 
to be an independent risk factor for developing asthma [233]. Indeed rhinitis and 
asthma are considered to be part of the same disease continuum, the ‘unified 
airway’ [234]. We therefore conducted a pilot study to assess the combined 
effects of chlorine and exercise on the unified airway of adolescent elite 
swimmers, including estimating the prevalence of rhinoconjunctivitis and EIB. 
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Methods 
Participants and study design 
The Scottish Midland District swimming squad (36 swimmers) were assessed 
during a 2 hour training session. All swimmers underwent exhaled tidal (FENO) 
and nasal (NNO) NO measurement peak nasal inspiratory flow rate (PNIF), and 
FEV1 before and after swimming. A sport-specific exercise test was carried out 
during an intensive aerobic set. All swimmers completed a health questionnaire. 
Swimmers were asked to withhold anti-histamines, leukotriene receptor 
antagonists (LRTAs), nasal steroid sprays, and long acting β2- agonists (LABAs) 
for 1 week before the training session. Inhaled corticosteroid inhalers could be 
taken as normal. Participants were asked to refrain from taking short acting β2-
agonists (SABAs) 12 hours before the session. This study was approved by the 
local ethics committee (REC ref: 09/S1402/6) and all participants gave written 
informed consent. 
 
Measurements 
NO measurement  
All participants underwent measurement of FENO using a portable MINO (NIOX 
MINO® Airway Inflammation Monitor; Aerocrine AB, Solna, Sweden). A single 
reading was obtained in accordance with manufacturer’s guidelines. Nasal 
exhaled NO was measured using an adapted MINO device, as previously 
described [235]. 
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Sport-specific field-based exercise challenge 
The swimmers performed a sport-specific field-based exercise challenge 
following a low intensity warm up. Swimmers were required to maintain >80% 
maximum heart rate (220-age) for at least 8 minutes in order to optimally provoke 
EIB. Heart rate was measured objectively using pulse oximetry (M-pulse™, 
Merlin Medical, UK). FEV1 (forced expiratory volume in 1 second) was measured 
using a Piko-6® portable spirometer (Ferraris Respiratory). Heart rate and FEV1 
were measured at baseline, immediately following challenge and at 5 and 10 
minutes during recovery. A positive challenge was defined as a fall in FEV1 of 
≥10%. 
 
Peak nasal inspiratory flow 
Peak nasal inspiratory flow (PNIF) was measured using the In-Check® PNIF 
meter (Clement Clarke International Ltd, Harlow, UK). After horizontal positioning 
and restoration to zero, participants forcefully inhaled through their nose from 
residual volume to total lung capacity. The best of three measurements was 
taken. 
 
Health questionnaire 
A modified version of a questionnaire previously used in studies on elite athletes 
was used to assess the presence of exercise-induced symptoms [176]. 
Symptoms of chlorine-induced rhinitis were assessed using a visual analogue 
scale. Atopy was defined as a history of intermittent rhinoconjunctivis  (in 
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accordance with current ARIA definitions) and/or a positive skin prick test or/ IgE 
specific RAST test within the last 2 years. 
 
Statistical analysis  
SPSS version 15 (SPSS Inc, Chicago, Illinois) was used to perform the statistical 
analysis. Non-Gaussian data were log transformed prior to analysis. Normalized 
data were assessed using paired t-tests. A P value of less than 0.05 (two tailed) 
was considered significant. As this was a pilot observational study, no formal 
power calculation was used. 
 
Results 
Combined and free chlorine levels on the day were 1.66 and 0.3 mg/l 
respectively. Baseline characteristics are described in Table 13. Complete 
baseline data was available on 31/36 swimmers. Eight swimmers (22%) had 
known asthma. 18 (50%) had rhinitis according to the 2008 ARIA guidelines (11 
= intermittent rhinitis, 7 = persistent rhinitis). There were no significant differences 
in FENO or NNO pre vs post exposure: mean (95% CI) for FENO 17.9 (13.5 to 23.5) 
ppb vs 17.0 (12.8 to 22.5) ppb (P = 0.12); NNO 47.5 (36.3 to 62.1) ppb vs 45.4 
(34.0 to 60.6) ppb respectively (P = 0.71). Mean PNIF increased from 124.4 
L.min-1 (107.8 to 143.5) vs 136 L.min-1 (121.3 to 152.5): (P = 0.04). Baseline 
FENO readings in asthmatics and non-asthmatics were 35.7 (8.57) and 18.5 
(3.01) respectively. 
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13/36 (36%) of swimmers had a positive exercise challenge. 10/13 (77%) of 
these were not previously known to asthmatic. 3/8 (38%) of asthmatic swimmers 
had a positive challenge. During the challenge swimmers achieved a mean 
(SEM) heart rate of 81.3% (1.5) maximum predicted. 
36% (13) had a positive exercise challenge. 46% (6) of participants with a 
positive challenge were symptomatic, 54% (7) were asymptomatic. 42% (15) 
swimmers complained of worsening nasal symptoms post swimming, but only 
13% (2) had a demonstrable fall in PNIF (mean fall 33 l/min), 87% (13) had no 
change. 9/15 (60%) had a pre-existing diagnosis of either intermittent or 
persistent rhinitis. 
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Table 13: Lower airway outcomes 
Study 
no. Age/Sex 
Known 
Asthma 
Asthma 
meds* 
FEV1 
% 
change 
FEV1 † 
Baseline 
FENO 
(ppb) 
Change 
in FENO 
(ppb) 
Symptoms 
suggestive 
of EIB 
1 16/M N  6.28 -29.0 22 +1 Y 
2 15/M Y L,A 4.65 -2.6 24 +5 N 
3 16/M N  5.57 -2.3 11 -2 Y 
4 16/M Y  5.27 -23.3 17 +1 N 
5 15/M Y L,A,S 4.11 +9.0 28 +1 Y 
6 21/M Y S,A 5.37 -6.1 76 -6 Y 
7 15/F N  4.26 -24.6 15 -1 N 
8 15/F N  4.27 -7.3 55 +17 N 
9 13/F N  3.44 -4.9 NA NA N 
10 12/F Y A 3.63 -20.7 NA NA Y 
11 18/M N  3.51 -7.7 NA NA Y 
12 15/M N  6.32 -32.8 16 +1 N 
13 15/M N  4.56 -11.6 9 0 N 
14 15/F N  3.83 -14.1 12 -2 N 
15 12/F N  3.08 +7.5 22 0 N 
16 12/F N  2.70 +21.9 NA NA Y 
17 13/F N  3.26 -5.2 32 -11 Y 
18 12/F N  3.86 -14.2 13 NA N 
19 13/F Y S 3.10 +1.3 11 +1 Y 
20 11/M N  3.74 -0.8 13 +5 Y 
21 14/F N  3.11 +7.1 6 -1 Y 
22 12/F N  3.37 -4.2 10 -2 N 
23 13/F N  3.44 -17.2 17 -5 Y 
24 11/M N  2.85 -5.6 58 -23 Y 
25 13/M Y S 3.24 +5.2 52 -3 Y 
26 12/M N  2.50 -0.8 6 -1 N 
27 11/M N  4.50 -30.4 10 -2 Y 
28 12/M N  3.19 -9.1 9 +6 Y 
29 12/M N  3.31 -3.3 12 0 N 
30 12/M N  2.32 -3.4 5 0 N 
31 11/F N  2.64 +1.5 13 -2 N 
32 11/F N  3.44 -11.6 11 -1 Y 
33 11/F Y S 2.45 -17.1 42 -6 Y 
34 11/F N  3.15 -10.5 10 -2 N 
35 12/F N  2.88 +1.0 24 -2 N 
36 11/F N  3.16 -7.0 52 -1 N 
Mean 
(SEM) 
13.3 
(0.38) 
17M:18F 
8 (22%)  3.73 (0.17) 
-7.6 
(1.96) 
22.28 
(3.20) 
1.1 
(1.10) 18 (50%) 
* L= Leukotriene receptor antagonist, A= antihistamine, S= inhaled corticosteroid 
† = maximal % change in FEV1 observed during exercise challenge. 
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Table 14: Upper airway outcomes and training 
Study 
no. 
Known 
Rhinitis† 
% fall 
PNIF  
Change 
in NNO 
(ppb) 
History 
of Atopy 
Decrease in 
nasal visual 
analogue score 
post exposure 
Training 
(hr/wk) 
Training 
(years) 
1 I 0.0 11 Y Y 15 10 
2 I -11.1 -72 N N 12 5 
3 P +5.0 20 Y Y 11 5 
4 I 0.0 29 Y Y 12 9 
5 I +58.8 38 Y Y 14 8 
6 P +50.0 21 Y Y 17 14 
7 N +100.0 -30 N Y 12 7 
8 N +22.2 29 Y N 12 6 
9 N +27.3 NA N N 9.5 3 
10 N NA NA Y Y 11 4 
11 I NA NA Y N 11 4 
12 I +50.0 -24 N Y 14 2 
13 N -23.1 -38 N Y 14 8 
14 P 0.0 19 N N 6 3.5 
15 N -31.6 -32 N Y 12 4.5 
16 N NA NA N N 9.5 5 
17 P +16.7 5 Y N 10.5 3.5 
18 I NA NA Y N 9.5 5.5 
19 P 0.0 14 N N 11 3.5 
20 N +8.3 46 N N 11 3 
21 I -18.8 36 Y N 12 9 
22 N +7.7 NA N N 13 7 
23 P +14.3 21 N Y 12 2 
24 N +40.0 4 N Y 5 3 
25 P 0.0 51 N N 11 6 
26 N 0.0 -29 N N 8 8 
27 N +11.1 18 N N 7.5 2 
28 N +16.7 -16 N Y 6 4 
29 N -5.9 26 N N 6 5 
30 N +33.3 -1 N N 7.5 4 
31 N +44.4 -5 N N 6 3.5 
32 N -26.7 1 N N 9 2 
33 I -9.1 -75 Y N 5 6.5 
34 N +15.4 -20 N N 6.5 3 
35 I 0.0 -28 Y Y 6 8 
36 I 0.0 26 Y Y 7 3.5 
Mean 
(SEM) 
I=11(31%) 
P=7(19%) 
N=18(50%) 
+12.3 
(4.88) 
-1.5 
(5.85) 14 (39%) 15 (42%) 
10.2 
(0.5) 5.3 (0.5) 
† I= intermittent, P= persistent, N = none 
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Discussion 
This study aimed to assess the combined effects of chlorine and exercise on the 
unified airway of adolescent elite swimmers. We found no significant change in 
either tidal (FENO) or nasal (NNO) NO following a 2-hour training session, which 
included a high intensity anaerobic set. Using linear regression analysis, this 
change in NO was not influenced by asthma, presence of EIB or history of atopy. 
Furthermore, there was no correlation between upper and lower airway NO 
(r=0.12, P=0.81). We elected to use FENO as it is non-invasive, reproducible and 
easy to perform at the poolside. FENO is an established surrogate in asthma, 
which correlates closely with airway inflammation [60]. It is also used as a 
surrogate marker of inflammatory diseases in the upper airway [236], enabling us 
to examine effects on the unified airway. Additionally, FENO has been shown to 
rise in elite runners following a marathon [237]. The absence of any acute rise in 
FENO was therefore unexpected. Whilst forced vital manoeuvres are known to 
‘washout’ FENO from the airways [194], there are no reports of exercise or 
hyperventilation decreasing FENO. Indeed, our results did not show any reduction 
post-swimming. It is also conceivable that the short duration of exposure was not 
sufficient to induce NO synthase, however, FENO has previously been shown to 
be elevated during an osmotic challenge suggesting that there is rapid induction 
of this enzyme [238]. We did not assess whether a late phase response was 
present in either the upper and lower airway. This is supported by anecdotal 
reports from swimmers who frequently complain of nasal congestion and 
symptoms, 4-6 hours after training. 
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The significant increase observed in PNIF post-swimming may not represent an 
improvement in inflammation, but paradoxically may signify a ‘nasal douche 
effect’. Saline irrigation is known to significantly improve nasal congestion 
through a combination of improved mucociliary clearance and reduction of 
mucosal oedema [239]. 18 (50%) of swimmers had a pre-existing diagnosis of 
rhinitis, which is in line previously reported rates [240].  Rhinitis did not 
necessarily predict worsening of nasal symptoms post swimming, however, 
large-scale epidemiological studies are needed to investigate this issue further. 
 
As part of this study we carried out a standardised field-based exercise 
challenge. Traditional field based testing in which athletes perform a challenge 
using their primary exercise, is usually limited by an inability to standardise both 
the cardiovascular workload and environmental conditions [177]. We therefore 
decided to use a standardised protocol based on the ATS (1999) guidelines for 
exercise challenge, using an objective measure of heart rate monitoring. In the 
current study, swimmers achieved an average heart rate of 81.3% of maximum, 
which was maintained for an average of 8 minutes. 
 
We found a high prevalence (36%) of EIB in our cohort of adolescent elite 
swimmers. This is a unique finding, as previous figures are biased towards adult 
swimmers [172]. Indeed, 77% of our swimmers with a positive exercise challenge 
were not previously known to be asthmatic. Moreover, only 46% of swimmers 
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who were exercise-positive reported symptoms suggestive of EIB. The diagnosis 
of EIB based on symptoms alone, is known to be highly inaccurate [241]. This 
suggests that solely testing symptomatic athletes is grossly insufficient. At elite 
level small changes in physiological reserve could potentially translate into 
tangible improvements in performance. More importantly, adolescent swimmers 
with undiagnosed EIB may not reach their full potential, preventing them from 
progressing to compete at adult level. We therefore feel that universal screening 
of all elite swimmers for EIB and rhinoconjunctivitis and should be advocated. 
 
We recognize some limitations in our study. It could be argued that the non-
intensive exercise preceding the challenge may have induced a refractory period 
in some swimmers, which may have led to an underestimate of the true 
prevalence of EIB. However, previous studies have shown that low intensity 
warm-ups to not induce refractoriness prior to challenge [242].  4/5 asthmatic 
swimmers with a negative exercise challenge were on inhaled corticosteroids, 
which may explain the low incidence of EIB in this group. Ideally, these would 
have been stopped; however, this would have interfered excessively with 
training.  As expected FENO was elevated at baseline in asthmatics, but not in 
non-asthmatic swimmers. This is in keeping with previous studies. It is possible 
that the swimmers in this cohort were too young to develop major airway 
inflammatory changes. A larger study in a cohort of older more experienced 
adolescent swimmers would help eliminate this as a confounding factor. Whilst 
this study does not allow us to differentiate between the relative contributions of 
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exercise and chlorine on the airway we felt it was important to study swimmers in 
a “real life” situation.  
 
Conclusions 
In conclusion, we found that a 2 hr training session, including a high intensity 
anaerobic set, in a chlorinated indoor pool did not affect surrogate markers of 
inflammation in the unified airway. There was a high prevalence of undiagnosed 
EIB, highlighting the importance of screening of all elite swimmers for asthma. 
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Critique 
In this study we were able to determine that there was a high prevalence of 
undiagnosed EIB in adolescent elite swimmers, highlighting the need for an 
effective screening test. Standardised field-based exercise testing in swimmers 
did appear to be a viable option, as environmental conditions in the pool were 
relatively constant. Although, one criticism, which was made during the 
presentation of this paper, was that a single low FEV1 immediately post exercise 
did not effectively differentiate between EIB and exhaustion. We therefore made 
the decision to define EIB as a drop in FEV1 >10% at two separate time points 
post exertion in subsequent studies.   
 
The lack of response in FENO was somewhat surprising in view of the increase 
that had been reported in marathon runners. We hypothesised that we had 
perhaps missed a late phase response in airway inflammation, similar to that 
seen following allergen challenge. The decision was therefore made to measure 
this in a subsequent study. We also felt that it was important to compare field-
based exercise challenge to the gold standard test (EVH). However, EVH 
requires a great deal of machinery, experienced technical staff and is not readily 
available at the poolside. We therefore decided to use mannitol challenge in our 
follow-up study, as this has been shown to correlate very closely with EVH.  
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Disconnect between standardised field based testing and 
mannitol challenge in Scottish elite swimmers 
 
Introduction 
Exercise-induced bronchoconstriction is defined as a transient increase in airway 
resistance that occurs after vigorous exercise [133]. Proposed aetiological 
mechanisms include airway drying and cooling as a consequence of increased 
ventilatory rates during strenuous exercise [243, 244]. Exercise is an indirect 
airway challenge which has been found to have a high level of specificity, but a 
low sensitivity for identifying EIB in cold weather and track athletes [179]. Sport-
specific exercise in the field (FBT) is limited with respect to the standardization of 
both the workload and environmental conditions such as allergens, temperature, 
and humidity. Eucapnic voluntary hyperpnoea (EVH), a laboratory based 
challenge involving hyperventilation with dry air, has therefore been 
recommended as the ‘gold standard’ test for the diagnosis of EIB by the 
International Olympic Committee [175]. Mannitol, an osmotic challenge, has been 
found to correlate strongly with EVH [146]. 
 
Elite swimmers have higher rates of rhinoconjunctivitis and exercise induced 
bronchoconstriction (EIB) compared with any other groups of athletes [168, 231]. 
This may seem counterintuitive as they exercise in a warm moist environment. In 
a recent study Pedersen et al evaluated airway response in swimmers following 
four different challenge tests and found that EVH had a much lower sensitivity 
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than had been previously reported in other athletes [245]. Chlorine and chlorine 
metabolites are known to induce bronchial hyper-reactivity following accidental 
intense exposure [171]. Swimmers are repeatedly exposed to chlorine gases and 
their metabolites, which accumulate at the water/gas interface on the swimming 
pool surface. It has been reported that adult elite swimmers have significantly 
higher levels of airway inflammatory cells compared with healthy controls [172]. 
 
In a recent preliminary study of young swimmers attending the district level 
squad, we evaluated the acute response to chlorine and exercise using FENO, a 
well recognised surrogate of airway inflammation, and found no increase 
following a 2 hour training session [246]. We hypothesised that we may have 
missed a late phase response and therefore performed a follow up study in elite 
swimmers attending the national level training squad. In the present study we 
have evaluated the early and late phase FENO response in both the upper and 
lower airways. We have also compared the response to mannitol and sports 
specific physiologic exercise challenges.  
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Methods 
Participants and study design 
The Scottish National swimming squad (61 swimmers) were assessed over a 
three day residential training weekend at the National Swimming Academy in 
Stirling. Swimmers are subdivided into 2 squads: the national squad, and the 
national development squad. Swimmers underwent exhaled tidal (FENO) and 
nasal (NNO) NO measurement, peak nasal inspiratory flow rate (PNIF), and FEV1 
before, immediately after, and 4-6 hours post swimming. A sport-specific 
exercise test was carried out during an intensive lactate set. All swimmers 
underwent mannitol challenge, and completed a health questionnaire. Challenge 
tests were incorporated into the training programme. Swimmers were asked to 
withhold anti-histamines, leukotriene receptor antagonists (LRTAs), nasal steroid 
sprays, and long acting β2- agonists (LABAs) for 1 week before the training 
session. Inhaled cortico-steroid inhalers could be taken as normal to avoid 
significant negative impact on training. Participants were asked to refrain from 
taking short acting β2-agonists (SABAs) 12 hours before the training weekend. 
This study was approved by the local ethics committee (REC ref: 09/S1402/6) 
and all participants gave written informed consent. Combined (free) chlorine 
levels on each of the three training days were: 1.66 (1.42), 1.58 (1.44), and 1.68 
(1.40) mg/l, which are within UK recommended limits. 
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Demographics 
Baseline characteristics are described in Table 15. The national squad were 
significantly older, trained more hours per week, over more years than the 
national development squad (table 16). Ten swimmers (17%) had physician 
diagnosed asthma, 3 were taking inhaled corticosteroids, one was taking a 
leukotriene receptor antagonist. 24 (40%) had rhinitis according to ARIA 
guidelines (16 = intermittent rhinitis, 8 = persistent rhinitis).  
 
Table 15: Subject characteristics 
 National squad 
(n=19) 
National 
development 
squad 
(n=42) 
All swimmers 
(n= 61) 
Age (years)* 17.74 (0.51) 14.95 (0.15) 15.2 (0.25) 
Physician diagnosed asthma 4 (21%) 6 (14%) 10 (17%) 
Rhinitis 8 (42%) 16 (38%) 24 (40%) 
Weekly training (hrs)* 19.39 (0.86) 15.45 (0.55) 16.69 (0.52) 
Duration of competitive sport (years)* 8.47 (0.48) 5.95 (0.28) 6.74 (0.29) 
Atopy 6 (40%) 7 (17%) 14 (24%) 
Baseline FENO * 25.0 (1.1) 16.5 (1.1) 18.8 (0.2) 
Positive FBT* 2 (13%) 7 (42%) 9 (16%) 
Positive mannitol challenge* 5 (33%) 3 (8%) 8 (14%) 
Data expressed as mean (SEM) unless otherwise stated. 
*Significant difference between squads 
 
Timing of tests 
Complete baseline data were available on 60/61 swimmers. Exercise challenge 
was available in 57 (2 were injured and thereby unable to take part, and 2 did not 
stay for the full training camp). 59 swimmers carried out a mannitol challenge; 
one was unable to tolerate the procedure due to excessive coughing. Challenge 
tests were incorporated to fit into into the training programme, consequently the 
National squad underwent mannitol challenge 5.01 (0.01) hours post exercise; 
whereas the development squad had their mannitol 18.28 (0.33) post exercise. 
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Immediate post swim measures were performed after a 2 hour swimming 
session. Delayed post swim measures were carried out 4.66 (0.18) hours after 
swimming. These were performed prior to mannitol challenge. During the 
challenge swimmers achieved a mean (SEM) heart rate of 85.0% (1.12) 
maximum predicted. 
 
Measurements 
FENO  
All participants underwent measurement of FENO using a portable MINO (NIOX 
MINO® Airway Inflammation Monitor; Aerocrine AB, Solna, Sweden). A single 
reading was obtained in accordance with manufacturer’s guidelines. Nasal 
exhaled NO was measured using an adapted MINO device, as previously 
described [235]. 
 
Sport-specific field-based exercise challenge 
The swimmers performed a high intensity sport-specific field-based exercise 
challenge during an intensive lactate set. This was preceded by a standard low 
intensity warm up of approximately 15-20 minutes, to avoid muscular injury. 
During the high intensity lactate set, swimmers were required to maintain >80% 
maximum heart rate (220-age) for at least 8 minutes in order to optimally provoke 
EIB. Heart rate was measured objectively using pulse oximetry (M-pulse™, 
Merlin Medical, UK). FEV1 (forced expiratory volume in 1 second) was measured 
using a Piko-6® portable spirometer (Ferraris Respiratory). Results from PIKO 
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devices have been found to be highly reproducible, and to correlate well with 
results from other portable and office based spirometers [247]. Heart rate and 
FEV1 were measured at baseline, immediately following challenge and at 5 and 
10 minutes during recovery. The best of two reproducible readings was utilised. 
A positive challenge was defined as a fall in FEV1 of ≥10% at ≥ 2 time points 
during recovery (in accordance with recommendations by drug-free sport UK for 
ATUE (therapeutic use exemption) certification)[174]. 
 
Mannitol challenge 
Mannitol challenge was performed by administering spray-dry mannitol powder in 
gelatine capsule form (AridolTM Pharmaxis Ltd, Sydney, Australia), inhaled from a 
dry powder device (Osmohaler, Pharmaxis Ltd. French’s Forest, NSW, Australia) 
as previously described by Anderson and colleagues [136][183]. FEV1 was 
measured 60 seconds after delivery of each dose (5, 10, 20, 40, 80, 160, 160, 
160 mg) using a Piko-6® portable spirometer (Ferraris Respiratory). This device 
was used to ensure standardisation between both challenge tests. The test 
continued until the FEV1 had fallen 15% or the maximal dose of 635 mg had 
been administered. The provoking dose of mannitol to cause a 15% fall in FEV1 
(PD15) was calculated by log linear interpolation. A positive challenge was taken 
as being either a 15% fall in FEV1 at the threshold dose (PD15) or a 10% fall at 
successive time points.  
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Peak nasal inspiratory flow 
Peak nasal inspiratory flow (PNIF) was measured using the In-Check® PNIF 
meter (Clement Clarke International Ltd, Harlow, UK). After horizontal positioning 
and restoration to zero, participants forcefully inhaled through their nose and the 
best of three measurements was taken. 
 
Health questionnaire (symptoms) 
A modified version of a questionnaire previously used in studies on elite athletes 
was used to assess the presence of exercise-induced symptoms [176]. 
Symptoms of chlorine-induced rhinitis (blockage/ running) were assessed using a 
visual analogue scale. Atopy was defined as a history of rhinoconjunctivis (in 
accordance with current ARIA definitions) and/or a positive skin prick test or IgE 
specific RAST test within the last 2 years. 
 
Statistical analysis  
SPSS version 15 (SPSS Inc, Chicago, Illinois) was used to perform the statistical 
analysis. Non-Gaussian data were log transformed prior to analysis. Normalized 
data were assessed using repeated measures ANOVA with Bonferroni 
correction. Chi Squared test was used to check for associations in non-
parametric data. Pearson’s correlation was used for parametric data. A P value 
of less than 0.05 (two tailed) was considered significant. As this was an 
observational study, no formal power calculation was used. 
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Results 
Challenge tests 
8/59 (14%) of swimmers had a positive mannitol challenge 9/57 (16%) of 
swimmers had a positive exercise test. Only one swimmer was positive to both 
tests. There was no correlation between maximum FEV1 drop in mannitol 
challenge and maximum FEV1 drop in exercise challenge. 3/10 asthmatics were 
positive to mannitol, while only 2/10 were positive to exercise. 
 
Results of subjects who achieved a ≥10% fall in FEV1 are detailed in table 16. 7/9 
subjects deemed to have a positive exercise challenge had a fall immediately 
post exercise which was sustained at 5 minutes (7/7) and 10 minutes (5/7) 
recovery. The mean (SEM) %fall for these subjects immediately post exercise 
was 18.9 (7.0), and 15.2 (6.0) at 5 minutes. 3 subjects had a fall of ≥10%, which 
was not sustained; their mean (SEM) %fall was 11.1 (1.7) immediately and -0.47 
(1.7) at 5 minutes recovery. Two subjects developed a sustained ≥10% fall 
during recovery. The geometric mean (95% CI) mannitol PD15 was 209.9 (128.7 
– 342.3). The degree of bronchial reactivity, measured in terms of response-dose 
ratio (final % fall in FEV1 divided by the total administered dose of mannitol), was 
similar in swimmers with EIB and those who did not respond to either test, 0.01 
and 0.01 respectively. The response-dose ratio in those with a positive mannitol 
was higher at 0.06.  
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Table 16: % fall in FEV1 in those with a fall ≥ 10% 
Time post exercise Immediately post-exercise 
At 5 minutes 
recovery 
At 10 minutes 
recovery 
Positive/ negative 
test 
8.92 12.45 20.12 P 
-11.55 -0.19 10.06 N 
13.59 13.36 3.23 P 
29.25 23.03 22.61 P 
21.23 10.31 10 P 
26.03 13.7 9.13 P 
11.53 -5.9 -6.7 N 
18.61 14.93 14.52 P 
11.03 4.93 -2.82 N 
12.41 15.95 15.19 P 
11 15.16 11.98 P 
4.59 10.1 18.37 P 
% Fall in FEV1  
 
10.67 -0.46 -2.09 N 
P= exercise test considered to be positive, N= test considered negative 
 
FENO 
Baseline FENO was 26.7 (16.3 to 43.6) ppb in asthmatic swimmers and 17.4 (14.9 
to 20.4) ppb in non-asthmatic swimmers (P=0.03). Swimmers with a positive 
mannitol had a significantly higher baseline FENO than those with a positive 
exercise challenge (figure 11). There was a significant association between 
positive mannitol challenge and baseline FENO >25 ppb (X2=7.76, P=0.01). There 
was a weak correlation between maximal fall in FEV1 during mannitol challenge 
and baseline FENO (r=0.26, P=0.03). There was no association between positive 
exercise and high baseline FENO (x2= 0.127, p=0.54). A significant decrease in 
FENO was observed pre vs. immediate and delayed post chlorine exposure: 
mean (95% CI) 18.7 (15.9 to 22.0) ppb vs. 15.9 (13.3 to 19.1) ppb (P <0.01), and 
13.9 (11.5 to 16.7) ppb (P<0.01) respectively (table 17). This was irrespective of 
squad, atopic or asthmatic status.  
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Figure 11: Comparison of baseline FENO in patients with a positive exercise 
and positive mannitol challenge. 
 
Presented as geometric mean and 95% CI 
 
NNO 
There was no significant difference in NNO between pre exposure, immediate, or 
delayed post exposure: 98.7 (5.4) ppb, 100.9 (5.0) ppb (P = 0.70), and 98.2 (4.5) 
(P=0.94) respectively (table 17). 
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PNIF 
Mean PNIF increased from 142 L.min-1 (6) at baseline to 162 L.min-1 (6) 
immediately post exposure (P <0.01). Delayed post exposure PNIF was not 
significantly different from pre-exposure readings (P=0.90) (table 17). There was 
no significant increase in visual analogue scale at any point post exposure. 
 
Table 17: Effects of swimming on FENO, NNO and PNIF 
 Pre-swim Immediate post-
swim 
4-6 hrs post-swim 
FENO (ppb) * 18.7 (15.9 - 22.0)  15.9 (13.3 - 19.1) ‡  13.9 (11.5 - 16.7) ‡ 
NNO (ppb) † 98.68 (5.39)  100.93 (5.00) 98.22 (4.45) 
PNIF (l/min) † 142 (6)  162 (6) ‡ 143 (6) 
* Shown as geometric mean (95% CI) 
†Expressed as mean (SEM) 
‡ Statistically significant change from pre-swim measure 
 
Symptoms 
43% (26) of swimmers complained of exercise related symptoms. 36% (8/22) of 
these had a positive exercise challenge (4 symptomatic swimmers were unable 
to take part in the challenge). 30% (7/26) of symptomatic swimmers had a 
positive mannitol challenge. 44% (4) of participants with a positive exercise 
challenge were symptomatic, 56% (5) were asymptomatic. 75% (6) of 
participants with a positive mannitol challenge were symptomatic, 25% (2) were 
asymptomatic. 
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Discussion 
This study aimed to compare the response to standardised exercise testing and 
mannitol challenge in elite national level, swimmers. We also aimed to 
investigate the combined effects of chlorine and exercise on the unified airway. 
No association was found between mannitol and exercise challenge. 14% 
swimmers were positive to mannitol, 15% were positive to exercise challenge, 
while only one swimmer was positive to both. Whilst these findings are not 
supported by studies performed in cold weather or track athletes [177, 178], they 
are consistent with the findings of Pedersen et al who reported that EVH had a 
relatively low sensitivity in swimmers [245]. This is not entirely unexpected as the 
humidified air inspired by swimmers during exercise should decrease the rate of 
expired water loss during hyperpnoea. Despite this, swimmers have one of the 
highest prevalences of EIB, which would suggest that the theories of heat and 
water loss as a cause of EIB might not be totally applicable and other factors 
(such as the presence of chlorine) may be pertinent. 
 
In the current study a disconnect was observed between AHR detected by 
standardised-FBT and mannitol challenge. Traditionally, FBT in athletes has 
been non-standardised and centred on a challenge using their primary exercise 
[177]. This will limit the ability to standardise both the cardiovascular workload 
and environmental conditions for repeated challenges or between athletes, 
making it inappropriate for direct comparison to highly standardised tests such as 
EVH or methacholine challenge. For example, a sprinter whose main event is a 
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50m freestyle will be unlikely to sustain the adverse effects on the airways for 
long enough to induce bronchoconstriction, however EIB in longer aerobic 
training sets may still have a significant effect on training and may still therefore 
be of importance to the swimmer. We therefore decided to use a standardised, 
rather than event specific protocol based on the ATS (1999) guidelines for 
exercise challenge and using an objective measure of heart rate monitoring 
[183]. In the current study all athletes were required to achieve an average heart 
rate of 80% of maximum, and maintain this for at least of 8 minutes. 
Environmental conditions within the pool over the 3-day period were constant. A 
positive test required the presence of a sustained fall in FEV1 post exercise (i.e. 
a fall of ≥10% at two time points post exercise) in order to exclude those who 
may have had a drop secondary to exhaustion.  
 
In this study mannitol challenge was positively associated with high baseline 
FENO, whereas exercise challenge was not, suggesting that mannitol challenge 
may be more sensitive at picking out swimmers with a traditional ‘inflammatory’ 
asthmatic phenotype, rather than EIB. Leukotrienes are known to play a 
significant part in sustaining the contraction of airway smooth muscle and airway 
narrowing in EIB. It is therefore also of interest that mannitol positive swimmers, 
who have demonstrated that their airway is susceptible to endogenous release of 
leukotrienes, do not respond to exercise. This suggests that a different 
mechanism is responsible for the fall in FEV1 with high intensity swimming. 
Mannitol challenge has previously been shown to correlate very closely with 
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eosinophils in induced sputum [248]. Swimmers are thought to have higher levels 
of eosinophils and neutrophils in their sputum [172]. However, closer inspection 
of the data by Helenius et al reveals that most swimmers with sputum 
eosinophila were in fact known asthmatics, whilst the greater majority of study 
population had eosinophil levels comparable to controls. Findings in participants 
without known asthma or AHR to methacholine (14/29) were not separately 
reported. A study by Boulet et al suggested that sputum neutrophils are up-
regulated in swimmers following high intensity training [249]. This is of interest as 
asthmatic subjects with high sputum neutrophil counts have been found to have 
milder AHR to mannitol compared to those with a preponderance of other 
inflammatory cell types [250]. However, high sputum neutrophil counts would not 
serve to explain the disconnect observed between the two challenge tests. 
 
In this regard, the current study used FENO as a surrogate of airway inflammation 
[194]. There was a significant fall in FENO following a 2-hour swim, and a trend 
towards a continuing drop at 4-6 hours post exposure. This was seen in both 
squads, and was not affected by asthmatic or atopic status. Forced vital 
manoeuvres are known to ‘wash-out’ FENO from the airways, however this effect 
has not been established in relation to exercise or hyper-ventilation [194]. 
Indeed, the continued decrease in FENO 4-6 hours post-exposure would not 
support a ‘wash-out’ effect and suggests another action. Case series describing 
airway changes following accidental high intensity chlorine exposure have 
described significant drops in FENO which persist for up to 2 months post- 
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exposure [171]. It has been suggested that acute chlorine exposure causes 
widespread oedema of the respiratory mucosa, degeneration and desquamation 
of the bronchial epithelium, resulting in exposure of vagal receptors and 
consequently enhanced vagal activity with bronchial hyper-reactivity [251]. 
Therefore, it seems plausible that repeated low-intensity exposure to chlorine 
may cause bronchial hyper-reactivity by a non-cellular inflammatory response. 
This would explain the high prevalence of EIB diagnosed by standardise-FBT, 
even in swimmers with normal baseline FENO. There have been several case 
reports of acute pulmonary oedema in swimmers and divers. In 2004 Adir et al 
published a case series of 70 swimmers with “swimming-induced acute 
pulmonary oedema” [252].  However, they reported clinical haemoptysis and a 
decrease in mean oxygen saturations to 76%. Adir and colleagues hypothesised 
that the pulmonary oedema may have been due to exercising in the prone 
position, as this will have affected the distribution of blood throughout the lung. 
Whilst no decrease in oxygen saturations was noted in our swimmers it is 
possible that a combination of exercising in the prone position and exposure to 
toxic metabolites may have caused a mild degree of airway oedema, which led to 
a decrease in bronchial flux. An alternative mechanism for the suppression of 
FENO is direct blockage of production through inhibition of NO synthase (the 
enzyme responsible for NO production). 
 
Unlike FENO, there was no change in NNO following a 2 hour swim. The cause for 
this is unclear, however, a possible explanation is that at exercise capacity 
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athletes mouth breath rather than breathing through their nose. Given this, the 
paranasal sinuses will have comparatively little gas exchange or chlorine 
exposure. There was also no change 4-6 hours post exposure, suggesting that 
there is no late phase response in NO. This is substantiated by the PNIF results 
which increase immediately post exposure but returns to baseline after 4-6 
hours. The immediate improvement is most likely due to a ‘nasal douche effect’, 
given that saline irrigation is known to significantly improve nasal congestion 
[239]. There was additionally no significant change in visual analogue scale 
either immediately or 4-6 hours post-exposure. 27/60 swimmers had a PNIF 
≤120 l/min at baseline. Given that national elite swimmers train on a daily basis 
during the season, it was not possible to establish a truly chlorine free baseline.   
 
The diagnosis of EIB based on symptoms alone, is known to be highly inaccurate 
[241].  In the current study 43% of swimmers complained of exercise related 
symptoms. However, only 38% of these had a positive challenge, which is in 
keeping with the results of our previous study [246].  
 
There were significant differences in baseline values between the two squads. 
The National squad (NS) were significantly older, trained more hours per week, 
over a greater number of years compared to the National Development squad 
(NDS). They also had a greater proportion of asthmatics, and a higher mean 
baseline FENO. It has been suggested that regular pool attendance is associated 
with an increased risk of asthma [253], which could explain why the older more 
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experienced team has a higher prevalence. However, this discrepancy may 
simply be due to the smaller number of swimmers in the NS.  
 
We recognize some limitations in our study. Ideally both challenges would have 
been done on separate days; however, due to constraints of the training 
timetable, this was only possible for the national development squad. Edmunds 
et al found little evidence of a refractory period 4 hours post exercise [254], 
therefore the mean of 5.05hrs between challenges in the national squad should 
have been sufficient to re-establish stored inflammatory mediators.  In addition, 
Anderson et al noted that exercising whilst breathing in warmed humidified air, 
did not induce mast cell degranulation, bronchoconstriction or not prevent the 
development of severe exercise induced asthma in response to a standard 
exercise challenge 30 minutes later [255]. These results are further substantiated 
by those of Hahn et al who found that exercise challenge with warm humidified 
air led to significantly lower fall in FEV1 post challenge, and did not induce a 
refractory period [256]. The national development squad performed mannitol 
challenge 18 hours post exercise, therefore refractory period is not relevant in 
this group. Although, the national squad performed mannitol challenge 5 hours 
after exercise, only one swimmer had a positive exercise challenge subsequently 
followed by a negative mannitol challenge. 
  
In the current study we measured FEV1 for 10 minutes post exercise. It has been 
reported that peak fall in FEV1 may occasionally occur up to 30 minutes [257]. 
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However, the ATS guidelines on exercise testing conclude that “including a 30-
minute post-exercise observation is controversial, because such a delay is 
infrequently seen” [183]. As a compromise, to minimise the interference with the 
athlete’s intensive training session, we decided that 10 minutes should be 
sufficient to pick up the majority of cases. It could additionally be argued that the 
non-intensive exercise preceding the challenge may have induced a refractory 
period in some swimmers, which may have led to an underestimate of the true 
prevalence of EIB. The low incidence of positive mannitol challenge in swimmers 
with a physician diagnosis of asthma was unexpected. Of those that were 
negative (7/10), 2 were taking regular ICS. Ideally, all preventer therapy would 
have been stopped prior to assessment, however it was felt that this would have 
interfered excessively with training. Of the remaining 5 swimmers, 2 had a high 
FENO (>30), and 3 had normal readings (<20). A normal FENO in the presence of 
a negative mannitol and exercise challenge suggests that these patients were 
wrongly diagnosed with asthma. 
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Conclusion 
We have found no association between mannitol and standardised-FBT in elite 
swimmers. Mannitol challenge was associated with a high baseline FENO, 
however exercise challenge was not. This suggests that whilst mannitol may 
select swimmers with a ‘traditional’ inflammatory asthmatic phenotype, there may 
still be a role for a standardised field based challenge in high performance 
swimming, where the bronchoconstrictor response may have a more complex 
aetiology. Swimmers show a sustained fall in FENO following chlorine exposure 
suggesting that a non-cellular, perhaps neurogenic, type-inflammation may be 
important in airway dysfunction in this group of athletes. Further large scale 
studies are warranted to understand the pathophysiology of lose dose chronic 
chlorine exposure in elite swimmers. 
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Critique 
The results of this study were unexpected, and led us to realise that several 
potential aetiologies may be at play in elite swimmers, making the use of a single 
diagnostic test problematic. We recognise that further studies are required to 
confirm the existence of ‘a swimming-specific bronchoconstrictor response’, 
however such studies would be inherently difficult to perform. Ideally, 
standardised field-based challenge would be performed in a chlorine-rich and 
chlorine-free environment; unfortunately there are no chlorine-free pools in 
Scotland. If such a comparison were to be made, it would be important to find a 
group of elite swimmers who exercise solely in a chlorine-free environment, in 
order to exclude the effects of chronic low-grade chlorine exposure on the 
respiratory epithelium. It has been suggested that sea swimmers could constitute 
such a group, however such a comparison is problematic in that the focus of sea 
swimming is endurance whereas indoor swimming requires high intensity 
exercise of relatively short duration. In other words, elite indoor swimmers are 
therefore far more likely to exercise at the physiological extremes required to 
trigger EIB. Furthermore, the different strokes utilised in the two disciplines allow 
for the development of different muscle groups, making a direct comparison 
impossible. As an alternative, field-based challenge could be compared to 
standardised exercise challenge in a different discipline, e.g. CPET (which 
involves exercising on a treadmill or static cycle whilst breathing in air of a fixed 
temperature/ humidity). The difficulty with this is that swimmers develop certain 
muscle groups, and are frequently unable to maintain similar exercise intensities 
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whilst running or cycling. It has been suggested that ’chlorine challenge’ could be 
employed, however as chlorine is known to induce reactive airways dysfunction 
syndrome (RADS) the ethics of this would have to be closely debated. It is likely 
that even in swimmers a battery of tests would need to be performed in order to 
determine the most appropriate test to monitor response in clinical trials.  
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Chapter 5: 
Discussion and 
conclusions 
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This work aimed to investigate potential mechanisms for improving the 
management of asthma utilising current available therapies. To this end the 
thesis is divided into two distinct sections: Establishing the role of surrogate 
markers of inflammation in clinical and research settings and tailoring treatment 
according to asthma phenotype. 
 
It is estimated that as many as 300 million people of all ages, and all ethnic 
backgrounds, suffer from asthma, and that the burden of this disease to 
governments, health care systems, families, and patients is increasing [1]. 
Scotland has been reported to have the highest proportion of asthma per head of 
population worldwide, with 18.4% of inhabitants affected [1]. Worryingly, Scotland 
has been also ranked in the top third of countries with regard to asthma mortality, 
with 0.6 asthma deaths per 100 000 5-35 year olds [1]. This ranking is 
significantly higher than countries with lower GDPs such as Ecuador and Latvia, 
which is surprising, as >95% of the Scottish population have access to essential 
drugs [1]. National guidelines were introduced with the aim of standardising the 
management of asthma, however, the majority of asthmatics remain 
symptomatic. In 2006 an observational study of 9467 asthmatic patients, of all 
ages and clinical severities, in 319 general practices throughout Scotland was 
carried out [258]. They aimed to calculate the ‘human cost’ of asthma though the 
assessment of symptoms and lifestyle disruption, and to assess direct health 
care costs through a study of health service utilization. It was found that only 1/3 
of patients were free from asthma symptoms. 4211 (66%) had experienced 
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symptoms due to asthma in the past month; with 12% (770) reporting lost time 
from work/school due to asthma. In the preceding 12 months 20% (1916) had 
experienced an acute exacerbation, 321 (3%) patients had attended an Accident 
and Emergency (A&E) department because of an asthma related problem, 455 
(5%) had attended out patients, and 237 (2.5%) were admitted to hospital. 
Fifteen of these patients experienced a total of 28 days stay in an intensive care 
unit. These results indicate that the human and economic costs of asthma remain 
a substantial burden to the Scottish population. It is clear that a new approach to 
asthma management is urgently required. 
 
Currently asthma therapy is titrated on the basis of symptoms and markers of 
airflow limitation, both of which are known to correlate poorly with the underlying 
asthmatic inflammation. Strategies in which asthma therapy has been targeted to 
suppress surrogate markers of inflammation have proved very successful [37, 
38]. However, applying this strategy to a wider ‘community’ setting has proved 
problematic. The main difficulties lie with the identification of an appropriate 
surrogate marker of inflammation. Both sputum eosinophils and methacholine 
bronchial challenge are time consuming to perform and require the presence of 
highly trained staff and expensive machinery, making them impractical for use in 
the community. FENO was a promising candidate, especially following the 
development of the portable MINO device. However, a recent community based 
study by Menzies et al found that FENO was an insensitive method (sensitivity, 
66.7%; specificity, 51.9% at a cutoff value of 20 ppb) for identifying patients who 
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subsequently exacerbated [76]. This was likely due to frequently exacerbating 
patients receiving higher doses of maintenance inhaled corticosteroids, leading 
to suppression of FENO. Bronchial challenge is a well-established surrogate 
marker of inflammation. The development of a challenge test utilizing dry powder 
mannitol offers an exciting opportunity, as only a portable spirometer and dry 
power inhaler are required [136]. In this respect, the first study to be included in 
this thesis looked at the use of mannitol challenge to identify changes in airway 
inflammation during community-based down titration of asthma medication. 
Establishing patients on the lowest dose of inhaled steroids, in order to reduce 
the risk of dose related side effects, is recommended in current guidelines, but 
rarely carried out in clinical practice. In this study we were able to demonstrate 
that mannitol challenge can easily and safely be used in a community setting. In 
addition we showed that a significant reduction in ICS dose could be achieved in 
a without any worsening of airways inflammation, lung function, or quality of life. 
34% of subjects demonstrated an improvement (and 41% showed no change) in 
AHR post step-down, suggesting that compliance improved on entry into the 
clinical trial. Only a minority of patients showed a worsening of AHR, which would 
be expected if subjects were initially concordant with treatment. A rate of 19% is 
consistent with concordance rates reported in previous studies [197]. Treatment 
of asthmatic patients in primary care has been driven by results obtained from 
randomised controlled trials, during which treatment compliance is reinforced. 
These therefore, do not reflect a real life scenario. This study highlights the 
potential pit falls of extrapolating data to a primary care setting where compliance 
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rates may be poor. Perhaps there is a need for the development of more 
effective strategies which support asthmatics to use established therapies 
correctly rather than continue a culture of escalating therapy, without frequent 
review and step-down if appropriate. Improvement of asthma care in the 
community may require an approach that includes more effective supervision and 
targeted assessment to enhance adherence and reduce airways inflammation. 
Further studies are required to assess the impact of such a strategy in a 
prospective manner. Large randomised control trials are required to further 
evaluate the use of mannitol challenge as a tool by which to titrate inhaled 
therapy in a community setting. 
 
The importance of identifying appropriate surrogate markers of inflammation is 
not restricted to clinical practice, and is equally important in the research setting. 
This is particularly true when determining therapeutic equivalence between 
inhaled products. A successful therapeutic equivalence study requires 
demonstration of a significant dose-response relationship with at least two doses 
of the test compared with, if possible, two doses of the reference product [259]. 
An ideal clinical efficacy study design for establishing a dose response needs to 
be sensitive (i.e. steep-dose-response slope), reproducible, have low inter- and 
intra-subject variability, and be achievable with low patient numbers. Current 
EMEA guidelines state that the most well-used study design is the double-blind, 
randomised, parallel group comparison of test and reference product [259]. 
However, this design requires the careful matching of cases and controls, which 
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is problematic due to the inherent heterogeneity of asthma. The alternative is a 
crossover study, which has the advantages of allowing cases to act as their own 
controls, and allows the use of a much smaller population, however this requires 
the use of a reliable, repeatable endpoint measure. In addition, the lack of a 
carry-over effect much be demonstrated. The EMEA currently recommend that 
the primary efficacy variable should be a pulmonary function measure, preferably 
FEV1 measured regularly, if possible daily at home or at least every two weeks in 
the clinic [259]. Alternative primary variables can be considered but their 
sensitivity to detect differences between adjacent doses of inhaled corticosteroid 
must be demonstrated. The purpose of utilizing inhaled steroids in the 
management of asthma is to suppress the underlying airway inflammation. It 
therefore appears nonsensical to select a marker that is distant from this 
process. The aim of the second study was therefore to determine which 
inflammatory outcome measures provided sufficient assay sensitivity, as part of a 
crossover design, for detecting dose response effects on airway and systemic 
markers. Methacholine challenge was selected as the primary outcome variable 
as significant dose separation has previously been reported with 100µg vs. 
500µg fluticasone propionate [213]. In this respect, we also demonstrated 
sensitivity of the methacholine bioassay, as there was a significant dose-
response relationship for both formulations. The common slope for the overall log 
dose-response relationship was highly significant, demonstrating that the doses 
selected coincided with the steep part of the dose-response curve for BHR. The 
95%CIs for the relative dose potency ratio of HFA vs. CFC were close to unity at 
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1.10, however, the 95%CI (0.49–2.66) was outside predetermined equivalence 
limits of +/-50% (0.5-2.0) [212]. Current EMEA guidelines state that 
bioequivalence in respect of systemic exposure can be demonstrated if the 90% 
confidence interval is entirely contained within 80 – 125%. However, the FDA 
also accept a +/-33% limit (i.e. 0.67-1.5) for PD studies. Whilst we accept that 
these limits are valid when comparing across doses (e.g. 200ug HFA vs CFC or 
800ug HFA vs CFC), such limits are not appropriate for calculating relative 
potency from the slope of the DRC from a Finney bio-assay. We have found, 
from previous experience, that it is not possible to achieve confidence intervals 
within these extremely tight boundaries for pharmacodynamic endpoints [260]. In 
a previous study from our department involving 27 patients we found that the 
95% confidence interval for the relative dose potency of two formulations of 
budesonide was 0.5-2.46. In order to increase the power in the present study we 
doubled the number of patients, and utilized methacholine challenge as opposed 
to adenosine-5-monophosphate (AMP) challenge, as this is considered to yield 
lower variability. The decision to aim for a relative potency of 0.5 – 2 from Finney 
was based on this study [212]. However, even with more than double the number 
of patients, lower equivalence limits were not achieved. 
 
Several studies have suggested that FENO may be able to discriminate doses of 
ICS [69, 71, 81, 261] however; significant limitations in their study design put 
these results into question. For example, a number of these studies utilized a 
cumulative-dose design, suggesting that the observed dose–response 
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relationship may have been due to a time effect rather than a dose effect. In the 
current study a significant dose response relationship was seen for both HFA and 
CFC, however, the 95% confidence interval was also outside of predetermined 
equivalence limits. In this study, cumulative dose was also an issue for FENO, 
however the same cannot be said for methacholine challenge. Sovijvari et al 
demonstrated that the doubling dilution difference between FP and placebo was 
1.19, 1.33 and 1.27 after 72 hours, 2 weeks and 4 weeks respectively [214].  
Thereby demonstrating that near-maximal effects on methacholine PC20 are 
obtained within the first two weeks of treatment. In the present study we 
observed PC20 shifts of 1.55dd and 2.16dd following 200µg and 800 µg of HFA 
budesonide, giving a mean difference of 0.51dd which is too large to be simply 
due to a time effect. The current evidence suggests that the tight equivalence 
limits recommended by both the EMEA and FDA cannot be achieved in PD 
studies, without the recruitment of hundreds of participants. Among the study 
designs that have been examined to date, a crossover design utilizing 
methacholine challenge as the primary endpoint seems to hold the most promise; 
but even for this primary endpoint, more than doubling of the study subjects, did 
not achieve the required confidence intervals. This suggests that wider 
confidence interval will have to be accepted if bioequivalence is to be 
demonstrated using pharmacodynamic endpoints.  
 
These two studies have demonstrated that the selection of appropriate surrogate 
markers of inflammation can potentially improve the clinical management of 
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asthma and play an important role in asthma research. Clearly the titration of 
steroid therapy in asthma is of vital importance, however, it must be noted that no 
two individuals have the same response to the same dose of the same steroid. 
This is in effect a reflection of the degree of steroid responsiveness, or 
resistance, and any understanding of the individual’s responsiveness to 
proposed steroid therapy should allow improved therapeutic options, tailored to 
the individual. It is likely that there is a spectrum of steroid responsiveness in 
asthma, with rare complete resistance at one end, but a relative resistance in 
patients who require high doses of inhaled or oral corticosteroids [262]. True 
(complete) corticosteroid resistance is very rare, with an estimated prevalence of 
1:1000 asthmatics [262]. The reasons for the variability in individual therapeutic 
responses to drugs used to treat asthma are complex, involving both genetic and 
environmental factors as well as levels of adherence with therapy [263, 264]. 
One of the most influential environmental factors is cigarette smoking, which is 
known to significantly worsen asthma control though a combination of epithelial 
toxicity, oxidative damage, and recruitment of inflammatory cells [152, 153]. In 
addition, smokers with chronic asthma are less sensitive to the beneficial effects 
of both inhaled and oral corticosteroids compared with nonsmokers with asthma 
[157, 158, 160]. Therapeutic studies, which form the basis for current asthma 
guidelines, often exclude current smokers due to concerns about recruiting 
participants with chronic obstructive pulmonary disease (COPD). Consequently 
information on which drugs are most appropriate to treat smokers with asthma is 
severely lacking. Knowing how best to manage this group of patients is of 
	  151	  
considerable importance because smoking is common among patients with 
asthma, current smoking rates among asthmatic patients have been reported as 
ranging from 17-35% [148, 150, 151, 161, 162]. Although smoking cessation has 
been shown to improve asthma control, lung function and lead to a decline in 
sputum neutrophil counts many asthmatics are either unable or unwilling to stop 
smoking [217]. The lack of available evidence means that guidelines do not 
recommend alternative treatment strategies for smokers, other than suggesting 
that ‘higher doses of inhaled steroids may be required’ [8].   
 
Only a handful of studies to date have investigated this issue. In 2007, Lazarus 
and colleagues compared the response to low-dose inhaled steroid 
(becomethasone 400mcg daily) with an oral leukotriene receptor antagonist 
(montelukast 10mg daily) for 8 weeks in smokers and non-smokers [265]. Their 
main findings were that inhaled steroid significantly increased pre-bronchodilator 
FEV1 in non-smokers only, whereas montelukast increased morning peak flow in 
smokers only. Unfortunately, these changes were only seen within group and not 
between groups. Furthermore, neither montelukast nor beclomethasone lead to 
improvements in either sputum eosinophils or methacholine challenge. A more 
recent study by Spears and colleagues investigated the potential additive effects 
of theophyllines on ICS [266]. The recruitment of histone deacetylase (HDAC) is 
known to partly mediate the anti-inflammatory actions of corticosteroids. HDAC is 
a nuclear enzyme involved in the switching off of activated inflammatory genes 
[267]. Cigarette smoke has been shown to reduce HDAC activity in vitro [268], 
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which could explain corticosteroid insensitivity seen in smokers with asthma. In 
vitro studies have shown that HDAC activity can be restored by low-doses of 
theophylline [269]. Spears et al therefore set out to determine whether 
theophyllines, in combination with low-dose ICS had any additive effects on lung 
function over ICS or theophyllines alone [266]. They found that subjects treated 
with the combination demonstrated significant improvements in morning PEF and 
mean pre-bronchodilator FEV1. These improvement were noted to be superior to 
those seen with montelukast [265] and high dose inhaled steroid [159]. However, 
no differences were observed in sputum inflammatory cells, other than a 
decrease in lymphocyte count, the clinical significance of which was unclear.  In 
our study we investigated the benefits of combination therapy with LABA and ICS 
over doubling the dose of inhaled steroid in smokers and non-smokers, and were 
able to demonstrate an improvement in lung function similar to that seen in non-
smokers. Furthermore, smokers appeared to gain proportionally greater benefit 
from the addition of salmeterol than non-smokers on methacholine AHR. These 
results support the observation made by Pedersen and colleagues during a post-
hoc analysis of the Gaining Optimal Asthma controL (GOAL) study’ that smokers 
would need 18 years less treatment, by taking FPSM vs. FP alone, to prevent an 
exacerbation than non-smokers [163]. In our study we found no significant 
benefit, in any primary or secondary outcome, from high dose inhaled FP 
(1000ug/day) in smokers, which goes against current recommendations that 
smokers may benefit from higher doses of ICS [8]. This assumption was based 
on a study by Tomlinson et al, who demonstrated that high dose ICS decreased 
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peak flow variability to a similar degree in both smokers and non-smokers [159]. 
Peak flow, like spirometry, reflects airway caliber and as such is relatively distant 
from the underlying asthmatic inflammatory process [21].  In this respect we saw 
no significant improvement in either peak flow dairy cards or ACQ in smokers. 
Whilst the results of our study suggest that smoking asthmatics gain no benefit 
from inhaled steroids, we would not advocate that they be treated with salmeterol 
alone. The use of LABAs as monotherapy has been shown to lead to an increase 
in asthma related deaths [270]. Further safety research would be required prior to 
making such a declaration. Similarly, although our results suggest similar 
improvements in spirometry to those seen during smoking cessation, we would 
still advocate smoking cessation as the first line intervention in smoking 
asthmatics. The detrimental effects of smoking are not solely limited to poorer 
asthma control, significant increases in cardiovascular risk and increased risk of 
malignancy dictate that smoking cessation be discussed on a regular basis.  
 
We had hoped to provide a mechanistic explanation for this improvement by 
including both methacholine and mannitol challenge. The intention was that 
mannitol would provide a sensitive marker of inflammation, whereas methachline 
would provide a measure of airway tone. Interestingly, similar results were seen 
with both challenge tests (although differences between treatments in smokers 
did not reach significance with mannitol). We would have expected to see a 
greater improvement in mannitol PD15 following treatment with double dose FP 
compared to FPSM, as was observed during a similar study which utilised AMP 
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challenge [271]. In view of the fact that salmeterol has been shown to have no 
meaningful in vivo activity we have to hypothesise that the improvements 
conferred by LABAs was either due to their stabilizing effect on airway smooth 
muscle [225] and mast cells [272], or to their ability to preserve the integrity of the 
respiratory epithelium [227]. These findings suggest that mannitol may be less 
may be less specific for inflammation than originally thought. Further studies are 
required to determine the exact mechanism of action of this indirect bronchial 
challenge test. However, despite this, we have successfully demonstrated that 
alternative, treatment approaches tailored to different subgroups of asthmatics 
may be beneficial.  
 
Another group of individuals in whom the traditional approach to asthma 
management may not be appropriate is elite athletes. It is has been well 
documented that the mechanism of bronchoconstriction in athletes involves the 
drying and/or cooling of airways [134]. However, even within this category there 
are athletes to which this mechanism of action is unlikely to apply. Swimmers, for 
example, exercise in a warm, humid environment and are therefore not subject to 
the same environmental strains as cold weather or endurance athletes. It 
therefore seems unlikely that tests designed to reproduce hyperosmolar shifts 
will have the same diagnostic sensitivity in swimmers as they do in these other 
groups of athletes. The aim of the fourth and fifth studies included in this thesis 
was therefore to compare various diagnostic tests in elite swimmers, in order to 
determine which were the most sensitive. This would allow us to determine which 
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test would be most specific for future use in studies monitoring benefit from 
medical therapy. 
 
We hypothesised that exposure to chlorine had to play an important part in the 
underlying pathogenesis of EIB in swimmers, as traditional explanations did not 
fit, and wanted to determine the effect of chlorine and exercise on the unified 
airway prior to undertaking studies comparing the different tests. Adult elite 
swimmers have been shown to have significantly higher levels of airway 
inflammatory cells compared with healthy controls [172]. We therefore conducted 
a pilot study to assess the combined effects of chlorine and exercise on the 
unified airway of adolescent elite swimmers, including estimating the prevalence 
of rhinoconjunctivitis and EIB. We elected to use FENO as it is a non-invasive, 
reproducible, well-established marker of airway inflammation, which can be used 
to assess both the upper and lower airways [236], In addition, FENO had been 
shown to rise following a marathon [237]. The absence of any acute rise in either 
tidal or nasal FENO post exercise challenge was therefore unexpected. We 
hypothesised that we may have missed a late phase response, similar to that 
seen during allergen challenge. This assumption was supported by anecdotal 
reports from swimmers who complained of nasal congestion and symptoms, 4-6 
hours after training. The use of a standardised field based test was a novel 
approach. Traditional field based testing, in which athletes perform a challenge 
using their primary exercise, was previously limited by an inability to standardise 
both the cardiovascular workload and environmental conditions [177]. We 
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therefore decided to use a standardised protocol based on the ATS guidelines for 
exercise challenge, using an objective measure of heart rate monitoring. Using 
this test we were able to identify a high prevalence (36%) of EIB in our cohort of 
adolescent elite swimmers. 
 
The next step was therefore to compare our standardised exercise test to 
mannitol challenge, as a surrogate for the gold-standard test, EVH. We found a 
disconnect between the challenge tests, in that 14% swimmers were positive to 
mannitol, 15% were positive to exercise challenge, while only one swimmer was 
positive to both. Whilst these findings were not supported by studies performed in 
cold weather or track athletes [146, 177, 178], they were consistent with the 
findings of Pedersen et al who reported that EVH had a relatively low sensitivity 
in swimmers [245]. Interestingly, swimmers with a positive mannitol challenge 
had a significantly higher baseline FENO, than those who were positive to 
exercise, suggesting that mannitol challenge may be more sensitive at picking 
out swimmers with a traditional ‘inflammatory’ asthmatic phenotype, rather than 
EIB. When we looked at FENO we found that there was a significant decrease 
post exercise, which was maintained 4-6 hours post exercise. Case reports of 
children exposed to high doses of chlorine have shown increased bronchial 
hyper-reactivity and persistently low FENO levels. We therefore hypothesised that 
a similar pathogenic mechanism may be at play in the swimmers, a sort of 
‘swimmer-specific bronchoconstrictor response’ thereby explaining why they 
didn’t respond to both challenges. Interestingly, similar results have been 
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reported previously. Bonsignore et al compared the effects of a 5km race on 
spirometry and FENO in competitive outdoor pool swimmers and sea swimmers. 
Although the chlorine levels in the outdoor pool were extremely low, they noted a 
significant decrease in FENO post-exercise, which was not observed in sea 
swimmers. No differences were seen in sputum inflammatory cell composition, 
and no changes in FEV1 were noted post exercise, however, again the field-
based challenges were not standardised [273]. Furthermore, neither group was 
considered to be ‘elite’, indicating that perhaps the intensities of exertion required 
to trigger EIB were not reached.  
 
Unfortunately, subsequent publications do not correlate these results. Castricum 
et al recently published a study comparing standardised field-based challenge, 
EVH and lab-based challenge in 33 adult swimmers [274]. They found that only 1 
of the 33 subjects had a positive field swim challenge compared to 18 with a 
positive EVH challenge, and 4 with a positive laboratory cycle challenge. Only 1 
of the 33 subjects was positive to all 3 challenges. Whilst the disconnect between 
the challenge tests reflects our results, the low prevalence of EIB diagnosed by 
field challenge is somewhat surprising. The prevalence of EIB diagnosed in both 
studies presented in this thesis were 36% and 15% respectively. Rates in the first 
study may have been artificially high as positive challenge was defined as a 
single >15% drop in FEV1 post exercise. In the second study these criteria were 
tightened to >15% drop at two time points post exercise, with the aim of 
excluding those with a drop secondary to exhaustion. In the study by Castricum 
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et al the field-based challenge took place in an ozone filtered pool, which would 
have resulted in significantly lower concentrations of chlorine. Further studies are 
therefore required to compare standardized field based challenge in high and low 
chlorine environments.  
 
Much controversy surrounds the diagnosis of EIB itself. It has been suggested 
that EIB in elite athletes is simply a reflection of very mild asthma, which only 
becomes symptomatic due to extremes of exercise. Whilst this is almost certainly 
true in a subgroup of athletes, such as the swimmers who were positive to 
mannitol in the 5th study, I believe that EIB occurs as a distinct clinical entity. 
Exercise is the most common trigger of bronchospasm in those who are known 
to be asthmatic, affecting between 50 and 90% of all individuals with asthma 
[275]. However, EIB also occurs in up to 10% of subjects who are not known to 
be atopic or asthmatic [276]. Elite athletes claim that exercise is the most 
prominent trigger of asthma symptoms, and rarely complain of diurnal variation or 
nocturnal symptoms [241]. The pathogenesis of asthma-like symptoms in elite 
athletes is likely to be multifactorial, and is not completely understood. However, 
during competitive sport the use of full lung capacity means that large volumes of 
atmospheric air that is cold, dry and polluted are inhaled on a regular basis. This 
overcomes the ability of the upper airways to warm up and humidify the air 
reaching the smaller airways [277], bringing about airway narrowing through 
water and heat loss [134]. These airway differences, together with some degree 
of inflammation, lead to EIB or “sports asthma” [278]. Several studies have 
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suggested that athletes have different patterns of airway inflammation compared 
to ‘traditional inflammatory’ asthmatics [279-281]. Furthermore, unlike traditional 
asthma, EIB and airway inflammation have been shown to attenuate on 
cessation of competitive sport [173]. However, no study to date has excluded 
subjects with either a physician diagnosis of asthma or ‘typical’ asthma 
symptoms (e.g. nocturnal waking or diurnal variation). It is therefore unclear 
whether subjects who are responsive to exercise have a different pattern of 
inflammation than those who are responsive to direct challenge, or what role 
inflammation actually plays in the pathogenesis of EIB. Karjailinen et al carried 
out a study in which elite skiers were classified according to their response to 
methacholine challenge [279]. They found that all skiers, irrespective of 
challenge, had significantly higher neutrophil counts on bronchial biopsy than 
asthmatic controls. However, methacholine-responsive skiers had significantly 
higher eosinophil counts than non-responders, suggesting that methacholine 
challenge may select out those with more traditional ‘inflammatory’ asthma [279]. 
Unfortunately, this study did not compare response to exercise between the two 
groups. Lab-based studies have shown that exposing healthy subjects to cold air 
whilst running can induce an increase in the number of granulocytes and 
macrophages in the BAL [282]. Repetitive hyperpnoea itself has been shown to 
recruit eosinophils to the airways and to promote the release of inflammatory 
cytokines [283]. Although inflammatory cells have been documented in the 
airways of non-asthmatic subjects with EIB, it should be stressed that their role in 
the development of airway hyper-responsivness is currently unknown. Smooth 
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muscle dysfunction on the other hand undoubtedly plays a large role in the 
pathogenesis of traditional asthma, hence why bronchial challenge tests to direct 
stimuli have such a strong negative predictive value. The same however, cannot 
be said for EIB, and direct challenge has been shown to be a poor diagnostic tool 
for EIB in athletes [176, 179], adding yet further weight to the argument that a 
different pathogenesis is at play in this group of individuals. 
 
The current gold standard test for the diagnosis of EIB is EVH. However, as a 
positive results is seen in up to 50% of athletes [179, 245], one has to wonder 
whether it is over-diagnosing EIB? Whilst the lack of environmental 
standardisation makes field-based testing a relatively poor diagnostic tool in track 
and cold weather athletes, the same cannot be said for elite swimmers. Which 
begs the question: What is the clinical significance of a positive EVH challenge in 
a swimmer who doesn’t bronchoconstrict during a standardised exercise 
challenge? In other words, is EVH simply identifying a normal response at the 
extremes of physiology?  Further research is require to investigate the role of 
inflammatory cells in the pathogenesis of EIB, and to investigate whether athletes 
who bronchoconstrict to exercise, EVH or direct challenge have different 
inflammatory cell compositions or airway dynamic effects. 
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Conclusions 
 
1. The use of inflammatory surrogates has opened many possibilities in 
both the fields of clinical management and asthma research. We have 
demonstrated that mannitol challenge can safely be used in the 
community, and that down-titration of inhaled steroid is possible 
without a significant rise in airway inflammation. These findings 
suggest that an approach that includes effective supervision and 
targeted assessment, to enhance adherence and reduce airways 
inflammation, may be beneficial. 
2. Methacholine challenge has sufficient assay sensitivity to be used as 
the primary outcome measure in crossover studies examining the 
bioequivalence of inhaled corticosteroids. However, wider confidence 
intervals will have to be accepted if bioequivalence is to be 
demonstrated using pharmacodynamic endpoints.  
3. Fluticasone/salmeterol combination affords more bronchoprotection, 
and greater bronchodilation than doubling the dose of fluticasone in 
smoking asthmatics. This study adds further weight to the argument 
that smoking asthmatics require a different approach to treatment than 
their non-smoking counterparts.  
4. Mannitol challenge may not be as specific for inflammation as originally 
thought, as it appears to be attenuated by LABA induced smooth 
muscle stabilisation.  
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5. Adolescent elite swimmers have a high prevalence of asthma and 
rhinitis.  
6. Swimmers are not exposed to the same environmental strains as other 
cohorts of elite athletes, and the pathogenesis of their EIB is likely to 
be different. The disconnect observed between swimmers with high 
FENO and a positive mannitol, and those with a positive field-based 
challenge, suggests that a ‘swimmer specific bronchoconstrictor 
response’ may be at play. This is substantiated by the persistent drop 
in FENO observed 4-6 hours post exercise.  
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Poster presentations arising from this thesis 
 
Disconnect between standardised field based testing and mannitol challenge in 
Scottish elite swimmers.  
• Association of Physicians of Great Britain and Ireland (APAM) 
Annual Meeting  (Dundee, 16th April 2010) 
 
Establishing equivalence of inhaled corticosteroids using pharamacokinetic and 
pharmacodynamic outcomes   
• Scottish Thoracic Society meeting (Stirling, October 2009) 
• European respiratory Society meeting (Barcelona, September 2010)  
 
Effects of chlorine and exercise on the unified airway in young elite Scottish 
Swimmers.  
• Scottish Thoracic Society meeting (Scone, April 2009) 
• American Thoracic Society meeting (San Diago, May 2009) 
• European Thoracic Society meeting (Vienna, September 2009) 
 
Supervised step-down in a community setting does not increase airways 
inflammation in mild-to-moderate asthmatics. 
• American Thoracic Society meeting (San Diago, 16th May 2009) 
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Fluticasone/Salmeterol combination confers significant benefits in smoking 
asthmatics 
 European respiratory Society meeting (Barcelona, September 2010) 
 British Thoracic Society meeting (London, December 2010) 
 Scottish Thoracic Society meeting (Stirling, October 2010) 
 
Oral Presentations arising from this thesis 
 
Disconnect between standardised field based testing and mannitol challenge in 
Scottish elite swimmers.   
 British Thoracic Society meeting (London, December 09) 
 Scottish Thoracic Society meeting (Stirling, October 09) 
  
Supervised Step-down In a Community Setting Does Not Increase Airways 
Inflammation In Mild-to-Moderate Asthmatics 
 British Thoracic Society meeting (London, December 09) 
 Scottish Thoracic Society meeting (Stirling, April 08) 
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